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ABSTRACT 
The uroepithelium lines the urinary bladder, urethra and the lower renal pelvis. It provides a tight 
blood-urine barrier that prevents the unregulated movement of solutes, ions and metabolites 
present in the urine. Apart from forming a robust barrier, a growing body of evidence supports 
the role of the uroepithelium as a sensory transducer that is sensitive to extracellular biochemical 
and mechanical stimuli. One of the mediators that is released from the uroepithelium and impacts 
bladder activity is adenosine. Adenosine is a well-known stress relieving hormone in other organ 
systems and the bladder lumen is a region of constant stress due to cyclical filling and voiding of 
urine, therefore I hypothesized that adenosine has an impact on urinary bladder function under 
stress.  First I assessed the mechanism of adenosine turnover and how luminal adenosine affects 
bladder function. I report that adenosine is released from the mucosal and serosal surfaces of the 
uroepithelium when the tissue is maximally stretched. The released adenosine it actively turned 
over by distinct pathways at either surfaces of the uroepithelium. Further, enriching the luminal 
adenosine concentration by blocking its routes of turnover or by specific activation of apically 
localized A1AR by using CCPA, bladder function was modulated by decreasing the threshold 
pressure of bladder voiding. In the second study, I looked at the impact of adenosine on 
exocytosis and membrane trafficking in umbrella cells. I report that activation of A1AR at the 
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apical surface of umbrella cells increased apical exocytosis in umbrella cells. The apical 
exocytosis was similar to late phase stress-mediated exocytosis and required transactivation of 
EGFR. The pathway involved Gi-Gβγ-PLC-PKC and ADAM17 which in-turn cleaved and 
released HB-EGF leading to EGFR transactivation and downstream ERK1/2 MAPK. Further, 
Ser811 in the cytoplasmic tail of ADAM17 was important for A1AR-mediated activation of the 
protein. Finally, ADAM17 was also involved in late-phase stretch-mediated apical exocytosis in 
rats but not in rabbits. In conclusion, my studies show that adenosine plays a protective role in 
the bladder both at the organ and cellular level. At the organ level, adenosine alleviates luminal 
stress by reducing the threshold pressure for voiding and at the cellular level, it triggers apical 
exocytosis and increase in membrane surface area of umbrella cells thus mitigating the stress 
induced by mechanical stretching associated with bladder filling.     
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1.0  INTRODUCTION 
1.1 OVERVIEW OF THE UROEPITHELIUM 
1.1.1 The uroepithelium 
The uroepithelium is the epithelial lining of the urinary bladder, urethra and the renal pelvis. It is 
a stratified tissue that consists of the outermost umbrella cells, followed by 1-5 layers of 
intermediate cells and finally a single layer of basal cells (Figure 1) (1). The umbrella cells are 
polarized epithelial cells with distinct apical and basolateral surfaces. The apical surface directly 
interfaces with urine in the bladder lumen while the basolateral surface faces the intermediate 
cells.  
The primary functions of the uroepithelium are to provide a robust blood-urine barrier 
that prevents the leakage of urine into the underlying tissue and regulates the movement of water, 
ions and solutes across the mucosal surface (1-3). The outer umbrella cells are highly specialized 
to perform these tasks. Some of the key features of the umbrella cells are their specialized apical 
surface, high transepithelial resistance and the presence of numerous discoidal-and fusiform-
shaped vesicles (DFVs) beneath their apical surface  
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Figure 1 The urinary bladder mucosa 
 
A., an image of a rabbit bladder that has been filled with buffer and held by the neck is depicted. 
B. The multiple layers of the bladder mucosa are presented. The uroepithelium consists of the 
outer umbrella cells, the intermediate cells and the basal cells. Beneath the uroepithelium is the 
lamina propria which is followed by the submucosa. The Submucosa is followed by the three 
layers of smooth muscles called detrusors. Finally, the organ is enveloped by the adventitia layer.   
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Specialized apical surface of the umbrella cells 
The most immediately identifiable feature of the umbrella cells when examined under the 
microscope is the scalloped nature of the apical surface, characterized by plaques and intervening 
hinge regions (1,4,5).  Closer observation of the ultrastructure of the plaque regions under 
scanning and transmission electron microscopes reveals that the outer plasma membrane leaflet 
is thicker than the inner leaflet, and forms what is known as the asymmetric unit membrane 
(AUM) (5-7). The AUM consists of crystalline arrays of particles, each of which is made up of 6 
proteins arranged in two tiers of three each. These proteins belong to the family of membrane-
bound proteins called uroplakins (UP), namely UPIa, UPIb, UPII, UPIIIa and UPIIIb (6-8). The 
UPs form the most abundant protein population of the apical surface of umbrella cells as the 
plaques cover almost 70-90% of the apical surface (9,10). The plaques contribute to the 
permeability barrier of the apical surface of umbrella cells. UPIIIa-/- mice have greatly 
diminished plaque assemblies at the apical surface and have significantly higher permeability to 
water and urea across the umbrella cells (3,11).  
The apical surface is also highly detergent resistant. This is due the unusual lipid 
composition of the apical surface, which is rich in cholesterol, phosphatidylcholine, 
phosphatidylethanolamine and cerebroside (9). Curiously, the lipid composition is similar to the 
composition of lipids in the myelin sheaths that envelope nerve fibers (9,12). The AUMs and the 
lipid composition of the apical surface together maintain a tight permeability barrier that 
regulates the exchange of water and solutes across the apical surface. 
High transepithelial resistance 
The second feature of the umbrella cells are their exceptionally high transepithelial 
resistance.  The umbrella cells are fused at the outer margin by a ring of high-resistance tight 
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junctions. The tight junctions regulate the flux of water, ions and solutes across the paracellular 
space. They are formed by the close positioning of anastomosing filamentous strands of plasma 
membrane from neighboring cells. The junctional complex in umbrella cells is made up of zona 
occludin-1, occludin, and claudins 4, 8, and 12 (13). The specialized apical membrane and the 
tight junction together contribute to the exceptionally high-resistance barrier formed by the 
umbrella cells (transepithelial resistance ranging from 20000-75000Ωcm2) (14,15). In addition, 
the apical surface of the umbrella cells is covered by a thick layer of heparin proteoglycans and 
mucin (16,17). This might provide additional protection by separating the urine from the 
underlying tissues.  
DFVs  
The third feature of these cells is the presence of numerous DFVs beneath the apical 
surface (18). The presence of the DFVs give the umbrella cells the ability to regulate the 
components and area of their apical surface without compromising on their barrier function 
(9,18). The plaques (described above) form the major component of the DFVs. The DFVs play a 
critical role in the dynamic maintenance of the apical surface. They are inserted into the apical 
surface and removed to modulate the apical surface area.  
While UPs form the major constituent of the DFVs, they are also the carriers of receptors, 
ion channels, and other surface proteins that populate the apical surface of the umbrella cells. 
Although not the focus of this dissertation, the identification of the other components of the 
DFVs would greatly enhance our knowledge of their function and regulation. In this study, I 
have used the expression of UPIIIa a marker for vesicles that populate the apical pole of 
umbrella cells. 
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In summary the specialized apical surface, the tight junctions and the DFV allow the 
umbrella cells to form the tight barrier that can accommodate large changes in the urine volume. 
However, the traditional view that the bladder is a passive sac that retains urine until voided does 
not hold true anymore. The uroepithelium is dynamically involved in regulating bladder 
function. The first line of evidence in support of this is: when the bladder fills with urine and the 
bladder mucosa unfurls to accommodate the increasing urine volume, the apical surface of the 
umbrella cells also unfurls, and intriguingly, increases the apical surface area by exocytosis of 
DFVs. Fresh membrane is inserted into the apical surface, and this contributes to the increase in 
luminal volume. When the bladder voids, the reverse occurs, the apical membrane is recaptured 
via endocytosis thus resulting in decrease in apical surface area.  
The dynamics of apical exocytosis and endocytosis has been studied in cell culture 
(19,20), in situ (21-23), and in isolated tissue using Ussing chambers (22,24-29). Many of the 
experiments that I performed in this dissertation were done on isolated rabbit uroepithelium or 
rat bladders that were mounted on Ussing stretch chamber apparatus. Therefore before 
introducing the apical membrane trafficking events in umbrella cells, a brief description of the 
apparatus and the electrophysiological technique used to determine apical membrane surface 
area is warranted.  
1.1.2 The Ussing stretch chamber apparatus 
The Ussing stretch chamber is a convenient way to study membrane trafficking events or release 
of mediators into the bladder lumen in isolated uroepithelial tissues. The apparatus consists of a 
serosal and mucosal hemichamber and a pair of Teflon rings that are sandwiched between the 
two chambers (28). One of the Teflon rings has stainless steel pins on its outer edge that holds 
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the tissue. Isolated uroepithelial tissue is held between the pins of the Teflon ring and is mated 
with the other ring. This sandwich is inserted between the mucosal and serosal hemichambers 
and clamped in position on a base with the help of adjustable screws. The chambers are filled 
with warm Krebs buffer simultaneously until the tissue is completely bathed in the buffer. The 
mucosal and serosal hemichambers allows the uroepithelium to be treated with specific agonist, 
drugs or other compounds on either of the surfaces. In addition, bladder filling can be simulated 
by filling buffer in the mucosal chamber which results in bowing out of the tissue (Figure 2 ) 
(28).     
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Figure 2 The Ussing chamber apparatus 
 
 
 
A, The top views of the Teflon rings are presented with the tissue held between the pins of the 
ring. B, The serosal and the mucosal hemichamber with the tissue rings in between them is 
represented. The tissue in B is marked in red. Filling buffer in the mucosal chamber causes 
bowing out of the tissue. Once the chamber is filled to capacity, additional buffer is added to 
mechanically stretch and stress the tissue. 
 7 
1.1.3 Determining tissue capacitance 
Changes in exocytosis and endocytosis at the apical surface of umbrella cells can be studied by 
measuring the apical surface area of the cells (26,30). In my studies, I measured the changes in 
apical surface area by determining the transepithelial capacitance (CT) of the apical membrane. 
Capacitance is the amount of charge stored between two parallel plates separated by a dielectric. 
The capacitance is represented using the formula: 
𝐶𝐶 = 𝜀𝜀𝜀𝜀
𝑑𝑑
 14𝜋𝜋𝜋𝜋 
Where C is capacitance; 𝜀𝜀 is the dielectric constant; A is area of each plate; d is the 
distance between the plates; k is a constant (9.0x1011cm/F) and 𝜋𝜋 has the usual value. The lipid 
bilayer of the plasma membrane in essence works like a parallel plate capacitor. It has a 𝜀𝜀 value 
of ~5 and a very small distance between the two leaves of the bilayer (3.5-7 nm) (31). Further, 
from the formula, it is clear that the capacitance of the membrane is directly proportional to 
surface area of the membrane (28). Epithelial tissue can be described as a simple circuit where 
the apical and basolateral plasma membrane are modeled as capacitors and resistors in parallel 
(Figure 3). The resistive pathway is the flow of ions via ion channels and the capacitive 
component is the ability of the plasma membrane to store charge. Because the tight junctions 
have no surface area, but conduct paracellular ion transport, they are modeled just as a resister 
(RTJ) (32).  
Capacitance in series in added inversely. therefore 1
𝐶𝐶𝑇𝑇
= 1
𝐶𝐶𝑎𝑎
+ 1
𝐶𝐶𝑏𝑏𝑏𝑏
 
 
 8 
 Rearranging the formula: 
𝐶𝐶𝑇𝑇 = 𝐶𝐶𝑎𝑎
�
𝐶𝐶𝑎𝑎
𝐶𝐶𝑏𝑏𝑏𝑏
� + 1 
 Where, CT is transepithelial capacitance; Ca is apical capacitance; and Cbl is basolateral 
capacitance. In the quiescent state, Ca is much less than the Cbl, therefore CT ~ Ca (25). In the 
umbrella cells the Ca/Cbl ratio is approximately 1:5, therefore the CT is an underestimation of the 
Ca by ~ 20% (33).  
To determine CT a pair of Ag/AgCl electrodes is inserted into the mucosal and serosal 
hemichambers of the Ussing apparatus and a pulse of square current waveform (I, 0.001A) is 
applied. The voltage response is recorded and the curve is fitted in the formula: 
𝑉𝑉𝑇𝑇 = 𝑉𝑉𝑚𝑚𝑎𝑎𝑚𝑚. 𝑒𝑒−1 𝜏𝜏�    
Where VT is the voltage, Vmax is the maximum voltage, 𝜏𝜏 is the time constant, which is 
the length of time it takes for the voltage to reach 63% of the maximum or decay to 37% from 
the Vmax. The value of τ is calculated from the formula.  
The resistance (RT) is calculated using Ohm’s law: 
𝑅𝑅𝑇𝑇 = 𝑉𝑉𝑚𝑚𝑎𝑎𝑚𝑚𝐼𝐼  
From the RT and τ values, CT of the membrane is calculated using the formula: 
𝐶𝐶𝑇𝑇 = 𝜏𝜏𝑅𝑅𝑇𝑇 
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1.1.4 Note on using CT to determine the apical membrane surface area of umbrella cells 
 The uroepithelium consists of the outer umbrella cells, the intermediate cells and the basal cells. 
The CT is measured by inserting the electrodes on either sides of the uroepithelium. Then the 
question arises, will the presence of the intermediate and basal cells between the two electrodes 
interfere with the CT measurements?   
To measure membrane capacitance, the biological membrane in question must be able to 
separate charge across the membrane. In the uroepithelium, the intermediate and basal cells do 
not impede the flow of ions or in other words lack resistance and hence cannot separate the 
charge. Therefore, the RT of the uroepithelium is essentially the resistance provided by the 
umbrella cells. This was confirmed by Lewis et. al. in experiments where a single electrode was 
carefully advanced in steps through the rabbit uroepithelium from the mucosal solution to the 
serosal solution and the fraction of transepithelial voltage was measured at each step. This 
fraction equals the fraction of transepithelial resistance at each position. This analysis showed 
that the transepithelial resistance is entirely concentrated at the umbrella cell layer of the 
uroepithelium and is negligible for the intermediate and basal cells. Furthermore, unlike other 
epithelia like frog skin, no detectable transverse coupling was observed in the rabbit 
uroepithelium.  
From these two observations, it can be argued that the RT calculated using the Ussing chamber 
apparatus is the resistance across the umbrella cell layer. Therefore, the capacitance, which is 
measured using this RT value, is a true representation of the capacitance of the umbrella cell 
layer with no interference from the intermediate or the basal cells (14,15,34). This model of 
resistance-dependent measurement of CT is suited for tight epithelia such as the uroepithelium. 
The capacitance signal is lost when the umbrella cells are permeabilized, thus allowing 
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unimpeded flow of ions. Other more complex cellular circuit models to calculate membrane 
capacitance are available for epithelia with low impedance such as the epithelial lining of the gut 
and gall bladder (35-37).         
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 Figure 3 Equivalent circuit of the epithelial cells 
 
 
 A polarized epithelial cell with the apical and basolateral surfaces and the tight junction is 
presented. Superimposed on this cell is an equivalent electrical circuit showing the junctional 
resistor (RTJ), the apical resistor (Ra) and capacitor (Ca) and the basolateral resistor (Rbl) and 
capacitor (Cbl). 
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1.1.5 Apical membrane trafficking in umbrella cells 
The bladder is capable of modulating its surface area to accommodate a wide range of 
urine volumes. This is accomplished by membrane trafficking events that occur at the apical 
surface of the umbrella cells. These membrane trafficking events ensure that the integrity of the 
uroepithelium is maintained as the mucosa is subjected to mechanical stress as the bladder fills 
and voids. In addition, the exocytosis and endocytosis also ensures the turnover of UPs, 
receptors, ion channels and lipids that are expressed at the apical surface of the umbrella cells.  
1.1.6 Stretch-mediated apical exocytosis 
The idea that the mechanically stretching the uroepithelium triggers apical exocytosis 
was first suggested two sets of evidence: First, stereological analysis of electron micrographs 
revealed that the umbrella cells from full bladders had fewer DFVs in their cytoplasm than 
contracted bladders (38); and second, CT measurements showed that mechanical stretching or 
osmotic stress triggered increased in apical surface area of umbrella cells (26). Numerous studies 
have since shown that mechanical stretching triggers apical exocytosis of DFVs 
(25,27,28,39,40).  
1.1.6.1 Stretch-mediated exocytosis is biphasic 
Studies done so far indicate that stretch-mediated apical exocytosis is a biphasic event 
comprising of an “early phase” and a “late phase” (Figure 4). The two phases are triggered by 
distinct signals and are controlled by distinct cellular pathways. Studies performed in Ussing 
chamber apparatus revealed that the rate of early phase exocytosis was directly proportional to 
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the rate of filling of the mucosal chamber (41). The rate of exocytosis increased if the rate of 
filling was increased. The exocytic event was triggered by mechanical stretch and was not 
dependent on changes in luminal pressure. The signal transduction mechanism that triggered this 
response was independent of protein synthesis, temperature and inhibitors of secretion. Further, 
the data indicated that a Ca2+ wave, likely initiated by opening of mechanosensors such as 
epithelial sodium channels (ENaC) and non-selective cationic channels (NSCC) was responsible 
for the exocytosis. The Ca2+-induced intracellular Ca2+ wave was released from IP3-dependent 
stores inside the cell and removal of Ca2+ from the buffer inhibited the early phase exocytosis 
(41).  
In experiments that I performed, the early phase response resulted in a large increase in 
CT to ~120% of the starting value. The early phase response could reflect the physiological 
bladder filling where increase in bladder volume causes mechanical stretching of the mucosa and 
triggers the exocytosis of a pre-existing pool of DFVs to increase the surface area. Following the 
early-phase exocytosis is a rapid phase of stretch induced endocytosis, where >60% of the 
exocytosed membrane is recaptured. It is likely to be regulated by the same mechanism that 
triggers compensatory endocytosis (42). However, further investigation is required to decipher 
the molecular signals that trigger the endocytic response.  
The late-phase response is governed by a very different signal transduction pathway and 
is independent of NSCC and ENaC. The exocytosis is slow, resulting in the gradual increase in 
the apical surface area over many hours. Work done by Balestreire et al. indicated that stress 
induced by stretching the uroepithelium to its maximum capacity triggered late-phase exocytosis 
(43). The exocytosis was sensitive to metalloproteinase inhibitors, diphtheria toxin (a specific 
inhibitor of HB-EGF), required the transactivation of EGFR and activation of MAPK signaling. 
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Significantly, the exocytic response was sensitive to treatment with inhibitors of protein 
synthesis and secretion. However, the metalloproteinase involved in the pathway was not 
identified. Further, the identity of the protein(s) that were synthesized downstream of EGFR 
activation are not known (discussed in the Chapter 4). 
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Figure 4 Early and late phase exocytosis 
 
 
A. The three stages of membrane stretching are depicted. 1. The quiescent phase where 
the tissue is not exposed to mechanical stimuli by stretch.  There is no appreciable change 
in CT. 2. The tissue is bowed out by filling buffer in the mucosal chamber. This results in 
the stretch-mediated early phase response. 3. The tissue is subjected to stretch-mediated 
stress. The mucosal chamber is filled to capacity and then additional buffer is added to 
stretch the tissue. This triggers the stretch-mediated late phase exocytosis. B. A 
representative CT curve clearly showing the early phase response, the endocytosis that 
follows and the late phase response.   
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1.1.6.2 Regulation of stretch-mediated exocytosis 
The vital cellular components and signaling molecules involved in exocytosis of DFVs 
include the cytoskeleton, Ca2+ signaling, cAMP, and the cellular machinery involved in 
membrane fusion such as SNAREs (soluble N-ethylmaleimide-sensitive factor attachment 
protein receptors) 
Cytoskeleton 
The involvement of the cytoskeleton in membrane trafficking events has been well 
documented in polarized epithelial cells. Because the cells have a distinct apical and basolateral 
surfaces, the cytoskeleton plays an important role in the spatial segregation of membrane 
trafficking complexes and directed membrane fusion.  In other secretory cells such as acinar 
cells, the actin network forms a dense mesh at the apical surface called the terminal web. The 
secretory granules have to traverse this actin barrier (44). Thus it is suggested as a regulatory 
component of granular secretion. The umbrella cells have a cortical actin network at the apical 
pole that plays a role in regulated apical exocytosis (24,26). Preventing actin polymerization by 
treating the tissue with cytochalasin D blocked stretch-mediated increase in CT (41). Further, 
Khandelwal et al. reported that the actin motor myosin5b works in association with the small 
GTPases Rab11a and Rab8a to promote apical exocytosis in umbrella cells. Though the 
mechanism is not clear, the motor protein can aid in the transit of DFVs across the apical cortical 
actin network (24).  
Ca2+ signaling 
The role of Ca2+-mediated signaling in exocytosis has been well-studied in numerous 
cells types. In the uroepithelium, treatment with calcium ionophores triggered apical exocytosis 
even in the absence of stretch. Both extracellular Ca2+ and Ca2+ released from inositol-3-
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phosphate-dependent ERs stores promoted apical exocytosis (28). Work done by Yu et al. 
indicated that tissue bowing triggered Ca2+  entry into the umbrella cells possibly via opening of 
ENaC, NCSS and other mechosensory channels.  Further, removal of Ca2+ from the media 
blocked stretch-mediated exocytosis (41). 
 
cAMP signaling 
Another important signal that promotes stretch-mediated apical exocytosis is cAMP. 
Mechanical stimulation leads to increased cAMP levels in many mechanically sensitive tissues 
(45,46). In the uroepithelium, mechanical stretching triggered more than 2-fold increase in the 
cAMP levels. Further, activating cAMP with an analog of adenylyl cyclase, forskolin 
dramatically potentiated stretch-mediated apical exocytosis. Though the signaling pathway is not 
fully known, cAMP possibly acts via PKA-mediated signaling in promoting exocytosis (27). 
SNAREs 
Finally, an indispensable protein complex involved in membrane fusion is the SNAREs 
(47). Briefly, fusion of vesicles to its target membrane is mediated by the formation of a trans-
complex between the SNARE proteins on the vesicle (v-SNAREs) to its cognate SNARE partner 
found on the membrane (t-SNARE). The complex forms a four-helix bundle that zippers towards 
the fusion pore, thus bringing the vesicle and the target membrane close enough to promote 
fusion. The formation of the SNARE complex is regulated by Ca2+ signaling and other 
associated SNARE regulatory proteins. In umbrella cells v-SNAREs synaptobrevin and t-
SNAREs syntaxin-1 and SNAP-23 have been reported (48).  They were found to colocalize with 
UPIIIa and the apical plasma membrane. These SNAREs are important for the fusion of DFVs to 
the apical surface. Though the SNARE regulatory proteins such as synaptotagmin and Sec-
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1/Munc-18-like proteins have not been reported so far in the umbrella cells, further investigation 
is required to identify how the SNARE machinery is regulating DFV exocytosis.   
 
Other proteins involved in membrane trafficking 
Aside from the cytoskeleton, Ca2+ signals and SNAREs, the signaling proteins such as 
the Rab family of small GTPases play a vital role in DFV exocytosis in umbrella cells. The 
uroepithelium expresses multiple Rab family proteins including Rab4, Rab5, Rab8, Rab11a, 
Rab13, Rab15, Rab25, Rab27, Rab28 and Rab32 (4). Rab 8, Rab11a and Rab27b are especially 
interesting because they are expressed in the umbrella cells and colocalize with DFVs. Blocking 
activity of Rab8 or Rab11a by expressing a dominant negative version of the protein in the 
umbrella cells impairs stretch-mediated apical exocytosis (22,49). Rabs function as adaptor 
proteins that tether DFVs to the cell’s cytoskeleton via molecular motors such as myosin5B and 
aid in the intracellular trafficking of the DFVs.  
At least one other proteins called myelin-and-lymphocyte (MAL), is known to be 
involved in apical membrane fusion. In experiments performed in MDCK cells, MAL did not 
affect apical sorting of UPs but impaired the rate apical incorporation of the protein (50).  
 The coordinated function of these signaling proteins and complexes mediated 
stretch-induced apical exocytosis in umbrella cells. 
  
1.1.7 Endocytosis 
The added membrane at the apical surface are reinternalized via endocytosis. Endocytosis 
upon voiding was first visualized by Minsky et al. who discovered the formation of new vesicles 
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upon removal of stretch (38). The rapid internalization of membrane upon release of stretch is 
called compensatory endocytosis (CE) (44,51).  Studies done by Khandelwal et al. elucidated the 
signaling events that govern CE (42). The endocytosis was initiated by increased tension at the 
basolateral surface as the umbrella cell expands, and resulted in the activation of β1-integrins. 
The endocytosis was triggered by a β1-integrin-dynamin-actin- and RhoA-associated pathway. 
The DFVs were internalized via a clathrin, caveolin and flotillin independent bulk endocytosis 
pathway and were destined to the lysosome for degradation.    Interestingly, CE in umbrella cells 
is similar to the endocytosis that follows the exocytic release of neurotransmitters from neurons 
and neuroendocrine cells such as insulin secreting cells, further highlighting the sensory nature 
of the cells (51,52). 
 
1.1.8 Exocytosis in the absence of stretch 
Intriguingly, DFVs are also trafficked when certain apically localized cell-surface 
receptors are activated. For instance, activation of apically localized epidermal growth factor 
receptors (EGFR), ATP receptors or adenosine receptors (AR) trigger apical membrane 
trafficking (23,43,53). However, the physiological significance of this receptor-induced 
membrane trafficking and the cellular machinery that regulates it is poorly understood. The focus 
of my work was to better understand how umbrella cells respond to extracellular stimuli such as 
activation of apically localized A1 adenosine receptors.  
To fully understand how umbrella cells respond to extracellular biochemical stimuli and 
how this might trigger membrane trafficking, an understanding of the sensory web of the 
uroepithelium, the receptors expressed on the umbrella cells and the neuronal circuitry of the 
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bladder are required. In the next section, I will introduce the sensory signaling web of the 
uroepithelium.  
 
1.2  THE UROEPITHELIAL SENSORY WEB 
1.2.1 Introduction 
The uroepithelium was long viewed a passive barrier that merely holds urine until voiding. This 
has changed over the years because of four critical observations: 1. Data showing that the 
uroepithelium is innervated; 2. Umbrella cells express numerous receptors that are associated 
with neuroendocrine cells and nerves; 3. The uroepithelium releases factors such as hormones 
and neurotransmitters that could potentially modulate bladder function by stimulating underlying 
muscles and nerve processes and 4. Adding substances such as ATP into the bladder lumen 
triggers bladder contraction.    
 
 
1.2.2 The neural circuitry of the urinary bladder: 
The efferent nerves: 
Bladder function is regulated by three sets of nerves: the sympathetic thoracolumbar 
(hypogastric) nerve, the parasympathetic sacral (pelvic) nerve and the sacral somatic 
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motorneuron (pudandal) nerves (Figure 5). The sympathetic innervations of the bladder arise 
from the thoracolumbar region (T11-L2). It is divided into two groups: those fibers that innervate 
the main bladder and those that innervate the bladder neck and the urethra (54). During bladder 
filling, the sympathetic fibers release norepinephrine (NE) that binds to β-adrenergic receptors in 
the smooth muscles and cause bladder relaxation. At the neck of the bladder and urethra, the NE 
released from the sympathetic fibers bind α-adrenergic receptors and trigger muscle constriction 
and closing of the inner urethral sphincter (54,55).   
The parasympathetic nerve processes arise from the sacral spinal cord (S2-S4) and 
innervate the bladder walls. These nerves release acetylcholine (ach) and ATP that bind to M3 
muscarinic receptor and P2X receptors respectively on the smooth muscles and trigger bladder 
contraction. The parasympathetic nerves also innervate the inner urethral sphincter, where it 
releases NO leading to relaxation of the smooth muscle and opening of the outlet (54).  
Bladder voiding in higher mammals in controlled by the group of cells located in the 
pontine medial tegmentum region of the brain, also called the pontine micturition center (PMC). 
PMC is the ultimate efferent nucleus that controls bladder voiding. Neurons arising from the 
PMC end in the S2-S4 sacral region, where they meet the parasympathetic nerves that innervate 
the bladder. Micturition is initiated in the PMC, travels down the spinal cord to the sacral region 
and trigger the parasympathetic neurons to release Ach and NO leading to bladder voiding (56-
58).    
The somatic nerves innervate the striated muscles of the outer urethral sphincter and 
regulate its function. During bladder filling they release ach that bind to nicotinic receptors on 
the striated muscles (54). During bladder voiding, PMC trigger inhibitory GABAergic and 
glycinergic neuron which mediate relaxation of the striated muscles (59). Thus the PMC 
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coordinates the contraction of the smooth muscles on the bladder walls and the relaxation of the 
striated muscles on the outer urethral sphincter resulting in the expulsion of urine.  
Afferent nerves: 
Sensory information from the bladder is conveyed to the spinal cord via the afferent 
pelvic and hypogastric nerves. The afferent component of the bladder consists of the myelinated 
Aδ fibers and the un-myelinated C-fibers. The Aδ fibers communicate mechanosensory 
information such as bladder fullness and interluminal volume change. The C-fibers on the other 
hand respond to noxious stimuli such as urethral infection and irritation and are the chief pain 
receptors of the bladder (55,60,61). 
Interestingly, ultrastructural and biochemical studies in humans have revealed that the 
afferent nerve processes that innervate the bladder namely the small myelinated Aδ or 
unmyelinated C fibers extend their dendritic processes deep into the uroepithelium, and rest close 
the basolateral surface of umbrella cells (62,63). Further, in animal studies, mechanical 
stretching of the bladder mucosa resulted in excitation of the afferent nerves which in-turn 
resulted in activation of the sympathetic fibers that innervate the bladder walls and urethral 
sphincter (64). However, the precise modulatory compound released by the uroepithelium on 
mechanical stretching is unknown, and whether these compounds activate the Aδ and C-fibers is 
not well understood. Nevertheless, these studies add weightage to the mechanosensory role of 
the uroepithelium. A likely scenario is that changes in mechanical forces such as stretching or 
release of neuro-modulatory factors such as ATP, adenosine and Ach from the uroepithelium are 
likely to directly bind and excite afferent nerve process leading to modulation of bladder 
function. 
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Figure 5 The neural circuitry of the urinary bladder 
 
The efferent pathway is depicted by the downward facing arrow heads.NE released from the 
hypogastric nerves (red) bind β-adrenergic receptors on the bladder walls and α-adrenergic 
receptors present on the inner urethral sphincter. Ach is released from the Pelvic nerves (green) 
that innervates the bladder walls and bind M3 receptors. NO is released from the Pelvic nerves 
that innervate the inner urethral sphincter. The pudendal nerves (blue) release Ach that bind to 
nicotinic receptors present on the striated muscles of the outer urethral sphincter. The afferent 
pathway is depicted by the upward facing arrow heads.     
      
 24 
1.2.3 Receptors and ion channels expressed on the apical and basolateral surfaces of the 
umbrella cells: 
The repertoire of receptors and ion channels expressed on the apical and basolateral 
surfaces of the umbrella cells are curiously similar to that found on nociceptive and 
mechanosensory cells. The sensory receptors and ion channels identified on these cells till date 
includes ATP receptors (P2X1–7and P2Y 1,2,4) (65-67), adenosine (A1,A2a,A2b and A3) (53), EGFR 
(EbbB1-3) (43),  norepinephrine (α and β), acetylcholine (muscarinic, M1-5 and nicotinic) 
(68,69), protease-activated receptors (PARs), amiloride- and mechanosensitive epithelial sodium 
channels (ENaC) (28), bradykinin receptors (B1 and B2) (70), and various TRP channels 
including TRPV1, TRPV2, TRPV4, TRPM8 and TRPA1 (63,71).  
Though the physiological importance of these receptors in regulating bladder function is 
not fully understood, it is possible that the presence of these receptors enables the umbrella cells 
to sense extracellular biochemical stimuli and modulate bladder function accordingly. For 
example EGF and HB-EGF present in the urine or released from the uroepithelium can bind to 
EGFR expressed on the umbrella cells, whereas mechnosensory cues such as mechanical stretch 
during bladder filling can act on mechanosensors such ENaC and NSCC (41,72). The 
downstream result of receptor activation is twofold, it alters the membrane trafficking events in 
the umbrella cells (via early and late phase exocytosis) and releases neurotransmitters and 
sensory compounds such as neurotrophins, vascular endothelial growth factor (VEGF), 
corticotrophin releasing factor (CRF1andCRF2) and estrogens (ERα and ERβ),  and peptides 
such as substance P, pituitary adenylate cyclase-activating peptide (PACAP) and calcitonin gene-
related peptide that can bind efferent and afferent nerve process and regulate bladder function by 
modulating sensory transmission from the spinal cord (60,71,73,74). 
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1.2.4 Release of hormones, neurotransmitters and signaling molecules from the 
uroepithelium: 
There is considerable evidence to show that the release of the signaling compounds from 
the uroepithelium impacts bladder activity under both normal and pathologic conditions. For 
example, uroepithelium release numerous hormones, neurotransmitters, and signaling peptides 
including ATP, adenosine, Ach, prostaglandins, prostacyclin, nitric oxide (NO), and other 
cytokines (23,53,75,76). Incidentally, the afferent sympathetic and parasympathetic nerves which 
innervate the uroepithelium carry receptors for these molecules (61,68,77). Therefore, it is 
tempting to believe that these modulatory compounds can bind and excite the afferent nerve-
processes, thereby modulating bladder function. There is some evidence in support of this 
hypothesis: For instance, intravesical instillation of oxyhemoglobin to oxidize luminal NO 
resulted in bladder hyperactivity (78). Further, in experiments where the uroepithelium was 
removed from the underlying musculature,  the detrusor muscles showed increased contractile 
response, suggesting that regulatory factors released from the uroepithelium have an inhibitory 
effect on the detrusors (79). The compound that caused this effect is however not known, and 
termed uroepithelium derived inhibitory factor (UDIF), but is likely to be NO, adenosine or 
GABA, or mediated by calcium and potassium channels (79). Another possible mechanism of 
activating the afferent neurons is by triggering Ca2+ waves, which originate from the basolateral 
surface of the umbrella cells, and are amplified as they traverse through the intermediate cells 
and basal cells (71).  
In summary, the “input”, which are biochemical compounds present in the urine and 
mechanical forces can activate receptors and ion channels on the umbrella cells. The umbrella 
cells in response to the ‘input’ can alter their apical surface are by modulating membrane 
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trafficking events or release signaling factors, the “output”, which can be picked up and sensed 
by the detrusors and afferent nerve processes and thus results in regulation of bladder function. 
 
Figure 6 The sensory web of the umbrella cell 
 
 
The most prominent cell surface receptors that have been studied to understand the 
sensory function of the uroepithelium are presented.  
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1.2.5 Conclusion 
Despite the wealth of information regarding ‘input’ and ‘output’ signals, the receptors and ion 
channels expressed on the umbrella cells and the innervation of the bladder, we still lack 
information regarding the precise signaling events in the umbrella cells downstream of the 
‘input’ signal and how these signals alter the membrane trafficking events in the cell or modulate 
bladder function. One of the chief modulators that have a big impact on the regulation of other 
organs is adenosine. Adenosine is a well-known stress response hormone in other organ systems 
and is known to play a beneficial role especially in the heart and brain (80,81). Because the 
bladder lumen is a stressful environment, and because we have evidence that adenosine is 
released in the mucosal and serosal surfaces of the uroepithelium during stress, a promising 
candidate to study the sensory function of the uroepithelium is adenosine and it’s associated 
signaling.   
1.3 ADENOSINE RECEPTORS 
1.3.1 Introduction  
 The idea that adenosine, could function as an extracellular signaling molecule was put forth by 
Alan Drury and Albert Szent-Györgyi in 1929. They found that injecting cardiac extracts 
intravenously into the whole animal caused a transient slowing of the heart rate. On further 
purification of the extract, they determined that the factor that caused the slowing of the heart 
was an “adenine component”(82). The field of adenosine signaling has progressed exponentially 
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since this initial finding, and today intravenous injection of adenosine is the mainstay treatment 
for rapid relief from supraventricular tachycardia and cardiac arrhythmia (83,84).   
 
 
1.3.2 Extracellular adenosine 
Adenosine is released from most tissues in the body into the extracellular space, from where it 
acts as an autacoid on adenosine receptors. The extracellular adenosine levels in the heart has 
been estimated to be ~100 nM and in the brain ~30 nM under normal physiological states 
(85,86). However, in severe ischemic stress conditions, the levels can rapidly increase. In 
circulation, adenosine has an extremely short half-life of < 5 seconds. It is released from 
intracellular stores via concentrative or equilibrative bi-directional nucleoside transporters 
(CNTs and ENTs, respectively) or formed in the extracellular space by the metabolism of ATP 
or cAMP (Figure 7). CNTs are Na+ - dependent. CNT 1 is primarily localized on epithelial cells 
whereas CNT 2 and CNT 3 are widely expressed in other tissue types (87). ENTs transport 
adenosine across the plasma membrane and play an important role in the provision of nucleoside 
derived from diet and synthesis (88). ENT1 and 2 are widely expressed in organs including liver, 
heart, testis, spleen, kidneys, brain, placenta, thymus, prostrate, and skeletal muscles. The cation 
dependent ENT 3 and 4 are more sparsely expressed. ENT3 is particularly abundant in the 
placenta and ENT4 is predominantly found in the heart and endothelial cells (89).  Extracellular 
ATP is broken down by the ectonucleotidases, of which there are several different classes and 
have promiscuous nucleotidase function or show substrate and tissue specificity. Ecto-
Nucleotide triphosphate diphosphohydrolase (E-NTDPases, CD39) hydrolyze extracellular tri- 
 29 
and di-phosphates, converting ATP  ADP  AMP. Ectonucleotide pyrophosphate 
phosphodiesterases converts cAMP  AMP. Ecto-5’nucleotidases (CD73) converts AMP  
adenosine (90). Adenosine can be rephosphorylated back to AMP by ecto-adenosine kinase or 
acted upon by ecto-adenosine deaminase and broken down to inosine which is the final product 
of adenosine metabolism. Inosine is broken down to hypoxanthine by the removal of the ribose 
sugar by the action of purine nucleoside phosphorylases (PNP). Hypoxanthine is converted to 
xanthine and that in-turn is metabolized to uric acid by the action of xanthine oxidase. Uric acid 
is the final product of purine metabolism and is excreted in the urine.    
 
Figure 7 Extracellular adenosine synthesis and turnover 
 
ATP released from nucleotide channels (NC) and via exocytosis is converted to 
ADPAMPAdenosine. Adenosine can be converted back to AMP, bind adenosine receptors 
(AR), taken back into the cell by CNTs and ENTs (NT) or degraded to inosine.  
 
 30 
1.3.3 A brief overview of G-protein coupled receptors (GPCRs) 
As adenosine receptors are GPCRs, a brief overview of GPCR biology is warranted to better 
understand the cellular functions of the receptors.  
Domain architecture and downstream signaling components of GPCRs 
GPCRs are single polypeptides with seven transmembrane α helices. The N-terminus 
faces the extracellular region whereas the C-terminus is in the cytoplasm. The seven 
transmembrane α helical region gives rise to three extracellular and intracellular loops. The 
extracellular loops are regions of glycosylation and the intracellular loops have conserved amino 
acid sequences that are essential for the internalization and degradation of the receptor. The third 
intracellular loop and the C-terminal tail together form the binding site for G-proteins (hence the 
name for the receptors) (91). 
G-proteins are called so because they are guanine-nucleotide regulatory protein 
complexes. Based on their activity, the G-proteins are divided into Gi (inhibits adenylyl cyclase 
activity), Gs and Golf (stimulates adenylyl cyclase), Gq/11 (activates phospholipase C), G0 
(stimulates K+ ion channels) and G12 (activates Rho guanine exchange factors) (92). The G-
proteins are normally in a tight heterotrimeric complex, consisting of α, β and γ subunits. Ligand 
binding causes conformational changes in the 6th loop of the receptor and leads to the formation 
of receptor-G-protein complex.  Here Gα which is initially bound to GDP (guanosine 
diphosphate) switches to an active GTP-bound state by the action of the GEF (guanine exchange 
factor) domain. The GTP-bound active Gα uncouples from the Gβγ subunits, which is free to 
interact with other downstream signaling proteins. The GTP-bound state is however short-lived, 
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and the G-proteins revert back to the GDP-bound state and re-associate with the βγ subunits to 
form the “resting” heterotrimeric conformation (93,94). 
 
1.3.4 Types of adenosine receptors 
Extracellular adenosine is a potent cytoprotective agent under both normal physiological 
conditions and when organs undergo stress (95,96). The protective response can be in the form 
of increasing blood supply via vasodilation (97), ischemic preconditioning that protects against 
subsequent episodes of ischemia (98-100) or suppression of inflammation and its associated 
production of free radicals and cytokines, infiltration of inflammatory cells (101-103). 
Extracellular adenosine can perform these functions by binding to specific cell surface receptors 
and activating specific signal transduction pathways. As mentioned earlier, adenosine binds to 
four GPCRs termed A1, A2A, A2B and A3. The A1 and A3 receptors are coupled to the Gi protein 
whereas the A2 receptors are coupled to the Gs or Go proteins. Their affinities to adenosine are 
A1>A2A>A3>A2B, (Ki of 10-30nM for A1 and A2A,  ~1μM for A3 and > 1μM for A2B) (104). In 
addition to Gs and Go proteins, A2B receptors, which have the lowest affinity to adenosine, also 
have the ability to activate Gq proteins (105). Physiological adenosine levels are thought to 
activate only few adenosine receptors, owing to the varying binding affinities of the receptors 
and the short half-life of the nucleoside. However, under stressful conditions such as ischemia, 
when the levels of extracellular adenosine increase rapidly, an all-out generalized activation of 
all the adenosine receptor subtypes can be observed (106,107). Recently it was reported that the 
human growth-hormone secretagogue receptor (GHS-R) also accepts adenosine as a partial 
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agonist in cell culture, in addition to its endogenous ligand ghrelin, and is likely to modulate the 
release of dopamine from hypothalamic neurons (108,109). 
The G-proteins that are coupled to adenosine receptors are defined by the downstream 
activation states of adenylyl cyclase. However, they are not the only effectors of adenosine 
receptors. In fact, the far reaching physiological relevance of adenosine is because of the wide 
array of downstream signaling cascades triggered by the adenosine receptors. These actions of 
adenosine receptors may be initiated through the Gβγ subunit of the G-proteins. They include 
activation of phospholipase C (PLC) (110,111), phosphoinositide 3-kinase (PI3K) (112), 
mitogen-activated protein kinase (MAPK) (113), extracellular receptor signal-induced kinase 
(ERK), arrestins and coupling to ion channels (113).  
1.3.5 A1 adenosine receptors (A1AR) 
 A1AR was the first identified adenosine receptor (hence the name) and incidentally this 
receptor was identified as a binding substrate for caffeine (114). They are coupled to Gi-proteins 
and are ubiquitously expressed. The role of A1AR in the central nervous system (CNS) and heart 
have been especially well studied. A1Ar is abundantly expressed in brain where it plays a major 
neuroprotective role by decreasing the release of excitatory neurotransmitters such as glutamate. 
A1AR, acting via Gi-proteins decreases cAMP levels, opens K+ channels and reduces calcium 
influx by blocking Ca2+ channels leading to inhibition of neurotransmitter release (115-118).  
In the heart, the dramatic increase of adenosine during myocardial ischemia was first 
demonstrated in 1970 (119). Since then a growing body of evidence has shown that adenosine 
acts as a ‘sensor’ of imbalances in energy supply and demand and a local regulator of coronary 
flow (120,121). Studies on A1AR-/- mice have shown that the receptor is involved in aortic and 
 33 
coronary vasoconstriction and protects the heart against injury caused by myocardial infracture 
and ischemia by inhibiting the production of cAMP and activating ATP-dependent potassium 
channels (122,123). In addition, cardiac-specific A1AR overexpression studies showed that the 
receptors were involved in reduction of diastolic dysfunction during ischemia/reperfusion and 
prolonged cardioprotection (124). Interestingly, it has been reported that the role of A1AR in 
cardio-protection could depend on its ability to transactivate EGFR (discussed later). 
In the kidney, adenosine modulates glomerular filtration rate (GFR), and prevents 
hypoxic injury in the renal medulla. The A1AR induces vasoconstriction in the afferent arterioles 
and the A2 receptors cause vasodilation in the post-glomerular arterioles, the concerted action of 
the adenosine receptors ensure smooth glomerular filtration and kidney function. A1AR-
mediated vasoconstriction occurs through Gβγ-mediated activation of PLC and its associated 
downstream signaling (125). Other functions of A1AR activation at the different sections of the 
nephron include: increase in reabsorption of fluid, Na+, HCO3- and phosphates in the proximal 
tubule, inhibition of NaCl reabsorption in the medullary thick ascending limb, uptake of Mg2+ 
and Ca2+ in the cortical collecting duct and counteraction of vasopressin effects in the inner 
medullary collecting duct (126-128).    
Despite the beneficial roles of A1AR, the activity of this receptor under certain 
pathological conditions could lead to deleterious effects. Numerous reports have been made 
where activation of A1AR during inflammation or pathological conditions has adverse effects. 
For instance: the expression of A1AR is upregulated in asthma patients and activation of the 
receptors lead to bronchoconstriction, leukocyte activation and inflammation, bronchial hyper-
responsiveness and mucous secretion (129,130). At least one anti-A1AR therapeutic drug (EPI-
2010) to treat asthma is currently in clinical trials (131). In diabetes and obesity, A1AR is highly 
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expressed in the adipose tissues and inhibition of lipolysis is mediated by adenosine acting on 
A1AR (132,133).  Further, in the urinary bladder, antagonism of A1AR reduced inflammation 
(134). Also, in my studies, I found further evidence in support of this, as activation of A1AR 
triggered smooth muscle excitability and bladder over-activity in cyclophosphamide-induced 
cystitis studies (further discussed in Chapter 2). Finally, there is evidence that A1AR antagonism 
resulted in reduced myocardial fibrosis and albuminuria in a model of uremic cardiomyopathy 
(135). These data indicate that, while A1AR has a beneficial role under normal physiological 
conditions, during many pathological conditions and inflammation its activity further 
exacerbates the pathological state.  
1.3.6 A2 and A3 adenosine receptors (A2AR and A3AR) 
Though the focus of this dissertation is on A1AR-medaited signaling, the uroepithelium express 
the other three adenosine receptors as well (53), thus a brief overview of the physiological role of 
A2 and A3 receptors will be beneficial in understanding the overall function of adenosine in the 
bladder.  
 
A2AR 
As mentioned earlier, there are two A2ARs: A2A and A2B. They are coupled to Gs and 
Gq/11 proteins and hence perform an excitatory function. As with A1AR, they are also 
ubiquitously expressed in the body including smooth muscles, vascular, intestinal, bronchial, 
chromaffin tissues, mast cells, heart, kidneys, lungs, and brain (136). They modulate cellular 
function by stimulating the production of inositol triphosphate (IP3)/diacylglycerol by the 
activation of PLC. They play a major role in manifestation of many diseases including asthma, 
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inflammation, wound healing, cancer, reperfusion injury of the heart and neurodegeneration 
(137). 
Physiologically, the role of A2 receptors in modulating organ function depends on their 
ability to limit inflammation and tissue injury.  A2A receptors are highly enriched on 
inflammatory cells including neutrophils, mast cells, macrophages, eosinophils, platelets, and T-
cells (138,139). The anti-inflammatory properties of the receptors include inhibiting T-cell 
activation and limiting the production of inflammatory mediators such as IL-12, TNF-α and INF-
γ (140,141).  
 In support of their role in immune suppression, studies have shown that in human 
neutrophils, activation of A2A reduces neutrophil adherence to the endothelium, inhibits formyl-
Met-Leu-Phe (fMLP)-induced oxidative burst and inhibits superoxide anion generation (142). 
Further, A2A-/- mice have increased oxidative stress in the lungs and airway smooth muscles due 
to activation of inducible nitric oxide synthase (iNOS) and nicotinamide adenine dinucleotide 
phosphate (NADPH), two event which are normally kept under control by action of A2A(143). 
In contrast, A2B activation aids in the progression of inflammatory diseases such as 
asthma. A2B can activate Gq proteins, and downstream cytokines including IL-4, IL-8 and IL-13, 
which can in-turn induce immunoglobulin E (IgE), the immunoglobulin involved in progression 
of allergic response and asthma (144,145). Hence antagonist therapy against A2B to treat asthma 
has been proposed. However, the full role of A2B in asthma progression is yet to be understood 
(131). 
In the brain, unlike A1AR which has a direct impact on neurotransmitter release at 
neuronal synapses, the functions of the A2 receptors in the brain rely predominantly on their 
ability to generate an immune response in the induction of long-term brain response to trauma 
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and ischemia (117). A2A occurs predominantly on the neurons in the striatum, cholinergic 
interneurons, hippocampus, cerebral cortex, nucleus accumbens and olfactory tubercles 
(117,146,147). A2B are distributed at low levels in the brain with moderate expression in the 
human cerebellum and hippocampus (95,148). There has been special interest in A2A/D2 
dopamine receptor interactions, because of its implications in the manifestation of Parkinson’s 
disease and basal ganglia dysfunction (149).  
In summary, A2 receptors are beneficial in instances where inflammation is a detrimental 
component, but adversely effects treatment of cancer or neurological diseases where an immune 
response is required. For instance, upregulation of A2 receptors protects cancer cells from attack 
by T-cells, and in fact A2A-/-  mice showed a remarkable decrease in tumor size and increased 
survival rate (150). 
A3AR  
A3AR were the last members of the adenosine receptor family to be cloned. It is 
expressed in the testes, lungs, kidney, heart and brain. Though, the distribution of the receptor in 
the brain differs by species (151). A3 receptors are also highly expressed in the inflammatory 
cells including human eosinophils, neutrophils, monocytes, macrophages, lymphocytes and 
dendritic cells. It is coupled to Gi proteins and hence has an inhibitory role on adenylyl cyclase, 
similar to A1AR (152).  
A3 receptor activation on immune cells has both pro- and anti-inflammatory responses 
and hence their role in progression of inflammatory diseases is controversial. Initially A3 agonist 
therapy was suggested for treating asthma, because of their role in mast cell degranulation (153). 
However, the impact of A3 receptors on mast cells has been challenged by many groups which 
claim that the response is actually mediated by A2AR (145,154,155). In addition, selective A3 
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antagonism prevented airway eosinophilia and mucous production in adenosine deaminase 
knockout (ADA-/-) mice. Similar results were found in ADA-/-/A3-/- double knockout mice 
suggesting that A3 activation plays a detrimental role in chronic lung diseases (156).  
The contradicting roles of A3 are evident in other organ systems also. For instance, the 
beneficial role of A3AR was demonstrated in murine septic peritonitis, where activation of the 
receptor decreased mortality and renal and hepatic injury. The effect was the result of blocking 
the release of TNFα, IL-12 and IFNγ (157,158). Similarly, A3 activation plays a protective role 
in lung injury and protection of skeletal muscles from ischemia and reperfusion injuries 
(159,160). On the other hand, its detrimental role was shown in studies where activation of the 
receptor exacerbates renal dysfunction and the expression of the receptors is increased in ocular 
ischemic diseases and in conditions with oxidative stress (161,162). 
1.3.7 Positive and negative impact of adenosine signaling 
Extracellular adenosine has an impact on most of the tissues and organ systems in the body by 
acting on its four receptors. It is apparent from the preceding section that all four adenosine 
receptors have both beneficial and detrimental effects. A1AR predominantly has a positive role in 
most organisms. Adenosine, binding and activating A1AR imparts neuro, cardio, skeletal- and 
smooth muscle-protection. Similar beneficial functions stem from A2AR receptor activation. The 
anti-inflammatory function of A2AR receptors are currently being aggressively studied for 
therapy against numerous auto-immune and other inflammatory diseases (163,164). However, it 
is also clear that activation of A1 and A2AR under pathological conditions such as inflammation 
of the gut, bladder overactivity and inflammatory disease such as asthma further exacerbates the 
pathological state. Therefore, adenosine receptors mediated therapeutics have to be approached 
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with caution, and a fuller understanding of the receptor biology under physiological and 
pathological states is necessary. 
Furthermore, it is interesting to note the gradient of adenosine having a beneficial 
function when activating A1AR and A2AR and beneficial and detrimental effects when activating 
A2bAR and A3AR. Intriguingly, this pattern reflects the affinity of adenosine to the receptors. As 
mentioned earlier, adenosine binding affinity is A1>A2a>A3>A2b. Excessive extracellular 
adenosine would activate A2b and A3 receptors whereas normal physiological levels of adenosine 
would primary activate A1 and in some cases A2a receptors. Hence, the level of adenosine in 
systemic circulation, i.e. extracellular adenosine may also be a deciding factor on whether it has 
a beneficial role or a detrimental role. 
1.3.8 Role of adenosine in membrane trafficking and EGFR transactivation 
Despite our deep understanding of the role of adenosine signaling in normal and physiological 
states in many organs we lack information on the role of adenosine in regulating the urinary 
bladder. Furthermore, though we understand AR’s role in activating or inhibiting cAMP, we do 
not have much knowledge of the other signaling pathways downstream of AR activation. 
Interestingly, William-Pritchard et al. recently reported that the cardioprotective role of A1AR 
occurs via EGFR transactivation. In mice heart perfusion experiments, they found that inhibitors 
of metalloproteinases, HB-EGF and EGFR blocked adenosine agonist-mediated reduction of 
post-ischemic diastolic pressure (290). In addition, studies performed on rat ventricular myocytes 
indicated that, A1AR stimulation lead to membrane localization of PKCδ (165). Further, in Cos-7 
cells, the Gβγ-subunit of A1AR stimulated PLC activation (111). PLC activation and PKC-
membrane localization are classic upstream signals for activation of membrane bound 
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metalloproteinases (described later) that lead to cleavage and release of EGFR ligands leading to 
EGFR transactivation. Because adenosine is released during bladder stress and because stress-
mediated late phase exocytosis requires EGFR transactivation, in the second part of my 
dissertation, I tested the hypothesis that A1AR transactivates EGFR in umbrella cells leading to 
apical exocytosis.   
 
1.4 GPCR-MEDIATED EGFR TRANSACTIVATION 
1.4.1 Introduction 
  Signal transduction pathways inside the cell are seldom linear events leading to a single 
endpoint. In most cases, signaling cascades are interconnected and proper cellular function 
requires the coordinated cross-communication between myriad signals. One of these intriguing 
‘cross-talk’ between cellular pathways is the phenomenon where GPCRs transactivate EGFR.  
Numerous GPCR ligands including Ach, bradykinin, adenosine and LPA, on binding to their 
respective receptors trigger a signal transduction pathway that leads to activation of certain 
membrane-bound metalloproteinases. These metalloproteinases, in-turn cleave membrane-bound 
EGFR ligands and release them into the extracellular space. The released EGFR ligands bind and 
activate EGFR and leads to ERK/p38 MAPK pathways (166-176).  EGFR transactivation is 
responsible for numerous stimuli-dependent cellular modulation, including protein synthesis, 
exocytosis, endocytosis, proliferation, and differentiation (175-181).  
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1.4.2 EGFR 
EGFR signaling is one of the most extensively studied areas of signal transduction. The ligands 
that bind and activate EGFR are EGF, heparin-binding EGF (HB-EGF), amphiregulin, 
transforming growth factor alpha (TGF α), epiregulin, neuregulin and betacellulin (182,183). 
EGFR belongs to the ErbB family of receptor tyrosine kinases, which also includes ErbB2, 
ErbB3 and ErbB4 (184). Umbrella cells express EGFR, ErbB2, and ErbB 3 (43). The receptors 
are expressed as single-pass membrane proteins. On ligand-binding they form hetro or 
homodimer and catalyze the phosphorylation of tyrosine residues in the cytoplasmic tail of the 
receptors  (185-187).  
The phosphorylated tyrosine residues serve as docking sites for phosphotyrosine binding 
scaffolding proteins including SH2 or PTB (phosphotyrosine binding) domain containing 
proteins (188). The adaptor proteins that contain the SH2 domains, such as Grb2 and docking 
proteins such as Gab1, LAT and Dos assemble a signal transduction complex which triggers 
ERK and p38 MAPK, phosphatidylinositol3-phosphate-Akt pathway and the p70S6k/p85S6K 
pathway (186,189,190). Which pathway is triggered and the potency of the pathway depends on 
the ligand that binds and activates the EGFR, and the EGFR heterodimer pair.  The signal 
transduction pathways that are initiated trigger distinct transcription programs in the nucleus. 
This is achieved by activating fos, jun, myc proto-oncogenes, zinc-finger containing transcription 
factors including Sp-1 and Egr-1 and GA-binding proteins (173,191,192). The output of this 
complex signaling network is cell proliferation, differentiation, adhesion, migration, apoptosis, in 
embryonic development and cellular remodeling (193,194).     
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1.4.3 Transactivation 
The first report on GPCR transactivating EGFR was discovered in 1996 by Axel Ullrich. They 
found that activation of GPCR in Rat-1 fibroblasts with lysophosphatidic acid (LPA) and 
endothelin-1 lead to the tyrosine phosphorylation of a 170kD glycoprotein. Further analysis 
revealed that this glycoprotein was EGFR (191). This was a landmark finding in cellular 
signaling and initiated a salvo of studies across the world to determine the molecular events that 
lead to EGFR transactivation and the identification of the proteins players involved in this 
intriguing pathway.   
Soon after the initial discovery, the transactivation pathway was discovered in a variety 
of cell types including PC 12 cells, astrocytes and vascular smooth muscle cells and was 
established as a widely relevant pathway towards activation of MAPK (171,195). GPCRs 
coupled to Gi and Gq proteins are known to be involved in this pathway. Studies performed on 
PC12 cells, vascular smooth muscle cells, intestinal epithelial cells and ovarian cancer cells 
showed that activation of GPCRs with ligands including Angiotensin II (AngII), bradykinin, 
endothelin-1 or carbachol resulted in a Gq-dependent spike in intracellular Ca2+ concentration 
that resulted in EGFR transactivation (178,195-197). Whereas in other cell types such as 
gonadotropin αT3-1 cells and rat liver epithelial cells, activating GPCRs with gonadotropin 
releasing hormone, AngII or bradykinin triggered a  GiPKC pathway that resulted in EGFR 
transactivation (198,199). Furthermore, in COS-7 and HEK293 cells, activation of Gi via β2 
adrenergic receptor resulted in transactivation of EGFR via a Src-dependent pathway (200).  
The transactivation pathway (figure 8) 
In addition to GPCRs, ROS, UV irradiation, mechanical and sheer stress also trigger  
EGFR transactivation (177). While there are still numerous gaps in our understanding of the 
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precise signaling pathway leading to transactivation, there seem to be few signaling molecules 
that play a major role in the pathway. I will focus on GPCR-mediated EGFR transactivation as 
that is relevant to this dissertation. EGFR transactivation by GPCRs is triggered by the Gβγ 
subunits and requires second messengers such as elevation of intracellular Ca2+, activation of 
PKC, Src or reactive oxygen species (169).  
While many second messengers are known to be involved in activation of ADAMs, most 
pathways seem on converge on PKC-mediated activation. The diacylglycerol analog PMA has 
been used in numerous studies to activate ADAMs.  PKC activates membrane bound 
metalloproteinases called ADAMs (described in the next section). The precise mechanism of 
activation is not clear and has been the focus of numerous research studies around the world. 
Data so far indicate that PKC could directly phosphorylate ADAMs or activate indirectly via 
other secondary messengers such as p38 MAPK and ERK1/2 (201,202).  ADAMs, on activation, 
cleave membrane-bound EGFR ligands. Following cleavage and release, the soluble EGFR 
ligands are free to bind EGFR and trigger receptor dimerization and phosphorylation in an 
autocrine or paracrine fashion. Subsequently ERK1/2 and/or p38 MAPK pathways are initiated 
leading to activation of transcription factors, which initiate numerous signaling pathways 
characteristic of EGFR signaling such as cell differentiation or proliferation, secretion of 
chemokines and hormones, autophagy, apoptosis, and cell migration (179). 
As mentioned earlier, in the uroepithelium stress induced by mechanical stretching 
trigger EGFR transactivation leading to apical exocytosis. However, the metalloproteinase 
involved, or the upstream signals that triggered it are not known. In my studies, I found that 
adenosine is released from the uroepithelium in response to mechanical stretching and activation 
of apical A1AR triggered apical exocytosis that mirrored late phase stretch-mediated apical 
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exocytosis. Further, I report that the exocytosis was dependent of EGFR transactivation, and 
ADAM17 is the metalloproteinase that mediated this pathway. In the following section, I will 
introduce ADAMs and ADAM17 in particular.   
Figure 8 EGFR transactivation 
 
The numerous extracellular stimuli that trigger EGFR transactivation, the known intermediate 
molecules, the list of ADAMs that cleave the EGFR ligands and the list of EGFR ligands that are 
involved in the transactivation pathway are shown. 
 44 
1.5 A DISINTEGRIN AND A METALLOPROTEINASE (ADAM) 
1.5.1 Introduction 
ADAMs (a disintegrin and a metalloproteinase) belong to the family of metalloproteinases called 
metzincins. They contain a zinc cation at their active site which imparts the catalytic property of 
these enzymes (203). Structurally, they closely resemble class III snake venom metalloenzymes 
or reprolysins. To date 21 functional ADAM proteins have been identified in the human genome, 
out of which only 13 have the HEXXHXXGXXHD motif, a  characteristic of the reprolysin-type 
catalytic site, and hence are presumed to be catalytically active (204).  
 Of the catalytically active ADAMs, 20, 21 and 30 are expressed in the testis and play 
roles in the capacitation of the sperm and fusion of sperm and egg. ADAMs 9, 10, 12, 15, 17, 19 
and 33 are widely expressed in somatic cells and are involved in the ecotodomain processing of 
numerous transmembrane proteins (204,205). Though not widely studied, ADAMs 9, 12, 11, 15 
and 28 display splice variants (206-209). At least one report has shown that ADAM17 displays a 
splice variant called SPRACT consisting of mostly the cytoplasmic tail (210). The physiological 
relevance of the splice variants and their role in ectodomain shedding are not well understood. 
1.5.2 Subcellular localization, domain architecture and functional regulation of ADAMs 
ADAMs are single pass transmembrane proteins that contain an N-terminal signal sequence, 
followed by a pro-domain, a metalloproteinase domain, a cysteine-rich domain, an EGF-like 
domain, transmembrane domain and a cytoplasmic tail. Studies indicate that the functional site 
of the protein is at the cell surface (201,211,212). However, other reports have suggested that the 
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metalloproteinase activity of ADAMs 10, 17 and 19 can also be detected in intracellular 
compartments (213,214).  
The catalytic domain has the conserved HEXXH motif (215,216). The active site 
contains a zinc ion and water atoms that are required for the hydrolytic processing of the 
substrates. The processing is aided by three histidines and a methionine which faces the 
conserved motif [refer to (217) for the structure of the catalytic site].  
The disintegrin domain gets its name because of high sequence similarity to snake-venom 
disintegrins (218). Disintegrins found in viper venom functions as an inhibitor of platelet 
aggregation and integrin-dependent cell adhesion. They contain the RGD peptide sequence, that 
binds with great affinity to the integrin IIa and IIb receptors on the surface of blood platelets and 
prevent aggregation by blocking fibrinogen binding. However, with the exception of ADAM15, 
none of the ADAMs contain the RGD motif which is a functionally important amino acid 
sequence present in the snake-disintegrins. Nevertheless, the disintegrin domain and cysteine 
rich domain have been suggested to play a role in the substrate specificity of the ADAMs 
(219,220).   
The cytoplasmic tails of ADAMs contain numerous motifs that may play important roles 
in the post-translational modification of the protein.  
1.5.3 ADAM17 
ADAM17, discovered in 1997 by two separate groups, is the metalloproteinase responsible for 
the cleavage and release of membrane-bound tumor necrosis factor-α (TNF-α). Therefore, it is 
also called TNF-α cleaving enzyme (TACE) (215,216). Because of the crucial role played by 
TNF-α in inflammation, the identification of the metalloproteinase that processes the cytokine 
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was a significant discovery. It is a transmembrane protein spanning 824 amino acids in humans 
and 827 amino acids in rats and mice.  It is widely expressed in most tissues including heart, 
lungs, brain, kidney, skeletal muscles and the bladder (205). In addition, ADAM17-mediated 
ectodomain cleavage plays an important role during embryonic development (221).  
Because of the wide array of substrates that ADAM17 handles, it has a major impact in 
the manifestation of many diseases. Elevated ADAM17 levels were found in patients suffering 
from inflammatory diseases such as osteoarthritis, rheumatoid arthritis and early systemic 
sclerosis. Further, ADAM17 plays an indirect role in inflammatory disease manifestation by 
cleaving a host of molecules such as L-slectins, JAM-1 and V-CAM which play critical roles in 
leukocyte activation and diapedesis (205,222). The role of ADAM17 in pulmonary 
inflammation, psoriasis, inflammatory bowel disease, septic shock, Alzheimer’s disease, multiple 
sclerosis, cardio-vascular diseases, diabetes, kidney disorders and a wide range of malignancies 
have also been discovered (205). These reports further highlight the significant role played by 
ADAM17 in normal physiology. Therefore, it is clinically relevant to understand how ADAM17 
is regulated at the transcriptional, translational and post-translational level.   
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Figure 9 ADAM17 domain architecture 
 
 
 
ADAM17 domain architecture: The different domains of ADAM17 once it reaches the cell 
surface are shown. The known phosphorylation sites in the cytoplasmic tail are also shown.   
 48 
1.5.4 Molecular structure and regulation of ADAM17 activity  
ADAM17 protein consists of the following domains: a signal sequence (1-17aa), a prodomain 
(18-214aa), a catalytic domain which contains the HEXXHXXGXXHD domain (215-473aa),   a 
disintegrin domain (474-572aa), a cysteine-rich domain (603-671aa), a transmembrane domain 
(672-694aa), and a cytoplasmic tail (695-824aa in humans and 827aa in rats and mice) (Figure 
9). The protein has numerous N-glycosylation sites, which may play a role in the regulation of its 
function.  Similar to other ADAMs the prodomain maintains the catalytic site in an inactive state. 
In a protein chimera study where ADAM9 and ADAM10 prodomains  were used to inhibit 
ADAM17 catalytic function, the key inhibitory amino acid was identified as Phe72 and the Asp-
Asp-Val-Ile (residues 134-137) motif (223). Others have identified a 19-amino acid leucin-rich 
region from amino acids 30-48 to play role in partial ADAM17 autoinhibition (224). The 
prodomain is however cleaved by furin at the last four amino acids (Arg-Val-Lys-Arg) preceding 
the catalytic site as the protein traverses through the trans-Golgi network (225,226). 
Interestingly, reports have indicated that the prodomain remains non-covalently bound to the 
mature ADAM17 even after furin-mediated cleavage, and plays a role in the proper trafficking of 
the enzyme (227,228).   
The catalytic domain cleaves ectodomains of numerous substrates, but the substrate 
specificity and the identity of the amino acid sequences identified in the substrates by ADAM17 
is not clearly understood. While in TNFα, the sequence was identified to be Ala76/Val77 (-Arg-
Ser-Ser-Ser) (229), in growth hormone receptor proteolysis, the cleavage site was identified as 
the eighth residue from the cell membrane (226). It is believed that the sequence of the substrate 
is less important when compared to the position of the sequence. ADAM17 seems to prefer 
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cleaving ectodomains at the ‘stalk region’ between the transmembrane region and the first 
globular part of the extracellular domain of the substrates.  
The catalytically active form of ADAM17 is released from the trans-Golgi network and 
reaches the cell surface. However, the enzyme does not indiscriminately cleave substrates, it 
requires a secondary signal, such as activation of GPCRs, ROS, UV irradiation or mechanical 
sheer stress to initiate a signaling pathway that ‘triggers’ ADAM17 to cleave its substrates. A 
prominent question in the field of ADAM17 research is: how do external stimuli trigger 
ADAM17 activity?  
1.5.5 Regulation of ADAM17 activity 
Inside-out signaling 
Understandably, the cytoplasmic-tail of ADAM17 has been intensively studied to 
identify protein binding partners that activate an inside-out signal response. These studies are 
driven by the fact that the 130aa length cytoplasmic tail of ADAM17 has a rich array of 
conserved motifs and protein binding sites. It contains a potential tyrosine phosphorylation site 
DKKLDKQYESL proximal to the transmembrane domain and an SH-3 binding site (731-738) 
PAPQTPGR. Thr735 in the cytoplasmic tail has been shown to be phosphorylated by ERK and 
p38 in response to phorbol-ester (PMA) and EGF treatments in transfected HEK293 cells 
(202,230). Other studies have shown that Ser819 is phosphorylated by ERK in response to PMA, 
though the phosphorylation did not seem to affect the activity of the protein. Interestingly, it was 
shown that Ser791 undergoes dephosphorylation in response to growth factor stimulation (210).  
Though numerous studies have used PMA as an activator of ADAM17, few studies have 
focused on physiological activation of the enzyme. Zhang et.al showed that phosphoinositide 
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kinase-1 (PDK1) directly phosphorylates serine and threonine residue in the cytoplasmic tail in 
response to activation by the GPCR-ligand gastric releasing peptide (231). In another study, 
mechanical stretching triggered src-mediated phosphorylation ADAM17 at Tyr702 in C2C12 
cells (232).    
Apart from phosphorylation studies, numerous proteins have been found to be bound to 
the cytoplasmic tail of the enzyme. Yeast two hybrid (Y2H) studies revealed that Mitotic arrest 
deficient (MAD2) protein bound between residues 706-740 in the cytoplasmic tail of ADAM17 
(233). Though the functional significance of this interaction is not clear, the data indicates that 
ADAM17 plays a role in cell cycle progression. Furthermore Y2H studies identified SAP9, 
which promoted ADAM17 activity by binding to the cytoplasmic domains of ADAM17 and 
TGFα (234). A possible mechanism of ADAM17 regulation could be via binding partners such 
as SAP9 that bind both the cytoplasmic tails of the substrate and the enzyme and thus brings 
them into closer proximity. Y2H studies also identified Eve-1, which also promoted catalytic 
function of the enzyme (235). Another protein, four-and-half LIM domain 2 protein (FHL2) 
interacts with ADAM17 between amino acids 721-739 and also the cytoskeleton and hence 
could potentially regulate the localization and activity of the enzyme (236). A study showed that 
that cytoplasmic tail of ADAM17 and ADAM10 interact with ACE-s (angiotensin converting 
enzyme-2) and facilitate entry of severe acute respiratory syndrome (SARS) causing coronavirus 
into the host cells (237).  
While these data underscore the importance of the cytoplasmic tail of ADAM17 and 
suggests an inside-out mechanism of regulation, where phosphorylation or binding of other 
protein partners could modulate the catalytic activity of enzyme, another set of studies indicate 
that the cytoplasmic tail of the enzyme is dispensable for the catalytic activity of the protein.  
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Cytoplasmic-tail-independent ADAM17 regulation 
Blobel et. al has shown that the ADAM17 constructs which lacked the cytoplasmic tail 
were still functional and trafficked to the cell surface which is the site of activity of the enzyme 
(238,239). In support of this, others have found that PKC-mediated phosphorylation of the 
substrate but not the enzyme or conformational changes in the substrate are critical for the 
substrate specificity and function of the enzyme (166,240). Further, the redox state of two highly 
conserved cysteine-X-X-cysteine group in the dinsintegrin domain of the enzyme is also known 
to play an important role in regulating ADAM17 activity, as discovered by its role in L-selectin 
secretion (241).   
In conclusion, we still require a deeper understanding of the mode or function of 
ADAM17 and how it is regulated by a complex network of cellular signals that integrate 
extracellular stimuli with intracellular events such as protein trafficking, exocytosis, endocytosis 
and cellular morphological changes.       
Tissue inhibitors of metalloproteinases 
Tissue inhibitors of metalloproteinases (TIMPs) are endogenously expressed proteins that 
bind and inactivate metalloproteinases. TIMP3 is released into the extracellular space, where it 
binds directly to the catalytic domain to ADAM17 in a 1:1 ratio. It is thought to be highly 
specific for ADAM17 (242). TIMP3 binds to the catalytic site of ADAM17 and keeps it in a 
dormant state. The enzyme regains activity when TIMP3 binding is removed (243). Therefore, 
many studies have focused on the activity of TIMP3 in regulating ADAM17. In a fascinating 
model that was recently reported, TIMP (possible dimers) binds ADAM17 dimers at the cell 
surface and keeps the enzyme in the inactive state. On activation of the enzyme by 
phosphorylation of the cytoplasmic tail, the dimerization is disrupted, thus removing TIMP3 
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inhibition. How exactly phosphorylation leads to monomerization of ADAM17 is yet to be 
understood, but a possible mechanism could be: phosphorylation could lead to binding of yet 
unknown proteins to the cytoplasmic tail of ADAM17 that causes monomerization of the 
enzyme (244). This data however, has been refuted by a study which found that TIMP3 binding 
does not affect ADAM17 activation (238). 
1.5.6 Role of ADAM17 in EGFR transactivation 
The role of ADAM17 in activating EGFR is of particular importance to this dissertation 
and hence warrants a brief overview of what is known so far in this regard. The ectodomain 
shedding function of ADAMs is one of the most well studied features of these 
metalloproteinases. The consequence of ectodomain shedding is to allow a membrane-tethered 
growth factor or cytokine to participate in paracrine signaling or enter the blood stream and carry 
the signal to distant regions. Although other somatically expressed ADAMs including ADAM 9, 
12 and 15 have been shown to process EGFR ligands, knockout studies revealed that these 
ADAMS are not essential for EGFR activation (245). However, ADAM17 and ADAM10 
together act as molecular switches that regulate the proteolytic processing of all seven known 
EGFR ligands. Specifically, ADAM17 was found to be the physiological metalloproteinase 
involved in the processing of EGFR ligands including TGFα, HB-EGF, epiregulin, epigen and 
amphiregulin (245,246).  
   
An important landmark in the study of ADAM17 came in 1998 when in vivo studies in 
Adam17ΔZn/ΔZn mice (which contain a mutation in the ADAM17 active site) revealed that these 
animals had abnormalities that resemble TGFα -/- such as defective maturation and 
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morphogenesis of epithelial structures including eyelid fusion and defective release of pro-TGFα 
(247-249). Exon deletion studies and genetically modified mice expressing ADAM17 versions 
lacking several key residues displayed the classic woe (waved with open eyes) phenotype which 
is a hallmark of defective EGFR signaling (250). In addition, Adam17ΔZn/ΔZn mice die between 
embryonic day 17.5 and their first day of birth with numerous defects including those that affect 
their eyes, their coat, and several of their organs. Furthermore, the phenotypes observed in 
Adam17ΔZn/ΔZn mice are phenocopied in TNFα-/-, TGFα-/-, HB-EGF-/- knockout mice, or mice 
expressing an uncleavable form of HB-EGF (221,247,249,251,252), findings that are consistent 
with a critical role for ADAM17 in EGFR transactivation. Finally, those phenotypes associated 
with defective EGFR activity (e.g. open eyes at birth and defects in heart-valve morphogenesis) 
are observed in ADAM17-/- mice, or in quadruple ADAM9-/-, ADAM12-/-, ADAM15-/-, and 
ADAM17-/- mice, but not in triple ADAM9-/-, ADAM12-/-, and ADAM15-/- mice (245). These 
results provide further evidence that of these four ADAM members, ADAM17 is likely to be the 
“physiologically” relevant metalloproteinase for EGFR transactivation. Based on these studies, it 
is now universally accepted that ADAM17 along with ADAM10 are important for EGFR 
transactivation under normal physiological conditions.  
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1.6 EGFR TRANSACTIVATION IN MEMBRANE TRAFFICKING  
1.6.1 Overview of the physiological importance of EGFR transactivation 
Cross-communication between diverse signaling pathways is essential for the translation 
of complex environmental stimuli into appropriate cellular reactions and adaptations. The 
transactivation phenomenon has placed EGFR at the convergence point of diverse extracellular 
stimuli. Cellular signaling components including GPCR ligands, cytokine and chemokines, cell 
adhesion elements, and environmental factors including UV and gamma radiation, osmotic 
shock, membrane depolarization, heavy metal ions, reactive oxygen species and sheer stress all 
trigger signaling pathways which result in activation of ADAMs (especially ADAM17), leading 
to the release of one or more of the seven EGFR ligands, which in-turn bind and activate EGFR 
(177). Thus EGFR signaling is critical for most functions of the cell and aberrant signaling can 
results in numerous developmental defects, metabolic disorders and cancer.  
1.6.2 EGFR transactivation in secretion and membrane trafficking 
One feature of polarized epithelial cells that is of special interest is membrane trafficking and 
exocytosis.  Little is known about the role of EGFR transactivation in membrane trafficking. 
Previous work from Dr. Apodaca’s lab have shown that mechanical stretching of the 
uroepithelium results in a late phase, slow apical exocytosis of umbrella cells, that is dependent 
on EGFR transactivation. However, the upstream signaling events or the metalloproteinase that 
is involved in the transactivation was unknown (43). Kanno et.al reported that in goblet cells that 
line the upper and lower epithelial lining of the eyelids, activation of M1 and M2 muscarinic 
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GPCR triggered EGFR transactivation and exocytosis resulting in secretion of mucin. The 
pathway involved the activation of Pyk2 and Src, which in-turn lead to EGFR phosphorylation. 
However, the ADAM involved in the transactivation pathway was not determined (176). In 
prostate cancers, parathyroid hormone-related protein (PTHrP), which plays an important role in 
bone formation and development, is released in higher amounts by the malignant organ. Yano, 
et.al reported that the secretion of PTHrP was a result of activated calcium sensing receptors 
transactivating EGFR. The phosphorylation was sensitive to inhibitors of MMPs and HB-EGF. 
However, the identity of the MMP or ADAM was once again not determined (253). Similarly 
EGFR-transactivation-mediated secretion of interlukin-8, urokinase-type plasminogen, 
collagenase-1 and numerous other secretory components have been reported (254-256). More 
recently, Mostov, et.al reported that transcytosis of activated polymeric immunoglobulin G 
receptors in polarized epithelial cells is dependent on Rab11a-mediated EGFR transactivation 
(257).  
These studies underscore the role played by EGFR transactivation in membrane 
trafficking and exocytosis. However, a fuller understanding of the transactivation pathway, the 
upstream signals that trigger the pathway, the identity of the metalloproteinase (ADAMs) , how 
the ADAMs are activated, and how they cleave they selectively cleave EGFR ligands are not 
clear. One of the goals of this dissertation was to understand the signaling mechanism that links 
A1AR-mediated signaling to EGFR transactivation and how it impacts membrane trafficking 
events of umbrella cells.    
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1.7 GOALS OF THIS DISSERTATION 
1.7.1 Broad focus of this dissertation 
I undertook this study to understand the role played by adenosine receptors in regulating 
bladder function. It is the offspring of two seemingly disparate sets of evidence that were 
previously reported. Yu et.al reported that A1AR is expressed at the apical surface of the 
umbrella cells and mechanical stretching of the uroepithelium resulted in release of adenosine 
from the apical and basolateral surfaces of the umbrella cells (53). Further, activation of the 
apically localized A1 receptors results in slow apical exocytosis, the kinetics of which was 
similar to stretch-mediated late phase exocytosis (53).  In the second study, Balestreire et.al 
reported that mechanical stretching of the uroepithelium results in EGFR-dependent late phase 
apical exocytosis (43). This dissertation is a bridge between the two studies. The goal of this 
dissertation is to understand a global picture of the cellular events of the umbrella cells where 
diverse signals and extracellular stimuli converge onto a common pathway and results in 
membrane trafficking. 
1.7.2 Goal 1: To study the mechanism behind adenosine release and turnover in the 
bladder and understand the physiological relevance of the same 
In the first study I focus on adenosine release and turnover at the apical and basolateral 
surfaces of the umbrella cells. As mentioned earlier, the umbrella cells express all four adenosine 
receptors and release adenosine from the apical and basolateral surfaces on mechanical 
stretching. The goal was to study the impact of this adenosine released upon stretching on the 
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overall regulation of bladder activity. I found that the level of adenosine on the mucosal surface 
of the uroepithelium is kept in check by adenosine deaminase and ENTs whereas the serosal 
adenosine levels were regulated by adenosine kinase. Further, specific activation of A1AR at the 
apical surface of the umbrella cells lowered the threshold pressure of bladder voiding. 
Intriguingly, in cyclophosphamide-induced bladder hyperactivity, I found that activation of the 
A1AR exacerbated the condition and did not ameliorate it as expected. Similar results were later 
reported by Aronsson et.al (134).  
1.7.3 Goal 2: To understand how activation of apically localized A1AR triggered apical 
exocytosis in umbrella cells 
In the second section of this dissertation, I focused on the signaling events downstream of 
A1AR activation that lead to apical exocytosis. Intriguingly, activation of apically localized 
A1AR triggered an exocytic response at the apical surface of umbrella cells that was very similar 
to the late phase stretch-mediated apical exocytosis. In addition, the exocytosis required protein 
synthesis and was sensitive to treatment with Brefeldin A. Because, these results were similar to 
EGFR transactivation-mediated late phase exocytosis, I tested the hypothesis that A1AR 
triggered apical exocytosis by transactivating apical EGFR. This hypothesis indeed turned out to 
be true and ADAM17 was identified as the critical player that linked A1AR signaling to EGFR 
transactivation. ADAM17 is expressed at the apical surface of the umbrella cells and activation 
of A1AR by a receptor specific agonist triggered an A1ARGiGβγPLCPKC signaling 
cascade that resulted in ADAM17 activation. ADAM17 in-turn cleaved HB-EGF which 
activated EGFR and initiated downstream ERK1/2 signaling leading to protein synthesis and 
exocytosis. Further, ADAM17 was also found to be important in stretch-mediated EGFR 
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transactivation and exocytosis though the signaling pathway that links mechanical stretching to 
ADAM17 activation is yet to be identified. 
1.7.4 Summary 
In summary, this dissertation furthers our understanding of the role of adenosine in regulating 
bladder function and A1AR-mediated membrane trafficking in umbrella cells. This work also 
underlines the importance of EGFR signaling in regulating membrane trafficking umbrella cells. 
Interestingly, ADAM17 has emerged from this study as a critical membrane protein that is at the 
epicenter of various signaling networks. It acts as a converging point for stretch- and A1AR-
mediated membrane trafficking pathways and hence a better understanding of the function and 
regulation of ADAM17 is warranted.    
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2.0  MODULATION OF BLADDER FUNCTION BY LUMINAL ADENOSINE 
TURNOVER AND A1 RECEPTOR ACTIVATION 
2.1 ABSTRACT 
The bladder uroepithelium transmits information to the underlying nervous and musculature 
systems, is under constant cyclical strain, expresses all four adenosine receptors (A1, A2A, A2B 
and A3), and is a site of adenosine production. Although adenosine has a well-described 
protective effect in several organs, there is a lack of information about adenosine turnover in the 
uroepithelium or whether altering luminal adenosine concentrations impacts bladder function or 
overactivity. We observed that the concentration of extracellular adenosine at the mucosal 
surface of the uroepithelium was regulated by ecto-adenosine deaminase and by equilibrative 
nucleoside transporters, whereas adenosine kinase and equilibrative nucleoside transporters 
modulated serosal levels. We further observed that enriching endogenous adenosine by blocking 
its routes of metabolism or direct activation of mucosal A1 receptors with 2-chloro-N6-
cyclopentyladenosine (CCPA), a selective agonist, stimulated bladder activity by lowering the 
threshold pressure for voiding. Finally, CCPA did not quell bladder hyperactivity in animals with 
acute cyclophosphamide-induced cystitis but instead exacerbated their irritated bladder 
phenotype. In conclusion, we find that adenosine levels at both surfaces of the uroepithelium are 
modulated by turnover, that blocking these pathways or stimulating A1 receptors directly at the 
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luminal surface promotes bladder contractions, and that adenosine further stimulates voiding in 
animals with cyclophosphamide-induced cystitis. 
2.2 INTRODUCTION 
Adenosine is a ubiquitously occurring nucleoside that is important for the homeostasis of diverse 
organ systems including the kidneys, heart, lungs, and brain (96,258,259). It is found both 
intracellularly and in the extracellular space, and its concentration in these compartments is 
dependent on its biogenesis and turnover (260,261). The intracellular pool of adenosine is 
synthesized de novo by the hydrolysis of S-adenosylmethionine or is generated from the 
nucleotidase-dependent breakdown of ATP to ADP to AMP to adenosine. The extracellular pool 
of adenosine is also formed from the hydrolysis of ATP by ecto-nucleotidases or alkaline 
phosphatases or by metabolism of cAMPs to AMPs to adenosine. In addition, sodium-coupled 
concentrative or equilibrative nucleoside transporters shuttle adenosine in a concentration-
dependent manner between the intracellular and extracellular compartments (262). The turnover 
of extracellular and intracellular adenosine is mediated by two enzymes: adenosine deaminase 
and adenosine kinase, which decrease adenosine by converting it to inosine or AMP, respectively 
(263-266). When present, adenosine elicits its effects on tissues by binding to and activating one 
or more members of a family of four heptahelical G-protein coupled receptors, which have 
distinct affinities for adenosine where A1 > A2A > A2B > A3 (95,99,267,268). The receptors are 
further differentiated based on their coupling to downstream heterotrimeric G proteins: A1 and 
A3 receptors couple to Gi, whereas the A2 receptors couple to Gs. 
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Adenosine can counteract the effects of excitatory mediators such as ATP and also has a 
well-known protective effect in several organs (267). An example of the former is observed in 
the brain, where activation of the A1 receptor has a sedative, anticonvulsant, and locomotor 
depressing effect, as opposed to the excitatory effects of P2X receptor activation by ATP (269). 
A prominent example of the protective effect of adenosine is seen in the heart, where during 
periods of metabolic stress and inflammation the concentration of extracellular adenosine 
increases by several orders of magnitude (99,270). Furthermore, when this organ is 
experimentally stimulated to produce large amounts of adenosine by exposure to short bouts of 
ischemia and reperfusion, there is a cardio-protective effect that limits tissue damage when the 
heart is exposed to a subsequent, larger occlusion (124,271). This effect is mediated downstream 
of adenosine receptors, which stimulate proteins kinase C (PKC) and may act to alleviate stress 
by stimulating NO production through induction of iNOS (95,270). Likewise, treatment with an 
A1 receptor agonist such as 2-chloro-N6-cyclopentyladenosine (CCPA) is also cardio-protective 
and similar roles for adenosine and its receptors have been identified in kidney and airway 
epithelial cells exposed to acute ischemic injuries (126,272-274). In contrast, adenosine can also 
potentiate events including the stimulation and activation of immune cells. For instance, 
activation of A2B receptors in T84 cells stimulates secretion of IL-6, resulting in a Ca2+ -mediated 
pro-inflammatory signaling loop (275,276). 
The role of adenosine in other organs and tissues, such as the bladder uroepithelium, is less 
well understood even though this tissue is exposed to high concentrations of waste products and 
is in a physiologically taxing environment that is in constant flux as the bladder fills and empties. 
Furthermore, the uroepithelium is not just a high resistance barrier but can act as a sensory 
transducer, responding to chemical and mechanical stimuli at its luminal surface by releasing 
 62 
mediators such as ATP, acetylcholine, adenosine, or NO from its basal side (1,71). In turn, these 
mediators transmit information to the underlying nervous and muscular systems, altering bladder 
function. Interestingly, all four adenosine receptors are expressed in the uroepithelium and this 
tissue is also a site of adenosine production (53), but the mechanism(s) of adenosine turnover at 
the mucosal or serosal surface of the uroepithelium is unknown. Furthermore, the A1 receptor is 
prominently expressed at the apical surface of the outermost umbrella cell layer and activation of 
this receptor by the mucosal addition of adenosine causes the umbrella cells to add apical 
membrane (53). However, it is not known if stimulating this lumen-facing receptor has any 
impact on overall bladder function, nor is there information about whether increasing adenosine 
concentrations can be used to quell or modulate bladder hyperactivity.   
Using isolated rabbit uroepithelial tissues mounted in Ussing stretch chambers, we find that 
adenosine production is increased during periods of extended stress. The mechanism for 
modulating adenosine turnover at the mucosal surface of this tissue is adenosine deaminase or 
equilibrative nucleotide transporters, while adenosine kinase and nucleoside transporters keep 
adenosine levels in check on the basal surface. We also observe that the A1 receptor agonist 
CCPA or drugs that impair adenosine turnover significantly lower the threshold pressure needed 
to trigger voiding in the bladders of rats undergoing cystometry. Furthermore, A1 receptor 
activation causes an increase in detrusor activity in animals acutely treated with 
cyclophosphamide, decreasing the cycle time between voids. Our results indicate that the 
uroepithelium, particularly in response to stress, is an active site of adenosine production and 
turnover. Furthermore, increasing luminal adenosine by blocking its turnover or stimulating A1 
receptors with CCPA lowers the threshold pressure for voiding in normal bladders and increases 
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the voiding frequency of bladders with acute cystitis. The latter effect appears to be independent 
of changes in A1 receptor expression or distribution in the uroepithelium. 
 
Figure 10 Adenosine turnover at the mucosal surface of the uroepithelium 
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 (A) Schematic of adenosine biosynthesis and turnover in the intracellular and extracellular 
spaces. Intracellular adenosine is formed either by the conversion of S-adenosylmethionine 
(SAM) to S-adenosylhomocystine (SAH) to adenosine, or by the hydrolysis of ATP. The latter is 
expelled from the cells via nucleotide channels (NC). The extracellular ATP is converted to 
adenosine by the ecto-nucleotide triphosphate diphosphohydrolases (NTDPases) ecto-NTDPase 
(CD39) and ecto-5’ nucleotidases (CD73). Extracellular adenosine can have multiple fates: 1) 
transport back into the cell by nucleoside transporters (NT); 2) binding to and activation of 
adenosine receptors (AR); 3) metabolism to inosine by adenosine deaminase; or, 4) conversion to 
AMP by ecto-adenosine kinase. (B-D) Rabbit uroepithelium was mounted in Ussing stretch 
chambers, and pretreated with the indicated drug for 60 min prior to start of experiment. The 
tissue was left in its quiescent state for 60 min and then stretched by increasing the fluid in the 
mucosal chamber for 30 min. The tissue was then left in this stretched state for an additional 60 
min. Samples were drawn at the indicated times and then analyzed by mass spectrometry to 
determine the concentration of adenosine, inosine and AMP. The experiment was performed on 
three separate occasions and the data are expressed as mean ± SEM (control n=7, EHNA n=7, 
IDT n=7, NBTI n=4). Statistically significant differences (p<0.05) between control samples and 
treated ones are indicated with an asterisk. 
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2.3 RESULTS 
2.3.1  Distinct pathways for adenosine biogenesis are found at the mucosal and serosal 
surfaces of the rabbit uroepithelium  
Isolated rabbit uroepithelium is ideal for studying adenosine biosynthesis and turnover because 
the tissue can be manipulated in a physiologically relevant manner and samples can be taken 
from both the mucosal and serosal surfaces of the tissue. We previously showed that the 
adenosine concentrations increased in the fluid bathing isolated rabbit uroepithelium mounted 
between two halves of an Ussing stretch chamber (53). Furthermore, in response to an abrupt 
change in stretch, there was a large increase in the amount of adenosine found in both 
hemichambers of the device (53). To gain a better understanding of the relationship between 
adenosine production and bladder filling, we again used these isolated rabbit preparations, but 
employed the following stretch protocol. First, following washing, we incubated the tissue for 60 
min in the absence of stretch to measure baseline production of the nucleoside. Then, to mimic 
the filling phase of the bladder micturition cycle, the mucosal hemichamber was slowly filled for 
~ 30 min during which time the tissue was in a dynamic state as it slowly bowed outwards. At 
the 90 min mark, when the tissue had completely bowed outwards, filling was stopped and the 
tissue was incubated for an additional 60 min under this potentially more stressful “filled” state. 
At the indicated time points, we took samples and then measured, using ultra performance liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), the concentration of adenosine, 
inosine, or AMP in the mucosal (Figure. 10) or serosal (Figure. 11) hemichambers of the stretch 
device.  
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Figure 11 Adenosine turnover at the serosal surface of the uroepithelium 
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 (A-C) Tissue was treated as in Figure 1, but samples were taken and analyzed from the serosal 
surfaces of the tissue. The data are expressed as means ± SEM (control n=7, EHNA n=7, IDT 
n=7, NBTI n=4). Statistically significant differences (p<0.05) between control samples and 
treated ones are indicated with an asterisk.   
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We found that the concentrations of adenosine, AMP, and inosine slowly increased in the 
mucosal hemichamber during the first 60 min when the tissue was left un-stretched (Figure. 10 
B-D). While the levels of adenosine remained somewhat stable during the period of experimental 
filling (i.e. 60-90 min; Figure. 10 B), the concentrations of inosine and AMP increased by 
~100% or ~50%, respectively (Figure. 10 C-D). By 90 min, and during the subsequent 60 min 
incubation in the presence of continual stretch, there was a pronounced increase in the 
concentration of the three nucleosides (Figure. 10 B-D).  
Next, we used inhibitors of enzymes known to be critical for adenosine turnover and 
assessed their impact on the levels of adenosine, AMP, and inosine. Inhibitors employed 
included: the adenosine deaminase inhibitor EHNA (262), the adenosine kinase inhibitor IDT 
(277), or the general blocker of the widely expressed equilibrative nucleoside transporter-1 NBTI 
(278) (Figure. 10 A). None of these drugs affected the production of adenosine in unstretched 
tissue or during experimental filling. However, by 90 min the concentration of adenosine in the 
EHNA-treated tissues was significantly increased by ~140% above that observed in the untreated 
samples (Figure. 10 B). The other drugs appeared to have some effect on the amounts of mucosal 
adenosine, but these effects did not reach statistical significance. A precursor-product 
relationship between mucosal adenosine and the other two nucleosides we examined was not 
clear-cut (Figure. 10 C-D). For example, the inosine concentrations trended downwards in tissue 
treated with the adenosine deaminase inhibitor EHNA but the effect was not significant. 
Furthermore, treatment with the nucleoside transporter inhibitor NBTI did not alter adenosine 
concentrations, but did significantly impact inosine concentrations in the absence of stretch or 
during filling (compare Figure. 10 B to 10 C).  
 70 
Similar measurements were made at the serosal surface of the tissue (Figure. 11). We found 
that the levels of adenosine, AMP, and inosine gradually increased over the length of the 
experiment; however, in these control samples there was no obvious change in rates of 
nucleoside production during the varying tissue manipulations (Figure. 11 A-C). In contrast, 
treatment with the adenosine kinase inhibitor IDT caused a significant increase in serosal 
adenosine toward the end of experimental filling, raising its concentration by ~160%, and was 
also stimulatory after the 90-min time point (Figure. 11 A). Furthermore, the nucleoside 
transporter inhibitor NBTI also caused a large increase in the concentration of serosal adenosine, 
an effect that was especially enhanced at time points ≥ 90 min (Figure. 11 A). In contrast, we 
found no evidence that adenosine deaminase plays a significant role in modulating adenosine 
concentration at the serosal surface of the uroepithelium. In general, there was no obvious 
correlation between effects of the drug treatments on adenosine versus its metabolites AMP or 
inosine (Figure. 11 A-C). However, treatment with the nucleoside transport inhibitor NBTI 
increased inosine concentrations by ~130% during the end of the experimental filling phase, 
continuing into the period of extended stretch (Figure. 11 B).  The AMP levels were generally 
unaffected by any of the drugs, expect for two time points which showed large variations in 
values (Figure. 11 C). 
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Figure 12 Effect of EHNA, NBTI, or IDT on adenosine release in the rat bladder 
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 (A-C)  Rat bladders were filled with PBS containing DMSO (control), EHNA, NBTI, or IDT at 
a rate of 6 µl/ min, and the intravesicle fluid collected for analysis. Subsequently, the bladder 
was slow filled for 60 min, and then maintained in its filled state for an additional 60 min prior to 
collecting samples. The concentration of adenosine (A), inosine (B), or AMP (C) are indicated. 
Data are mean ± SEM (n ≥ 4). Significant differences (p<0.05) are indicated by an asterisk 
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2.3.2 Adenosine release from the mucosal surface of filled rat bladders is sensitive to 
inhibitors of adenosine deaminase and concentrative nucleoside transporters 
To further confirm that adenosine was released from the uroepithelium in situ, we 
examined the release of adenosine and its metabolites from the luminal surface of filled rat 
bladders. Unlike ex vivo tissue, we did not have access to the serosal surface of the uroepithelium 
in this setting. We observed that adenosine was released into the lumen after slowing filling the 
bladder for 60 min, and the release was further potentiated by an additional 60 min in the filled 
state (Figure. 12 A).  Inosine and AMP were also released during bladder filling, but their levels 
appeared to decrease as the bladders were left in their filled state (Figure 12 B-C). The adenosine 
deaminase inhibitor EHNA caused adenosine concentrations to trend upwards during bladder 
filling (an effect that did not reach statistical significance), but did result in a significant increase 
in adenosine levels when the bladder was left filled for 60 min (Figure. 12 A). This was coupled 
with a significant decrease in inosine levels (Figure. 12 B). The nucleoside transporter inhibitor 
NBTI also caused a significant increase in adenosine concentrations during bladder filling and 
these trended higher upon extended time in the filled state, but did not reach significance (Figure. 
12 A). NBTI also caused a large decrease in inosine concentrations (Figure.12 B). The adenosine 
kinase inhibitor IDT significantly decreased inosine concentrations, but had no effect on 
adenosine levels, even though these values trended higher than control ones. Finally, none of the 
treatments affected the concentration of AMP in the experimental groups, although the amount 
of AMP trended downwards in all of the treatment groups (Figure. 12 C).  In sum, our data 
indicate that adenosine is released at the luminal surface of the bladder in situ, and that like 
isolated rabbit tissue adenosine release was sensitive to inhibition by adenosine deaminase. 
However, we also observed that nucleoside transporters played a more active role in rat bladder 
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uroepithelium versus that of rabbit bladders, possibly indicating a difference between species or 
a difference in our methods (i.e, ex vivo preparations versus analysis in situ).  
2.3.3 Stimulation of luminal A1 receptors decreases the threshold pressure of bladders 
during cystometry 
Considering its established role in modulating stress and countering the effects of 
stimulatory modulators such as ATP (279,280), we next sought to determine whether the luminal 
addition of adenosine had any impact on bladder function. To test such a role we used 
continuous cystometry, a technique in which a solution is introduced into the bladder lumen (via 
a catheter inserted in to the bladder dome) and the pressure monitored as the bladder fills and 
then actively empties (281). A representative cystometrogram (CMG) is shown in Figure. 13 A. 
We measured five parameters: 1) the basal pressure, which is the lowest pressure measured 
following a void; 2) the   threshold pressure, which is that measured just before the detrusor 
contracts and voiding is initiated; 3) the peak pressure, which is the maximum pressure during 
detrusor contraction and coincides with voiding; 4) the inter-contraction interval (ICI), which is 
the distance between two peaks, and correlates with the time between two consecutive voids; 5) 
the percent fluid recovery, which is a ratio of the volume of fluid released versus that infused 
into the bladder. This latter parameter is useful to evaluate if the bladder voids efficiently or if 
there is fluid retention that results from, for example, a spastic urethra that does not allow 
complete voiding. Average values for these parameters are shown in Figure. 13.  
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Figure 13 Adenosine does not alter bladder function 
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 Continuous cystometry was performed using the indicated concentration of adenosine or 
adenosine deaminase dissolved in BUS. The parameters measured included ICI (B), basal 
pressure (C), threshold pressure (D), peak pressure (E), and fluid recovered (F). Data are 
expressed as mean ± SEM (Control n=7, 100 µM adenosine n= 8, 10 µM adenosine n= 8, 1 µM 
adenosine n= 8, 100 nM adenosine n= 9, 10 nM adenosine n= 6, 0.3 U adenosine deaminase n= 
8, 0.15 U adenosine deaminase n=6). No parameters were significantly different from those of 
controls. 
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Cystometry is typically performed using unbuffered normal saline or low tonicity 
phosphate-buffered saline (PBS) that has a pH of 7.4. However, normal urine is decidedly more 
complex and contains electrolytes not found in saline or PBS. In addition, the average pH of rats 
housed at the University of Pittsburgh animal facility and fed rat chow was 6.5. Thus, we also 
tested BUS in addition to normal saline or PBS. We found that BUS had no adverse effects on 
the bladder and all the five parameters that we studied did not vary significantly between the 
three solutions (data not shown). Because BUS better reflects the physiological composition of 
urine, we employed it in our subsequent studies. 
We first determined what happened if adenosine was introduced into the bladder lumen 
during cystometry. A broad range of concentrations was used (10 nM – 100 µM), and although 
there was an upward trend in the ICI as the concentration of adenosine dropped, the difference 
failed to reach statistical significance (Figure. 13 B). Furthermore, there was no significant 
change in the basal pressure, threshold pressure, peak pressure, or fluid recovery (Figure. 13 C-
F). We also explored what happened to the CMG parameters when adenosine levels were 
decreased by continuously infusing the bladder with exogenous adenosine deaminase, which 
converts adenosine to inosine. Again, we did not identify any significant difference between the 
control group parameters and those in which adenosine was depleted (Figure. 13 B-F).  
We previously reported that the apical surface of umbrella cells expresses the A1 receptor. 
Hence, we infused bladders with BUS containing CCPA, which when used at low nM 
concentrations is an A1-selective agonist (282). In addition to its high affinity, CCPA has other 
beneficial characteristics including its lack of conversion to AMP or inosine and its failure to be 
shuttled from the lumen to the cell interior by nucleoside transporters (283). Remarkably, when 
CCPA was infused at a concentration as low as 1 nM it decreased the threshold pressure by 
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~55% (Figure. 14 C). There was no statistically significant effect at 1 µM, possibly because non-
A1 receptor targets were activated and counteracted the effects of CCPA-mediated A1 receptor 
activation at these high concentrations. There was no significant effect on the other parameters 
measured (Figure. 14 A-B, D-E). To confirm that these effects were a result of A1 receptor 
activation, we treated bladders with the A1 receptor antagonist DPCPX in addition to CCPA. 
This blocked the effect of CCPA, and raised threshold levels back to those of controls (Figure. 
14 C&F). DPCPX alone had no significant effect on the CMG parameters (data not shown). In 
summary, activation of luminal A1 receptors appeared to lower the pressure needed to stimulate 
bladder contractions, but without changes in ICI, basal pressure, peak pressure, or fluid recovery. 
2.3.4  Blocking pathways for adenosine turnover reveals an adenosine and A1 receptor-
like response  
The ability of CCPA to elicit responses, but not adenosine, led us to examine whether 
adenosine turnover could account for the differences. We infused EHNA, IDT, or NBTI, 
individually or in combination, and measured the effects on bladder function. Consistent with 
our in situ rat bladder experiments, we observed that the adenosine deaminase inhibitor EHNA 
and the nucleoside transporter inhibitor NBTI decreased the threshold pressure for voiding 
(Figure. 15 C), presumably because they increased luminal adenosine concentrations. These 
drugs did not alter the other parameters (Figure 15 A-B and D-E). The adenosine kinase inhibitor 
IDT was without affect (Figure 15). As expected, treatment with all three inhibitors also 
decreased threshold pressure (Figure. 15 C). We also assessed whether the inhibitors of 
adenosine turnover would unmask a further sensitivity to exogenously added adenosine. 
However we found no such effect (data not shown).  
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 Figure 14 Activation of apical A1 receptors with CCPA lowers the threshold pressure for voiding 
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Continuous cystometry was performed using the indicated concentration of drug dissolved in 
BUS. (A-E) Cystometry parameters were measured as described in Fig. 4. Data are expressed as 
mean ± SEM (DMSO control n=10, 1 mM CCPA n= 7, 100 nM CCPA n= 13, 10 nM CCPA 
n=12, 1 nM CCPA n=9). Statistically significant differences (p<0.05) between DMSO-treated 
bladders and CCPA-treated ones are indicated with an asterisk. (F) The specificity of the effect 
of CCPA was tested by including DPCPX in the cystometry buffer. Data are expressed a mean ± 
SEM (CCPA n = 7; DPCPX + CCPA n= 8). DPCPX significantly antagonized the affects of 
CCPA alone.   
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2.3.5 A1 receptor activation stimulates bladder activity in bladders with 
cyclophosphamide-induced cystitis 
Finally, we determined whether adenosine modulated the hyperactivity found in bladders with 
acute cyclophosphamide-induced cystitis. Cyclophosphamide is a chemotherapeutic agent that is 
converted to acrolein and can cause a hemorrhagic cystitis within a short period of time (284). 
After a 4-h treatment with cyclosphosphamide, we observed that this drug caused a marked 
decrease in ICI and an increase in the basal pressure (Figure.16 A-B, D). The threshold pressure, 
peak pressure, and fluid recovery were not significantly altered (Figure. 16 C,E-F). We then 
treated the inflamed bladders with 10 µM adenosine, but did not find any significant difference 
between control and test samples (Figure. 17 A-E). In contrast, 1 nM CCPA exacerbated the 
effect of cystitis by further reducing the ICI compared to animals treated with 
cyclosphosphamide and DMSO diluent (Figure. 17 A). However, no other parameters were 
altered in this setting (Figure. 17 B-E).  
One possible explanation for the altered effects of CCPA on cyclophosphamide-treated 
versus control animals is that cyclophosphamide changed the expression or distribution of A1 
receptors in the uroepithelium. However, we found that A1 receptor expression was largely 
limited to the apical surfaces and subapical region of the umbrella cells in both control and 
cyclophosphamide-treated tissues (Figure17  F-G).  Furthermore, there was no obvious effect on 
the amount of A1 receptor expressed in the uroepithelium (Figure 8H).  However, we did note 
that the submucosal region of the cyclophosphamide-treated tissue was edematous in some 
regions, which appeared as large dilated regions (compare submucosa in Figure. 17 F to Figure. 
17 I).  
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Figure 15 Inhibitors of adenosine turnover lower the threshold pressure for voiding 
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Continuous cystometry was performed using the indicated concentration of drug dissolved in 
BUS. (A-E) Comparison of CMG parameters for bladders treated with EHNA, NBTI, IDT or a 
cocktail containing all three inhibitors. The DMSO values in Fig. 14  are reproduced in panels A-
E to aid in making comparisons (DMSO control n=10, 10 µM EHNA n= 7, 10 µM NBTI n= 8, 
100nM IDT n= 8, drug cocktail n= 7). Statistically significant differences (p<0.05) between 
DMSO-treated bladders and those treated with drugs are indicated with an asterisk. 
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2.4 DISCUSSION 
We undertook this study to determine the mechanism(s) of adenosine turnover associated with 
the uroepithelium and to understand whether adenosine would exert a quieting effect when its 
concentration was increased in the normal or inflamed bladder. Our analysis revealed that there 
were distinct mechanisms of adenosine turnover operating at each surface of the uroepithelium, 
which limited the amount of available adenosine. Furthermore, and contrary to our expectations, 
we observed that adenosine, likely acting through A1 receptors, decreased the threshold pressure 
needed to stimulate bladder contractions and increased bladder hyperactivity in a model of 
cyclophosphamide-induced cystitis.  
 
2.4.1 Distinct mechanisms of adenosine turnover at either surface of the uroepithelium 
Stresses such as hypoxia promote the breakdown of extracellular ATP, leading to a sharp 
increase in tissue adenosine levels (267). Whereas free adenosine binds to its receptors and 
imparts an organ-protective function (99), chronic elevation of extracellular adenosine is harmful 
to the tissue (285). Hence, the half-life of extracellular adenosine is kept short (seconds to 
minutes, depending on species) through the action of enzymes and transporters. This may be 
particularly important at the luminal surface of the bladder, which is not only a site of adenosine 
biosynthesis, but is also impacted by adenosine produced by the kidney and present in the urine 
(286).  
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Figure 16 Cyclophosphamide treatment induces urinary bladder cystitis 
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Rats were either injected with saline (sham-treatment) or with 150 mg/kg cyclophosphamide. 
Four hours later the rats were prepared for cystometry and BUS was intravesically infused at a 
constant rate of 50 µl/min for a period of 90 min. (A) Representative images of CMGs obtained 
from sham- or cyclophosphamide-treated bladders. (B-F) CMG parameters for sham- or 
cyclophosphamide-treated bladders. Data are expressed as mean ± SE (Sham n=8, 
cyclophosphamide n=9). Statistically significant differences (p<0.05) are indicated with an 
asterisk. 
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We found that adenosine was released from mucosal surface of rat bladders in response to 
filling or from the luminal surface of isolated rabbit uroepithelium, particularly when the 
epithelial tissue was subjected to a prolonged stress. Blocking adenosine deaminase with EHNA 
further potentiated adenosine levels, indicating that adenosine concentrations are likely kept in 
check by ecto-adenosine deaminase, which converts the released adenosine to inosine. The 
importance of the adenosine deaminase pathway for turnover was further supported by our 
observation that EHNA reduced the threshold pressure for contractions in rat bladders 
undergoing cystometry. In rat bladders the EHNA-induced increase in adenosine release was 
coupled to a decrease in inosine levels. However, in isolated rabbit tissue the mucosal inosine 
levels trended downwards, but the effect was not significant. Thus, a simple precursor-product 
relationship was not immediately apparent. However, inosine can be phosphorylated to generate 
IMP and extracellular inosine levels are governed, in part, by nucleotide transporters (287). As a 
result, we may have been unable to detect correlative changes between adenosine and inosine 
levels in rabbit tissues. We further observed that when rat bladder equilibrative nucleoside 
transporters were blocked with NBTI, there was an increase in adenosine. This rise likely 
explains why NBTI mimicked the effects of CCPA and lowered the threshold pressure for 
contractions. In contrast, NBTI caused inosine levels to increase in rabbit tissue, but there was no 
effect on adenosine. This may indicate species differences, or differences in the models 
employed, but it is also possible that extracellular adenosine was increasing in the NBTI-treated 
rabbit tissue, but was rapidly converted to inosine by ecto-adenosine deaminase.  
While adenosine deaminase was important at the mucosal surface, adenosine kinase and 
nucleoside transporters played a more significant role at the serosal side of uroepithelial tissue. 
These results are in agreement with previous studies showing that the basolateral surface of 
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polarized epithelial cells show robust equilibrative nucleoside activity (288). Like the mucosal 
surface, we observed no simple precursor-product relationship between adenosine and its 
metabolites. For example, treatment with the adenosine kinase inhibitor IDT led to an increase in 
adenosine levels, but did not cause a corresponding decrease in AMP. The conversion of ATP, 
which is released from the serosal surface of the uroepithelium (23), to AMP could explain this 
anomaly. Equilibrative nucleoside transporters were of particular significance at the basal surface 
of the uroepithelium; their inhibition led to a significant increase in adenosine and inosine levels. 
We also observed that the levels of inosine increased in the presence of the adenosine deaminase 
inhibitor as the uroepithelial tissue reached its fully stretched state. Because there was no 
corresponding loss of adenosine, the source of this inosine is unknown but could be via the 
pathways described above. As a final note, while the uroepithelium is likely the predominant 
source of serosally released adenosine in our studies, the preparations we used contain scattered 
rests of endothelial cells, fibroblasts, interstitial cells, and smooth muscle cells, and that may also 
contribute to adenosine production and turnover at the serosal surface of this tissue. 
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Figure 17 CCPA exacerbates the hyperactive bladder phenotype 
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 (A-E) Rats were treated with cyclophosphamide for 4 h to induce an acute cystitis and then 
cystometry was performed. Data are expressed as mean ± SEM (Cyp-control n=9, 10µM 
adenosine n=8, DMSO control n= 7, 1 nM CCPA n= 7). Statistically significant differences 
(p<0.05) are indicated with an asterisk. (F-G, I) Cross sections of frozen uroepithelial tissues 
obtained from sham-treated animals or cyclophosphamide-treated ones. Images were captured 
with a confocal microscope and the Z-series projected. The A1 receptor is shown in green, actin 
staining is shown in red, and nuclei are shown in blue. The location of umbrella cells (UCs) is 
indicated. The asterisk in panel I shows a region of cyclophosphamide-treated bladders where the 
submucosal tissue is expanded, most likely a result of edema. (H) Western blot showing A1 
receptor expression in sham (control) or cyclophosphamide-treated animals. Epithelial lysates 
from at least two rats were pooled for this analysis.      
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2.4.2 Luminal adenosine, acting through A1 receptors, modulates threshold pressure 
The uroepithelium was long thought of as a passive barrier, but is now realized to play a more 
active role in regulating bladder function (1,73). Receptors and channels, sensitive to a broad 
array of chemicals, mediators, and noxious stimuli are found on the apical surface of the 
outermost umbrella cell layer, making it possible to detect small changes in the luminal milieu of 
the bladder (71). In the case of adenosine, A1 receptors are prominently expressed at this surface 
of the rat bladder (53), and we showed that luminally added CCPA, used at low nM 
concentrations (KD for CCPA is in the 1-5 nM range), was sufficient to trigger a change in 
threshold pressure. This effect was blocked when tissue was simultaneously treated with the 
highly selective A1 receptor antagonist DCPCX. While we cannot rule out a function for other 
adenosine receptors, our results indicate that A1 receptors play a critical role in this response. 
Intriguingly, adenosine cannot pass the high resistance barrier imparted by the apical plasma 
membrane and tight junctions of the umbrella cell (2). Thus, activation of the A1 receptor most 
likely initiates a signaling cascade that results in the release of mediators from the uroepithelium. 
Although known mediators include acetylcholine, adenosine, ATP, NO, and prostaglandins (73), 
we do not know which of these, if any, is responsible for transduction of the adenosine signal.  
On the receiving end are interstitial cells, which are subjacent to the uroepithelium and may 
interface with nerves and smooth muscle cells (289). In addition, there are neuronal processes in 
close proximity to the uroepithelium that transmit information from the lower urinary tract to the 
lumbosacral spinal cord (290,291). The afferent processes of these nerves are predominantly 
myelinated Aδ fibers and unmyelinated C-fibers, and subclasses of these processes intercalate 
deep into the uroepithelium where they can abut the basolateral surfaces of the umbrella cells 
(55). Interestingly, the effect of adenosine was highly specific and this nucleoside had no effect 
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on basal or peak pressure, the ICI, or fluid retention, but did decrease the threshold pressure. The 
latter was likely the result of sensitizing the sensory afferent nerve processes so that they 
responded to lower pressure stimuli. The nature of this sensitization is unknown but could be due 
to altered release of acetylcholine (292). However, we cannot rule out that adenosine also 
affected urethral function, possibly by stimulating nitric oxide synthesis and release resulting in 
urethral muscular relaxation (293).  
 
2.4.3  Adenosine as a stimulatory factor in bladder function 
In other organs, such as the heart, kidney, lungs and brain, adenosine has a well-established 
protective and anti-inflammatory effect, especially during stress and pathological insult. Thus 
A1-receptor dependent stimulation of micturition by lowering the threshold pressure could be 
viewed as a protective mechanism to accelerate the elimination of substances that may be 
injurious to the uroepithelium. However, we also observed that A1 receptor activation 
exacerbated the bladder hyperactivity seen in rats with cyclophosphamide-induced cystitis. 
Interestingly, only the ICI was affected in the cystitis model, and not the threshold pressure. This 
difference did not appear to be the result of altered A1 receptor expression or distribution. 
However, it is possible that cyclophosphamide-induced inflammation could alter signaling 
downstream of the A1 receptor, which could change the amount of, or types of, mediators 
released in response to adenosine. Furthermore, some classes of C-fibers, which are normally 
quiescent, become activated during cystitis (294), and it is possible that the effects of adenosine 
were a result of activating these nerve fibers. Thus, adenosine (or other mediators) released from 
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a damaged or inflamed uroepithelium could contribute to bladder hyperactivity by affecting the 
activity of other cell types and tissues in the bladder proper.    
In addition to its protective function, adenosine can also have a stimulatory effect and a 
strong pro-inflammatory role, which is cell type, adenosine concentration, and receptor 
dependent (99). For example, low concentrations of adenosine act through A1 receptors to 
promote neutrophil adherence to endothelial cells as well as their chemotaxis and tissue 
infiltration (295). In contrast, high concentrations of adenosine (e.g. at sites of inflammation) 
activate A2B receptors (EC50 = 25 µM), which are thought to suppress these responses (296). 
Furthermore, adenosine pre-exposure can affect the function of T-cells and dendritic cells (297). 
In the case of the umbrella cell, adenosine, acting through A1 receptors, stimulates bladder 
function by lowering the threshold for micturition. Such a response may be important as the 
bladder fills, which our data indicates would stimulate adenosine release and may aid micturition 
by modulating the threshold pressure. Adenosine-stimulated responses could also play a role in 
pathological conditions such as bacterial infections and other forms of cystitis, which are often 
accompanied by increased micturition and pain. Interestingly, gut strains of Escherichia coli may 
release adenosine in response to enterocyte-released beta-defensins (276). If adenosine were 
produced by uropathogenic E. coli, even at low levels, it could be sensed by the umbrella cell A1 
receptors, which could promote the clearance of the bacterial infection by lowering the threshold 
for micturition.  
In conclusion, we have identified likely mechanisms of adenosine turnover on the mucosal 
and serosal surfaces of the uroepithelium, which we show can govern the amount of free 
adenosine found within the bladder lumen. Furthermore, we have established that adenosine has 
a selective modulatory effect and can promote bladder function by lowering the threshold for 
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micturition. The latter role may be important during bladder filling and may also play a role 
during pathological conditions such as cystitis.   
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3.0  ADENOSINE PROMOTES UMBRELLA CELL EXOCYTOSIS VIA A PROTEIN-
KINASE C-STIMULATED, ADAM17-MEDIATED, EGF RECEPTOR 
TRANSACTIVATION PATHWAY 
3.1 ABSTRACT 
A disintegrin and a metalloproteinase 17 (ADAM17) is responsible for the shedding of 
transmembrane protein ectodomains, including those of a subset of ligands for the epidermal 
growth factor receptor (EGFR). Despite the importance of this cleavage to normal biology and 
disease, the effector pathways that promote ADAM17-dependent shedding and the mechanisms 
that control its activity remain unresolved. One reported mechanism of regulation is 
phosphorylation of residues in the cytoplasmic domain of ADAM17; however, other studies 
show that the cytoplasmic domain is dispensable for stimulus-evoked shedding. To further 
address the requirements for ADAM17-dependent shedding, we exploited the bladder umbrella 
cell, which in response to stress undergoes a form of apical exocytosis that depends on cleavage 
of heparin-binding EGF by an unknown proteinase and subsequent transactivation of the EGFR, 
resulting in MAPK activation, protein synthesis, and exocytosis. Using isolated uroepithelial 
tissues combined with biochemistry, electrophysiology, pharmacology, and in situ adenoviral-
mediated knockdown of protein, we report that the stress-relieving hormone adenosine binds 
apically localized A1 adenosine receptors and triggers a Gi-Gβγ-phospholipase C-protein kinase C 
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cascade that promotes ADAM17 phosphorylation and subsequent EGFR transactivation, leading 
to apical exocytosis. We further show that the cytoplasmic tail of ADAM17 contains a Ser 
residue at position 811, which resides in a canonical PKC phosphorylation site and when 
mutated to an Ala residue blocks A1AR-mediated secretion. We conclude that adenosine plays a 
protective role during bladder stress by stimulating exocytosis downstream of ADAM17-
dependent EGFR transactivation, and that this process may be regulated by phosphorylation of 
Ser811 in the cytoplasmic domain of ADAM17.  
 
3.2 INTRODUCTION 
Protein ectodomain shedding, a process regulated by proteolysis, is a fundamental 
mechanism for the release of cytokines, growth factors, and cell adhesion molecules (298), and is 
altered in cancer, autoimmune and inflammatory diseases, cardiovascular disease, and 
neurodegeneration (217). The best understood sheddases include the a disintegrin and a 
metalloproteinase (ADAM) family members ADAM10 and ADAM17 (also known as TACE), 
both of which shed a variety of substrates including the transmembrane ligands for the epidermal 
growth factor receptor (EGFR). Whereas ADAM10 targets betacellulin, EGF, and neuregulin, 
ADAM17 is the principal sheddase for transforming growth factor (TGF) , amphiregu  
epiregulin, epigen, and heparin-binding epidermal growth factor (HB-EGF) (245,246,299). 
Indeed, the physiological relevance of ADAM17 in shedding is supported by research showing 
that knockout mice lacking this proteinase have a similar phenotype to mice deficient in 
expression of TGF , amphiregulin, HB-EGF, and the EGFR (221,250,251,300,301). While the 
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physiological cues that trigger shedding are not completely defined, ADAM17-elicited shedding 
occurs in response to many stimuli including ligands for G-protein-coupled-receptors (GPCRs) 
and treatment with ionomycin or phorbol-12-myristate-13-acetate (PMA), a diacylglycerol 
mimic and activator of classical protein kinase C (PKC) isoforms, whereas ADAM10-dependent 
shedding responds to Ca2+ ionophores (e.g. ionomycin), but not PMA (when used for less than 2 
h)(167,239,302). Our understanding of the signaling and associated effector pathways that act 
downstream of these stimuli remains incomplete, although the extracellular signal-regulated 
kinase (ERK), as well as the p38 mitogen-activated kinase , PKC  PK     C-
regulated protein phosphatase inhibitor 14D have been linked to ADAM17-dependent shedding, 
and PKC  is required for shedding of neuregulin (166,167,230,303,304).  
An additional unresolved question is how these effectors promote ADAM-dependent 
shedding of EGFR ligands, although evidence to date indicates they work by multiple 
mechanisms and perhaps in a cell and stimulus dependent manner (168,202,210). Potential 
regulatory steps include membrane trafficking of the ADAM or its ligands (201), effects on the 
ADAM17 dimer-monomer equilibrium and association with tissue inhibitor of 
metalloproteinases (TIMP) 3 (244), or changes in the redox potential of extracellular protein 
disulfide isomerase, which is hypothesized to alter ADAM17 activity by rearrangements of its 
disulfide bonds (305). An additional regulatory mechanism is phosphorylation of ADAM17. 
Indeed, ADAM17 phosphorylation of cytoplasmic residues Ser791, Ser819, Tyr702 and Thr735 
is reported (210,232,303). However, Ser791 is phosphorylated prior to stimulation, and 
mutations of Ser819 do not appear to impact shedding (210). Tyr702 was phosphorylated by src 
kinase in response to mechanical stretching of rat myoblasts (232). In the case of Thr735, very 
high doses of PMA (1 µM) are reported to promote extracellular signal-regulated kinase (ERK)-
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dependent phosphorylation of this residue (201). However others report that phosphorylation of 
this residue is mediated by the p38 mitogen-activated kinase and this posttranslational 
modification is required for ADAM17-dependent shedding in response to various forms of 
stress, but not PMA (202). A significant argument against this hypothesis are several reports that 
show shedding of ADAM17-dependent ligands (in response to a variety of stimuli) occurs in 
cells expressing truncated versions of this metalloproteinase lacking its C-terminus 
(220,238,239). Finally, a recent study shows that substrate cleavage is regulated independently of 
a major change in ADAM proteinase activity, and that in the case of neuregulin it is PKCδ-
mediated phosphorylation of cytoplasmic residue Ser286 that regulates cleavage of this ligand by 
ADAM10 (166).  
A useful and physiologically relevant model system to study the signals, effector pathways, 
and mode of ADAM activation is the uroepithelium, a tissue that can be studied both ex vivo and 
in vivo (22,24,42). Bladder filling triggers the exocytosis of an abundant subapical pool of 
discoidal- and/or fusiform-shaped vesicle (DFV) in the outer umbrella cell layer (28,29). Stretch-
induced exocytosis progresses in two phases. “Early-phase” exocytosis occurs during bladder 
filling, as the epithelium is bowing outward, and is triggered by apical Ca2+ entry, likely 
conducted by a non-selective cation channel (41). In contrast, “late-phase” exocytosis is initiated 
once the tissue is maximally bowed outward (i.e. in response to a full bladder), and requires 
metalloproteinase-dependent cleavage of HB-EGF leading to “transactivation” of apical EGFRs 
and initiation of a downstream ERK pathway that culminates in protein synthesis and exocytosis 
(43). We now report that adenosine, which is released from the epithelium in response to stress 
(306), spurs a late phase-like response in umbrella cells, that a Gi-, Gβγ-, PLC-, and PKC-
dependent effector cascade in initiated downstream of the adenosine A1 receptor (A1AR), and 
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that a previously unreported canonical PKC site centered at Ser811 in the cytoplasmic domain of 
ADAM17 is critical for adenosine-induced exocytosis.  
 
3.3 RESULTS 
 
3.3.1 A1AR-stimulated apical exocytosis occurs through transactivation of the EGFR 
Late-phase exocytosis is triggered when uroepithelial tissue is maximally stretched (43), 
but if other stimuli promote a similar response is unknown. Because adenosine is dramatically 
increased as the bladder reaches its capacity (306), and because it can also trigger exocytosis 
(53), we tested the hypothesis that adenosine stimulates exocytosis by way of EGFR 
transactivation. Consistent with our previous report (306,307), the A1AR was distributed at the 
apical pole of umbrella cells (as well as in the underlying lamina propria; Figure. 18 A) and 
when adenosine was added to the mucosal surface of the tissue it stimulated increased tissue 
capacitance (CT; where 1 µF ≈ 1cm2) (Figure. 18 B), which in this tissue correlates well with 
other measures of apical exocytosis (27,28). Similar results were observed for the highly 
selective and high affinity A1AR agonist CCPA. Unlike adenosine, CCPA it is not rapidly 
converted to inosine (306,308), and was thus used in our subsequent studies. We next determined 
whether A1AR-stimulated exocytosis was dependent on protein synthesis and whether it was 
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sensitive to BFA. Indeed, treatment with BFA or cycloheximide significantly blocked CCPA-
mediated exocytosis (Figure 18 C), although the effect of BFA was particularly pronounced. 
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Figure 18 Activation of A1AR triggers apical exocytosis in umbrella cells 
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A. 4μm rat bladder cryosections were labeled with antibody to A1AR (green), rhodamine 
phalloidin to label the actin cytoskeleton and TOPRO-3 to label the nucleus. The merged panel is 
shown on the right. The white arrows mark the apical borders of the cell. B. Rabbit 
uroepithelium was mounted on using chambers and after equilibration, were either left untreated 
(Black), or treated with 1μM adenosine (Blue) or 500nM CCPA (Red) on the mucosal side. The 
CT measurements were recorded for a period of 300 min and plotted against time. C. Rabbit 
uroepithelial tissues were mounted on Ussing chambers and equilibrated as above. The tissues 
were then treated with either 5μg/ml Brefeldin A (BFA) for 30 min (Blue) or 100ng/ml 
Cyclohexamide for 60 min (Green). Then 500nM CCPA was added to the mucosal chamber and 
the CT was recorded for 300 min post addition and plotted against time. The CCPA alone data 
(Red) was reproduced from Figure 1B. In panels B and C, the mean changes in CT ± SEM (N≥4) 
are shown. Statistically significant difference of (p<0.05) relative to no drug in A and CCPA in B 
are marked by *.  In panel A, the umbrella cell is marked with the *. Scale bar is 12μM and the 
cell junctions are marked by white arrows. 
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We next determined whether CCPA triggered apical exocytosis by transactivating the 
EGFR. We first tested the effect of treating the mucosal surface of the tissue with CRM197, a 
mutant version of Diptheria toxin that binds with high affinity to membrane bound HB-EGF and 
prevents its cleavage (309). Indeed, we observed that CRM197 almost completely blocked 
CCPA-mediated apical exocytosis (Figure 19 A). Next, we pretreated tissue with AG1478, a 
small molecule inhibitor of EGFR, which also significantly blocked CCPA-mediated apical 
exocytosis (Figure 19 B). As further evidence that the EGFR was transactivated, we generated 
lysates from CCPA-treated epithelium, and then probed western blots with an antibody that 
detects phosphorylation of the EGFR at tyrosine 1173 (Y1173). This residue promotes assembly of 
a MAPK signaling cascade downstream of other G-protein-coupled receptors that stimulate 
EGFR transactivation (43). Phosphorylation of Y1173 was maximally stimulated 10 min after 
continuous treatment with CCPA, decreased at 30 min post treatment, and returned to control 
levels after 60 min (Figure 19 C). Y1173 phosphorylation was prevented when the tissue was 
pretreated with the EGFR inhibitor AG1478 prior to CCPA treatment (Figure 19 C-D), 
confirming that phosphorylation of Y1173 likely results from autophosphorylation.  Finally, we 
observed that U0126, an inhibitor of ERK1/2 activity, also caused a significant decrease in 
CCPA-stimulated changes in CT.  
Taken together, these data indicated that, like the previously described late-phase 
response (43), A1AR activation stimulates apical exocytosis by promoting transactivation of the 
EGFR downstream of HB-EGF cleavage, leading to MAPK activation and protein synthesis. 
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Figure 19 A1ar-mediated apical exocytosis occurs through transactivation of EGFR 
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 A. rabbit uroepithelium was mounted on Ussing chambers and equilibrated as explained earlier. 
The tissue was pretreated with 1μM AG1478 for 30min and then CCPA was added to the 
mucosal chamber to a final concentration of 500nM. The CT was measured for a period of 
300min and plotted against time (Blue). Control CCPA data was reproduced from Fig 1B (Red). 
B. The tissue was mounted and equilibrated as above. The mucosal surface was pretreated 
treated with 5μ/ml CRM-197 for 25min (Blue) or the tissue was treated with 10μM U0126 
(Green) for 60 min. CCPA was then added to the mucosal chamber to a final concentration of 
500nM and the CT was measured for 300 min. The CCPA control data was reproduced from Fig 
1B. The mean changes in CT ± SEM (n≥3) are shown. Statistically significant difference (P< 
0.05) relative to the CCPA data (Red in both the panels) are marked by *. C. Rabbit 
uroepitheliums were mounted on Ussing chambers and equilibrated as above. CCPA was added 
to the mucosal chamber to a final concentration of 500nM. At different time points (0’, 2’, 10’, 
30’ and 60’) the tissue was unmounted from the chambers, spread on rubber dissection mats and 
the uroepithelial lysates were prepared in the presence of 0.5% SDS lysis buffer (with protease 
and phosphatase inhibitors). In the case of inhibitor studies, the rabbit tissues were pretreated 
with either 1μM AG1478 for 25min, 15μM Tapi-2 for 90 min or 500nM Calphostin C for 60 min 
and then CCPA was added to the mucosal chamber to a final concentration of 500nM. 10min 
post CCPA treatment, the tissue was unmounted from the chambers and the lysate was prepared 
as expaliend. Equal amounts of the protein were resolved on 4-15% SDS PAGE and 
immunobloted with either rabbit-anti EGFR-phosphoY1173 antibody or rabbit-anti total EGFR 
antibody. D) Quantification of Y1173 in response to CCPA treatment, relative to untreated (t=0’) 
tissue samples.  The mean band density ± sem (n> 3) are shown. Statistically significant values 
(p<0.05) are marked by *. 
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3.3.2 ADAM17 is localized to the apical surface of umbrella cells where it stimulates 
CCPA-induced EGFR transactivation and exocytosis 
To determine the mechanism by which HB-EGF is cleaved, we performed qualitative 
reverse-transcriptase mediated (RT)-PCR and detected message for several ADAM family 
proteinases previously implicated in EGFR transactivation including ADAM-9, -10, -15 and -17, 
but not ADAM12 (Figure 20 A) (169). In our subsequent studies we focused our attention on 
ADAM17 because previous in vivo studies implicate it as the physiologically relevant ADAM in 
HB-EGF-mediated transactivation (245,300,310).   
Consistent with our hypothesis that ADAM17 is required for EGFR transactivation in 
umbrella cells, we observed that ADAM17 was localized to small vesicular elements under the 
apical surface of the umbrella cells (Figure 20 B), the site of HB-EGF cleavage and EGFR 
transactivation during the late-phase response (43). Rat tissues were employed in these 
experiments because our antibody was produced in rabbits. The signal for ADAM17 was 
diminished when the anti-ADAM17 antibody was preincubated with immunizing peptide, 
confirming the specificity of the antibody (Fig. 3C). ADAM17 showed a high degree of 
colocalization with uroplakin 3a, which is associated with DFVs and the apical surface of 
umbrella cells (Figure  20 D-E) (1). ADAM17 was also detected in the intermediate and basal 
cell layers of the uroepithelium, as well as cells in the underlying lamina propria (Fig. 3B and D). 
We also observed that the broad-spectrum metalloproteinase inhibitor GM6001 and the 
ADAM17 selective inhibitor Tapi-2 (43,311) both significantly inhibited the CCPA-mediated 
increases in CT (Figure 20 F). Moreover, Tapi-2 blocked CCPA-mediated phosphorylation of 
EGFR Y1173 (Figure 19 C-D).  
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Figure 20 ADAM17 is localized to the apical surface of Umbrella cells 
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A. Total RNA was isolated from rat uroepithelium and RT-PCR used to assess the expression of 
ADAMs 9, 10, 12, 15 and 17 and the positive control β-Actin. B. Rabbit uroepithelium was 
mounted on Ussing chambers and equilibrated as explained earlier. The tissue was pretreated 
with 15μM Tapi-2 (Blue) or 15 μM GM6001 (Green) for 90 min and then CCPA was added to 
the mucosal chamber to a final concentration of 500nM. The CT was measured for a period of 
300min and plotted against time. Control CCPA data was reproduced from Fig 1B (Red). Mean 
±SEM is presented for all data points, and the statistically significant values (n≥3; P<0.05) on 
comparison to CCPA alone data are marked with an *.  C. 4μm sections of rat bladder 
cryoblocks were treated with rabbit-anti ADAM17 alone (Red), Rabbit-anti-ADAM17 + 
inhibitory peptide (Red) or Rabbit-anti ADAM17 (Red) + mouse UP3 antibodies (Green). The 
proteins were visualized with Goat-anti Rabbit Cy3 in the upper two panels and with Goat-anti 
Rabbit Cy3 and Goat-anti mouse Alexa 488 in the bottom panel. TOPRO-3 was used to visualize 
the nucleus (Blue) in all the cases. The merge panel is presented in the far right column. The 
umbrella cells are marked with the * D. Colocalization of ADAM17 with UP3 was measured 
using the Mander’s co-localization index with a threshold of 40. >90% of UP3 positive vesicles 
colocalized with ADAM17 positive vesicles. Scale bar is 10μM and the cell junctions are marked 
by white arrows. 
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To provide further evidence that ADAM17 is required for EGFR transactivation, we 
exploited our previously described in situ viral transduction approach to express ADAM17-
specific shRNAs or scrambled shRNAs in the rat bladder uroepithelium. We used rat bladders in 
these studies because the volume capacity of the bladder, and therefore number of virus particles 
needed, was relatively small (~ 500 µl) when compared to the volumes required to fill the rabbit 
bladder (~ 60-100 ml).  This technique targets the umbrella cell layer and achieves transduction 
efficiencies of 70-95% (22,42). Indeed, we were able to achieve a > 90% knockdown of 
ADAM17 expression (Figure 21 A-B). By examining the expression and distribution of 
ADAM17 in cross sections of uroepithelium, we confirmed that knockdown was confined to the 
umbrella cells and that expression of ADAM17 in the intermediate and basal cells was not 
disturbed (Figure 21C). 
Next, we used ADAM17-specific shRNAs to test whether ADAM17 was required for 
CCPA-stimulated EGFR transactivation and exocytosis. Treatment with ADAM17-shRNA, but 
not scrambled shRNA, decreased EGFR phosphorylation (Figure 21 D-E). We also attempted to 
measure changes in CT in the rat bladders treated with apical CCPA; however, we did not 
observe a response. Because CT is dependent on the rates of membrane addition and removal, we 
reasoned that one possible explanation was that CCPA stimulated both exocytosis and 
endocytosis, thus obviating any change in apparent CT. Indeed, we observed that WGA-FITC, 
added to the apical hemichamber of mounted rat bladders, was endocytosed in CCPA-treated 
tissue, but much less so in control, untreated tissue (Figure 21F). To circumvent the effects of 
endocytosis, we measured release of exogenously expressed human growth hormone (hGH), 
which is packaged into DFVs and released from the luminal surface of the bladder into the 
urinary space (21,22). Compared to control bladders, CCPA stimulated a 2.7-fold increase in the 
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mucosal release of hGH from the tissue (Figure 21 G-H), whereas expression of ADAM-17 
specific-shRNA, but not scrambled shRNA, caused a large inhibition (> 95%) in mucosal hGH 
release (Figure 21 G-H). Taken together our results provide strong evidence that ADAM17 is 
critical for CCPA-induced transactivation and exocytosis.  
 
3.3.3 ADAM17 is also critical for stretch-mediated apical exocytosis in rat, but not rabbit 
uroepithelium 
Because stretch-mediated, late-phase exocytosis is dependent on EGFR transactivation 
and sensitive to metalloproteinase inhibitors (43), we hypothesized that ADAM17 may also play 
a role in stretch-mediated EGFR transactivation. Surprisingly, and despite the sensitivity of 
CCPA-induced exocytosis in rabbit tissue to Tapi-2, this inhibitor had no effect on the stretch-
induced, late-phase exocytic response in this tissue (date not shown). In contrast, in rat bladders 
shRNA-mediated ADAM17 knockdown significantly reduced the stretch-induced apical release 
of hGH by > 60% compared to tissues transduced with scrambled shRNA (Figure 21G-H). In 
sum, these data indicate that ADAM17 is required to promote EGFR transactivation downstream 
of the A1AR and stretch in rat tissues; however in rabbits a different metalloproteinase may be 
required for stretch-induced, late-phase exocytosis. 
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Figure 21 In situ knockdown of ADAM17 impairs A1ar- and stretch-mediated apical exocytosis: 
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 A. Equal volumes of rat uroepithelial lysates from scrambled shRNA and ADAM17 shRNA 
infected bladders were resolved in 4-15% SDS PAGE and the westernblots were probed with 
rabbit-anti ADAM17 antibody (top panel) or Mouse-anti actin (bottom panel). B. Quantification 
of intensity of ADAM17 bands in ADAM17 knockdown rat uroepithelial lysates. Data is 
presented as mean change in the band intensity ± SEM on comparison to ADAM17 band 
intensity in the scrambled shRNA group. Statistically significant values are marked by *(n≥4, p< 
0.05)    C. 4μm cross sections of scrambled shRNA expressing rat bladder (left) and 
ADAM17shRNA expressing rat bladder cryosections were stained for ADAM17 (red) and nuclei 
with TOPRO-3 (blue). D. Equal quantities of rat bladder lysate from the treatments were 
resolved in a 4-15% SDS PAGE and the western blots were probed with either rabbit anti-
EGFR-phospho-Y1173 or rabbit anti-EGFR antibody, E. Quantification of D. The quantification 
of the data is represented as band intensity ± sem on comparison to the control band. F. Rat 
bladders treated with WGA-FITC (green) , Actin with rhodamine phalloidin (red) and nuclei 
with TOPRO-3 (blue). G. hGH assay: In the top panel equal volumes of buffer concentrate from 
the various treatments were resolved in 4-15% SDS PAGE and the western blots were probed 
with rabbit-anti human growth hormone antibody. In the bottom panel, equal quantity of proteins 
from the uroepithelial lysates corresponding to the treatment groups of the top panel were 
resolved in 4-15% SDS PAGE and the western blots were probed with rabbit-anti human growth 
hormone antibody. H. Quantification of G. Data is presented as mean band density ± SEM on 
comparison to the control bands. In panel C the umbrella cell is marked by *. The scale bar in C 
is 13μM. The cell junctions are marked by white arrows. Statistically significant values are 
marked by * over a horizontal bar depicting the treatment groups used for the statistical analysis 
(n≥3, p<0.05). 
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3.3.4 Gi, phospholipase C, and PKC act upstream of ADAM17 to promote A1AR-
mediated EGFR transactivation 
How ADAM17 activity is coupled to A1AR activation was addressed next. Previous 
studies showed that A1AR signals through Giα to inhibit the activity of adenylyl cyclase, while 
the βγ subunits of Gi increase the activity of phospholipase C-β (PLCβ), which hydrolyzes 
phosphatidylcholine to generate IP3 and diacylgycerol (312-314). The latter stimulates the 
activity of PKC, a well-known regulatory kinase that was previously implicated in ADAM17 
activation (167,311,315). We found that pertussis toxin-mediated inhibition of Gi, or inhibition 
of Gβγ subunit activity by the inhibitor M119K (316), significantly impaired CCPA-mediated 
apical exocytosis in rabbit bladder umbrella cells (Figure 22 A). Furthermore, the PLC-selective 
antagonist U73122 caused a marked inhibition of CCPA-induced changes in CT (Fig. 22A). 
Thus, ADAM17 activation downstream of A1AR likely occurred by way of a classical Gi-
stimulated signaling cascade involving Gβγ and PLC.   
Next, we examined whether PKC was important for A1AR-dependent EGFR 
transactivation and exocytosis. Strikingly, the PKC inhibitor calphostin-C caused a marked 
decrease in CCPA-stimulated changes in CT and EGFR transactivation (Figure 19C-D and 22 B). 
In contrast, treatment with PMA, an activator of classical PKCs (317), caused a robust 
stimulation of exocytosis in the absence of CCPA (Figure 22 B). Interestingly, the kinetics of 
PMA-mediated exocytosis was faster than those mediated by CCPA, particularly during the first 
30 min, and then appeared to increase at a similar rate to CCPA thereafter. This may indicate that 
PKC not only stimulates late-phase-like responses, but perhaps early-phase ones as well. To 
confirm that PMA acted by way of ADAM17, we treated the tissue with Tapi-2, which 
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significantly inhibited PMA-mediated apical exocytosis (Figure 22C). Furthermore, we observed 
that AG1478 also blocked PMA-mediated exocytosis (Figure 22C).  
 
  
 117 
Figure 22 PKC mediates A1ar-induced ADAM17 activation 
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In A, B and C Rabbit uroepithelium was mounted on Ussing chambers and equilibrated as 
explained earlier. In A and B The CCPA alone data (red) was reproduced from figure 1B. A) The 
tissue was pretreated with 100ng/ml pertussis toxin (Green) for 90 min or 10μM M119K (Blue) 
for 60min or 10μM U73122 (yellow) for 60 min. Then CCPA was added to the apical surface to 
a final concentration of 500nM and the capacitance was measured for 300 min. B) The tissue 
was pretreated with 10nM  PMA (blue) on the mucosal surface or  pretreated with 500nM 
Calphostin C for 30 min and then treated with 500nM CCPA (Green). C) The tissue was 
pretreated with 15μM Tapi-2 for 90 min (red) or 1μM AG1478 for 30 min and then treated with 
10nM PMA. The PMA alone data was reproduced from figure 5 B. Data are presented as mean 
±SEM. Statistically significant values are marked with an * (n≥3, p<0.05). 
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To explore how PKC may act to stimulate ADAM17 activity we scanned its amino acid 
sequence using the proteomics tool Scansite and identified a canonical PKC phosphorylation 
motif (X-R/K-X-X-S/T-X-R/K-X) (318,319) in the cytoplasmic tail of the protein centered at 
Ser811 (Figure 23 A). To our knowledge, this potential phosphorylation site has not been explored 
previously. To test its possible role in CCPA-mediated exocytosis, we silenced endogenous 
ADAM17 using shRNA and then expressed an shRNA-resistant variant of wild-type ADAM17 
HA-tagged at its C-terminus (ADAM17r-HA) or mutants in which Ser 811 was mutated to an Ala 
residue (ADAM17r/S811A-HA) or a potentially “phosphomimetic” mutant in which Ser811 was 
mutated to an Asp residue (ADAM17r/S811D-HA) (Figure 23 A). The exogenous expression of 
ADAM17-HAr restored CCPA-induced hGH secretion in the shRNA background (Figure 23 B). 
The levels of hGH release were slightly higher than that observed for the endogenous protein 
(compare Figure 23 C with Figure 21 H). This could be due to the exogenous expression of the 
ADAM17 protein.  Remarkably, expression of ADAM17r/S811A-HA caused a significant 
reduction in the exocytosis of hGH by ~80% indicating a critical role for the specific amino acid 
in the A1AR-mediated activation of ADAM17. Importantly, ADAM17r/S811A-HA was expressed 
at >70% of the umbrella cells and was localized to the apical pole, indicating that the mutation 
did not impair the trafficking ability of the protein. (Figure 23 D). However, ADAM17r/S811D-HA 
did not significantly stimulate exocytosis above the wild-type protein (Figure 23 B-C).  
Together, these results indicate that adenosine-mediated increase in apical exocytosis 
are dependent on activation of PKC and that one possible target of this kinase is Ser811 in the 
cytoplasmic domain of ADAM17, a residue that may exert its effect in response to 
phosphorylation. 
 
Figure 23 Ser811 in the c-tail of ADAM17 is required for A1AR-mediated apical exocytosis 
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A) Schematic showing the different domains of ADAM17. The consensus PKC phosphorylation 
motif (Ser811) has been highlighted, and the conserved motif with the basic aminoa acids at the -
3 and + 2 sites marked by the arrows. The point mutations performed are depicted in the lower 
panels. B) hGH assay: in the top panel, equal volumes of buffer concentrate from the various 
treatments were resolved in 4-15% SDS PAGE and the western blots were probed with rabbit-
anti human growth hormone antibody. In the second panel, equal quantity of proteins from the 
uroepithelial lysates corresponding to the treatment groups of the top panel were resolved in 4-
15% SDS PAGE and the western blots were probed with rabbit-anti human growth hormone 
antibody. In the bottom panel equal quantities of proteins of the same lysates used in the middle 
panel were resolved in 4-15% SDS PAGE and the western blots were probed with rabbit-anti 
ADAM17 antibody. C) Quantification of B. Data is represented as mean band density ± SEM of 
the released hGH as a ratio to the total gGH expressed in the tissue. D) Rat uroepithelium 
expressing ADAM17 shRNA + ADAM17r/S811A-HA is stained with ADAM17 (red), Actin 
(green) and nuclei (blue). A cell where expression of ADAM17 is knocked out neighboring 
another cell where ADAM17r/S811A-HA is expressed is marked with the *. The cell junctions are 
marked by white arrows. 
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3.4 DISCUSSION 
The urinary bladder undergoes continuous cycles of filling and voiding, subjecting the 
bladder mucosa to constant mechanical stress. The uroepithelium has evolved numerous 
specializations to cope including: (1) the mucosal surface of the bladder is highly folded and is 
reversibly unfurled during bladder filling; (2) the umbrella cells maintain a robust tight junction 
barrier that can expand and contract with the bladder cycle; (3) the pre-existing population of 
umbrella cell DFVs undergo apical exocytosis, which when accompanied by cell-shape changes 
in the umbrella cell increases the luminal volume. There is however a fourth mechanism, which 
we call the late-phase exocytic response. It is triggered by stress (e.g. excess stretch), it ensures 
incorporation of additional apical membrane, and is characteristically dependent on EGFR 
transactivation, protein synthesis, and protein secretion. Currently, there is little information 
about which stimuli promote the late-phase response or how these events trigger EGFR 
transactivation. Our current results show that (1) adenosine, like stretch, also stimulates 
exocytosis via EGFR transactivation, that (2) ADAM17 is the relevant metalloproteinase (at least 
in rats), that (3) an A1AR GαiGβγPLCPKC signaling cascade acts upstream of ADAM17 
to promote HB-EGF cleavage, and that (4) the C-terminal tail of ADAM17 contains residues 
critical for its function.  
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3.4.1 Adenosine, like stretch, stimulates apical exocytosis via EGFR transactivation 
We previously showed that the late-phase exocytic response is triggered downstream of 
EGFR transactivation when uroepithelial tissue (mounted in an Ussing chamber) is maximally 
bowed outwards – akin to what the tissue experiences in a full bladder (43). In this case, EGFR 
transactivation functions to alleviate luminal stress by increasing apical surface area via 
exocytosis. Because adenosine also stimulates apical exocytosis in umbrella cells (53), because it 
is released from both surfaces of the epithelium in response to a full bladder (306), and because 
adenosine is reported to act as a stress-relieving hormone (104,320,321), we asked whether 
adenosine also stimulated EGFR transactivation. We found that like maximal stretch, adenosine 
stimulates a slow and gradual increase in apical exocytosis, which is dependent on the activity of 
a metalloproteinase that cleaves HB-EGF, resulting in EGFR transactivation. Furthermore, both 
responses require the downstream stimulation of ERK1/2 and both have a requirement for 
protein synthesis and secretion. Two studies have previously reported adenosine-mediated EGFR 
transactivation, but they did not identify metalloproteinase invovled, nor did they dissect the 
signaling pathway that linked A1AR to EGFR activation (322,323).  
While stretch and adenosine both stimulate exocytosis by way of EGFR transactivation, 
the pathways employed are not necessarily identical and there may be species differences. For 
example, in rabbit tissue the ADAM17 inhibitor Tapi-2 and the PKC inhibitor calphostin C 
impair adenosine-stimulated exocytosis, but have no apparent effect on the stretch-induced late-
phase response. Thus, in rabbit uroepithelium, stretch and adenosine likely utilize distinct 
upstream signaling pathways and metalloproteinases. This conclusion is further supported by our 
previous observation in rabbit tissue that the late-phase exocytic response is potentiated by 
adenosine, but not dependent on it (53). Physiologically, these additive events would allow the 
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umbrella cells to respond to stimuli generated in its immediate environment (e.g. stretch) but also 
to external stimuli such as adenosine, which can be produced locally or from other tissues in the 
lower or upper urinary tract (324).  
 
3.4.2 ADAM17 mediates adenosine-dependent EGFR transactivation 
We detected message for ADAM-9, -10, -15 and -17 in the uroepithelium, but focused 
our studies on ADAM17 because of the abundance of studies demonstrating the physiological 
relevance of this ADAM family member, including the observation that ADAM17 is the 
physiological convertase for several EGFR ligands including HB-EGF (221,245,250) . Several 
pieces of data support a critical role for ADAM17 function in late-phase exocytosis. First, we 
find that in umbrella cells ADAM17 is localized to UP3a-positive discoidal/fusiform vesicles, 
the major apically directed vesicle population in these cells. Second, we observe that ADAM17 
is expressed at or near the apical surface of the umbrella cells, which we previously showed is a 
primary site for EGFR and HB-EGF-dependent receptor transactivation (43). Third, we find that 
the ADAM17 inhibitor Tapi2 impairs exocytosis. Finally, we adapted our previously described 
in situ adenoviral transduction approach to express ADAM17-specific interfering RNAs. This 
technique resulted in an ~ 90% knockdown of ADAM17 expression in the uroepithelium and 
caused a >85% decrease in CCPA-induced hGH release. While we cannot rule out a role for 
other ADAMs in this process, the knockout of ADAM17 was sufficient to block the majority of 
A1AR-stimulated exocytosis in the uroepithelium. However, as noted above a different ADAM 
isoform is likely required for stretch-induced transactivation in rabbits.  
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3.4.3 A Gi  Gβγ PLC DAG PKC pathway promotes ADAM17 activation 
An important question is the upstream signaling events that lead to ADAM17 activation, 
as many studies employ non-physiological stimuli such as treatment with TPA and PMA. Work 
to date has shown roles for ERK, p38 MAPK, and several classical PKC isoforms 
(166,167,230,303,304). For example, in lung cells, PKCϵ-mediated ADAM17 activation has 
been shown to be necessary for premalignant changes post exposure to tobacco smoke (315), 
while in glioblastoma cells, migration was initiated by PKCα-mediated activation and membrane 
translocation of ADAM10 and the subsequent cleavage of N-cadherin (325). Furthermore, in 
African green monkey kidney cells (Vero-H cells), PKCδ was found to directly bind and activate 
ADAM9, leading to cleavage of HB-EGF (326). Our current data show that A1AR-mediated 
apical exocytosis requires Gi and Gβγ, confirming that the activation of ADAM17 occurs 
downstream of a bona fide A1AR, Gi-protein signaling event. Furthermore, we observe a 
requirement for PLC, which is known to generate IP3 and diacylglycerol, a well-known activator 
of PKC.  Finally we have shown a requirement for PKC in apical exocytosis, noting that the 
selective PKC inhibitor calphostin C inhibits adenosine-stimulated exocytosis, while TPA 
stimulates it. Importantly, we can show that these effects occur upstream of EGFR 
transactivation. While we do not know if there are additional effectors in the pathway, our results 
are consistent with the hypothesis that a Gi  Gβγ PLC DAG PKC cascade promotes 
ADAM17 activation. 
PKC may promote apical exocytosis by phosphorylation of Ser811 in the 
cytoplasmic domain of ADAM17  
An important but unresolved question in the field is how stimuli such as PMA promote 
ADAM-dependent shedding of EGFR ligands. PMA is reported to act, in part, by enhancing 
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membrane traffic of ADAMs to the cell surface (201); however, other reports indicate that the 
surface distribution of ADAM17 is not significantly altered by this treatment (215,327,328). 
Alternatively, the ligands themselves that may show enhanced traffic. An alternative hypothesis 
is that stimuli such as PMA promote ADAM17 function by altering its dimer-monomer 
equilibrium and association with tissue inhibitor of metalloproteinases (TIMP) 3 (244); however, 
the lack of TIMP3 expression was previously reported to be without effect on ADAM activity 
(238). Still yet, PMA is proposed to change the redox potential of extracellular protein disulfide 
isomerase, which may then alter ADAM17 activity by rearrangements of its disulfide bonds 
(305). Finally, PMA, acting through PKC, may function by promoting ADAM17 
phosphorylation. Current evidence indicates that PMA may activate ERK or p38 MAPK, both of 
which are reported to phosphorylate Thr735 in the cytoplasmic domain of ADAM17 (201,202). 
Furthermore, phosphorylation of Ser791 or Ser819 (by unknown kinases) is also reported 
(210,303), but Ser791 is apparently phosphorylated in the resting state, and mutations of Ser819 
do not appear to impact ADAM17 activity (210). Finally, there are several reports that ADAM17 
lacking its cytoplasmic domain can still trigger EGFR transactivation (238,327-329), a finding at 
odds with any role for phosphorylation in ADAM17 activation.  
We identified a canonical PKC phosphorylation site in the cytoplasmic domain of 
ADAM17, centered at Ser811. Mutation of this residue to an Ala residue almost completely 
blocked CCPA-induced hGH release, consistent with the possibility that this residue is critical 
for ADAM17-dependent EGFR transactivation in the umbrella cell.  While we hypothesize that 
this residues function is modulated by phosphorylation, mutation of Ser811 to a nominally 
phosphomimetic Asp reside was without effect. However, it is worth noting that phosphorylation 
is not always mimicked by substitutions with Glu or Asp residues (330-332).  Thus, we will need 
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to perform additional experiments to confirm whether Ser811 is indeed phosphorylated and 
whether this event correlates with ADAM17 function in umbrella cells. In either case, our result 
does indicate a critical role for the cytoplasmic domain of ADAM17 in the regulation of its 
activity, and is inconsistent with the hypothesis that ADAM17 functions independently of this 
domain.   
Assuming that Ser811 is phosphorylated, how might it act? One possibility is that 
phosphorylation of this residue alters the conformation of ADAM17, thus promoting its activity. 
If true, then this would represent a form of inside-out signaling. This could be a direct effect on 
ADAM17 or might be indirect, e.g. it could act by modifying the association of the proteinase 
with TIMP3 (243,244,333). An additional possibility is that phosphorylation or Ser811 forms a 
docking site for other proteins to bind and trigger ADAM17 activation and or association with its 
substrates. Potential interacting proteins include MAD-2, a component of mitotic spindle 
assembly (233), the protein tyrosine phosphatase-H1 (PTPH-1) and SAP9, both of which interact 
with the COOH-terminal of ADAM17 and negatively regulate its function (234,334), Eve-1 
(235), or the N-arginine dibasic convertase (nardilysin) that interacts with both HB-EGF and 
ADAM17 and regulates cleavage of the latter (335). Obviously, additional work is needed to 
understand the mechanisms by which ADAM17 activity is regulated.  
In summary we propose the following model of how ADAM17 activity is regulated in the 
in the umbrella cells: In the quiescent state, when the uroepithelium is not activated by adenosine 
stimulation, ADAM17 at the apical surface is kept in an inactive dimer state by the inhibitory 
effect of TIMP3 (Figure 24 A). On activation of A1AR, a GiGβγPLCPKC pathway is 
initiated leading to the activation of ADAM17, possibly by phosphorylation at Ser811 in the 
cytoplasmic tail. Active ADAM17 breaks away from the dimer conformation and loses TIMP3 
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inhibition. It cleaves and releases HB-EGF. Released HB-EGF binds and activates EGFR by 
phosphorylation at Tyr1173 leading to downstream ERK1/2 MAPK pathway, protein synthesis 
and exocytosis (Figure 24 B). While stretch-mediated apical exocytosis in rats also requires 
ADAM17 activity, the signaling pathway that activates the protein or the upstream-
mechanosensors that are triggered were not investigated in this study.    
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Figure 24 Schematic of A1AR-mediated EGFR transactivation 
 
 130 
 A. In the quiescent bladder where A1AR is not activated, ADAM17 is kept dormant by the 
inhibitory action of TIMP 3, HB-EGF in not cleaved and EGFR is not activated. B. In the 
bladder stimulated by adenosine, A1AR is activated which in turn triggers a 
GiGβγPLCPKC pathway that leads to the activation of ADAM 17 (by phosphorylation of 
Ser811). Activated ADAM17 is released from the inhibitory action of TIMP3 and in-turn cleaves 
and releases HB-EGF which binds and transactivates EGFR. Active EGFR, by means of Y-1173 
phosphorylation in its cytoplasmic tail establishes an ERK1/2 signaling cascade that results in 
protein synthesis and exocytosis.   
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4.0  CONCLUSION 
4.1  INTRODUCTION 
The bladder mucosa is constantly exposed to physiological stress induced by cyclical changes in 
bladder volume and constituents of the urine. I undertook this study to understand the various 
cellular mechanisms employed by the umbrella cells to cope with the stress. I focused my studies 
on the impact of adenosine and adenosine-mediated signaling because it is one of the most well-
known stress response hormones in the body (320,336). For example, during ischemic episodes 
in the heart adenosine protects by decreasing the metabolic load of the myocardium and by 
increasing the coronary blood flow by vasodialation (337). Further, the role of adenosine as an 
organ protective agent during hypoxia and numerous other pathological conditions has been 
studied (81,276). Not surprisingly then, I found that adenosine is released from the bladder 
mucosa when the uroepithelium is under stress. Further, my studies revealed that activation of 
A1AR lead to a decrease in the threshold pressure of bladder-voiding, and at the cellular level 
triggered EGFR transactivation and membrane trafficking. As my dissertation comes to an end, 
my research paves the way for future studies that will better our understanding of the 
uroepithelium and sensory transduction by epithelial cells in general. I first briefly summarize 
my findings and then put forth some ideas for areas of research that warrant further investigation.  
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4.2 SUMMARY OF RESULTS 
4.2.1  Impact of adenosine on bladder function 
While there are many studies that focus on ATP-mediated bladder regulation, it is well-known 
that ATP is actively converted to adenosine by CD39 and CD73 in the extracellular space 
(324,338). Further, we have evidence that all four adenosine receptors are expressed in the 
uroepithelium and especially A1AR is expressed on the apical surface of umbrella cells (53).  
Therefore, I studied the turnover of adenosine in the bladder lumen and the impact of activating 
apical A1AR on bladder function (Chapter 2). My studies revealed that extracellular adenosine 
levels significantly increased when the bladder was subjected to stretch-induced stress. While, 
the mucosal adenosine levels were regulated by the function of adenosine deaminases and ENTs, 
the serosal adenosine levels were maintained by adenosine kinase and nucleoside transporters. 
To understand the role of this increased adenosine level on the function of the organ, I performed 
CMG on anesthetized rats. Adenosine or the A1AR agonist CCPA was intravesically instilled 
and the intraluminal pressure monitored. Remarkably, activation of the A1AR with CCPA or 
enriching luminal adenosine by blocking its routes of turnover caused lowering of the threshold 
pressure of bladder voiding. This could be a mechanism through which adenosine relieves 
interluminal stress in the bladder, by allowing the bladder to void from a lower threshold 
pressure. 
While adenosine plays protective role during normal physiological processes, stresses 
such as ischemia, hypoxia, bacterial cystitis in the bladder, intestinal infection, and diseases such 
as asthma leads to an increase in extracellular adenosine which worsens the condition. This could 
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be because of activating A2A and A3 receptors on the NK cells, mast cells and neutrophils and 
triggering the release of inflammatory mediators such as TNFα, IL-12 and INFγ (137-141,158). 
The results of my studies align with these other reports on adenosine receptor signaling in 
inflamed organs (134,276). I studied the impact of adenosine on pathologic bladders. I artificially 
induced bladder cystitis by treatment with cyclophosphamide, and studied the impact of 
adenosine on it. Intriguingly, adenosine exacerbated the bladder pathology by causing increased 
detrusor activity and reducing the time between successive voids.   
Adenosine protects at the organ level by reducing threshold pressure of voiding and 
relieving interluminal stress. However, the umbrella cells are also subjected to stress when 
incomplete voiding on outlet obstruction leads to over full bladder. We lack information on how 
adenosine impacts these cells and whether it modulates membrane trafficking events in the cells 
to relieve stress. Therefore, in the second part of my dissertation, I studied the impact of 
adenosine at the cellular level on the umbrella cells.    
4.2.2 The network of signals that coordinate umbrella cell function 
I report that activating apically localized A1AR trigger a late phase-like exocytosis response that 
is dependent on protein synthesis and is sensitive to BFA treatment. Furthermore, A1AR 
triggered apical exocytosis occurs via a pathway that depends on apical HB-EGF-mediated 
EGFR transactivation and downstream ERK1/2 activation. Interestingly, kinetics of exocytosis 
and the EGFR transactivation were similar to stretch-mediated late phase exocytosis. This 
indicates that multiple stimuli, perhaps related to stress can activate these pathways. I next 
sought to understand how the A1AR triggered the response. I identified the cellular pathway that 
links A1AR to EGFR and report that an A1ARGiGβγPLCPKC pathway is involved. PKC 
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lead to the activation of ADAM17 which in-turn cleaved HB-EGF and resulted in EGFR 
activation. 
Importantly, I used a previously described method for in situ transduction to express 
shRNAs, allowing me to knockdown the expression of ADAM17 specifically in the umbrella 
cells. This tool is particularly exciting because it allows us to specifically target proteins in the 
umbrella cells and knock them down. A1AR- and stretch-mediated EGFR transactivation and 
apical exocytosis was blocked on ADAM17 knockdown.  
Finally, to determine how PKC activates ADAM17, I studied a previously unexplored 
canonical PKC phosphorylation motif in the cytoplasmic tail of ADAM17. I performed point 
mutations where the serine residue at site 811 was converted to Ala or Asp. The Ser811Ala 
mutation impaired A1AR-mediated apical exocytosis. Whether this serine residue is directly 
phosphorylated by PKC has yet to be investigated. But my studies revealed the importance of the 
cytoplasmic domain of the protein and is inconsistent with the whereby ADAM17-mediated 
substrate cleavage is not dependent on this domain.  
4.2.3 Conclusion of my studies  
The results of my two studies indicate that adenosine-mediated signaling plays a beneficial role 
in the bladder both at the organ and at the cellular levels. Adenosine is actively released during 
bladder stress and is constantly turned over. While at the organ level luminal adenosine, acting 
on A1AR lowered the threshold pressure of bladder voiding thus relieving stress, at the cellular 
level, adenosine has an additional role of promoting exocytosis in umbrella cells. The exocytosis 
leads to increase in the apical surface area of umbrella cells, thereby resulting in the increase in 
bladder volume. Thus the role of adenosine in the bladder can be summarized as: a protective 
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agent that, during stressful conditions promotes bladder voiding by lowering the threshold 
pressure and also increases the apical surface of umbrella cells to mitigate the stress induced by 
mechanical stretching of the cells. While the results of my studies help to better understand the 
role of adenosine in bladder function, it has raised few important questions that warrant further 
study. I have addressed some of the questions in the following section.  
    
4.3 FUTURE DIRECTIONS 
The role of the cytoplasmic domain of ADAM17 
The role of the metalloproteinase in other organ systems including the heart, kidney, 
brain, and embryonic development has been well studied (339-341). However, its role in bladder 
function is only now beginning to become clear. My data suggests that a PKC-mediated inside-
out signaling is essential for ADAM17 function. However, this is in contradiction to studies 
which showed that the cytoplasmic tail was not required for the function of the enzyme 
(238,329).  However, many of these studies were performed in immortalized cell lines where 
ADAM17 was exogenously expressed and artificially activated. The activity of ADAM17 in the 
physiological system might work differently and might require its cytoplasmic tail for its 
function. In conversations with other scientist working on ADAM17 signaling, I gathered that 
the role of cytoplasmic tail of ADAM17 is more essential for the trafficking of the protein than 
its catalytic activity. While the function of the metalloproteinase domain can be regulated 
differently, the role of the cytoplasmic tail could be to regulate surface expression of the protein. 
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Perhaps, the cytoplasmic tail, and its various interacting proteins adds another level of regulation 
by modulating surface expression. More studies are warranted especially in dissecting the 
regulation of its catalytic function from its trafficking pattern within the cell. 
Most importantly, I identified a canonical PKC phosphorylation site in the cytoplasmic 
domain of ADAM17 that has not been explored before. Point mutations where the critical serine 
residue (Ser811) was converted to alanine had a big impact on A1AR-mediated apical exocytosis. 
However, at this point, we still do not know if the serine residue is phosphorylated and if so, 
whether PKC directly phosphorylates it. More experiments are required to determine whether the 
residue is phosphorylated. Mass spectrometry analysis has proved to be challenging because of 
the proximity of the residue to trypsin cleavage sites (mass spectrometry is done post trysin-
mediated cleavage of the protein), hence an alternative strategy has to be employed. 
Immunoprecipitation of activated ADAM17, followed by immunobloting with phosphor-serine 
antibodies is another approach. However, the presence of other serine residues in the cytoplasmic 
tail that are phosphorylated (Ser791 and Ser 819) might complicate the results.         
I also identified mRNA message for ADAM10 in the uroepithelium. ADAM10 is the 
closest relative to ADAM17. The role of ADAM10 in the bladder was not elucidated in this 
study and warrants further research.           
How does adenosine lower threshold pressure? 
My studies using CMG revealed that activation of luminal A1AR relieved bladder 
pressure by lowering the threshold pressure of voiding. How might this happen? It is possible 
that activating apically localized A1AR on the umbrella cells triggers the release of factors from 
the basolateral surface. Subjacent to the umbrella cells are afferent nerve processes (Aδ fibers 
and C-fibers). As mentioned earlier, the Aδ fibers sense bladder fullness and interluminal stress 
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and could be a direct target of factors released from the basolateral surface of the umbrella cells. 
Furthermore, the intermediate cells could act as amplifiers of the signals received from the 
umbrella cells, thus enhancing the stress signals received from the umbrella cells (342,343).  
In support of my view that activation of apical adenosine can activate afferent neurons, 
numerous studies have shown that mechanical stretching of the bladder triggers firing of afferent 
nerves (290,344). My studies showed that stress induced by mechanical stretching cause release 
of adenosine from the uroepithelium. Taken together, these data indicate that stress-induced 
release of adenosine binds apical A1AR and triggers release of factors from the uroepithelium 
that could have a direct impact on the neuronal circuitry of the bladder. 
What could these factors be? Numerous studies have shown that neuro-modulatory 
effectors such as Ach, ATP and NO are released from the uroepithelium (71,73,75,345-347). 
Furthermore, I report that adenosine is also released from the serosal surface of the 
uroepithelium under stress. These are the likely factors to be released from the uroepithelium on 
adenosine-mediate signaling. The released factors might bind and activate the afferent nerve 
process, which have been reported to carry the receptors for these factors.   
However, the challenging task would be to study the factors released from the serosal 
surface of the uroepithelium in real time as bladder fills and its impact on the afferent nerves and 
muscles. The Ussing chamber apparatus is a good setup to collect factors released from the 
serosal surface. Apical A1AR can be activated and the factors released from the serosal surface 
can be determined by sampling the buffer bathing the serosal chamber at different time points 
and analyzing the sample for the presence of the candidate factors such as Ach, NO, and ATP.   
Another method of identifying the mediators released from the uroepithelium on A1AR 
activation is by specifically knocking down enzymes and proteins involved in the synthesis of 
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the factors. For example, choline acetyltransferase can be knockdown specifically in the 
umbrella cells by using the shRNA-mediated knockdown technique that I used in this 
dissertation, and synthesis of Ach can be blocked. CMGs can be performed in the knockdown 
rat, and CCPA can be intravesically instilled to determine whether Ach is involved in A1AR-
mediated bladder modulation. Similar approaches can be used to study NO or ATP involvement 
in A1AR-mediated bladder regulation.  
 
Does transactivation lead to lowering of threshold pressure of bladder voiding? 
From my studies on the umbrella cells, I found that activation of A1AR lead to EGFR 
transactivation. Could this pathway be how A1AR triggers lowering of threshold pressure and 
could this be a central pathway via which the bladder relieves luminal stress?  
This could be tested in CMG studies where EGFR is blocked by intravesicle 
administration of AG1478. In addition, CMG can also be performed on rats where ADAM17 is 
knocked out (as ADAM17-/- mice are not viable). These experiments would reveal the 
importance of EGFR transactivation in modulating bladder function.  
The adenoviral-mediated in situ knockdown technique that I have used to study the role 
of ADAM17 in my dissertation is a powerful tool to study specific pathways and the role of 
specific proteins in bladder regulation. Performing CMG on rats where specific proteins in the 
transactivation pathway such are EGFR, HB-EGF or PKC are knocked down will provide 
valuable, real-time information on the role of proteins in bladder regulation. 
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How does EGFR transactivation promote exocytosis?   
Adenosine stimulates exocytosis at the apical surface of umbrella cells via EGFR 
transactivation. My data indicates that protein synthesis is required for the exocytosis. However, 
the identity of the protein(s) synthesized is unknown. The protein synthesis could results in the 
manufacture of fresh vesicles and the machinery required to export them to the apical surface or 
could result in the expression of a yet to be identified protein that triggers the exocytosis of pre-
existing vesicles.  
The proteins synthesized downstream of EGFR transactivation and how it impacts late 
phase exocytosis definitely warrants further studies. It will be interesting to perform a microarray 
analysis of all the genes transcribed as result of adenosine- and stretch-mediated EGFR 
transactivation. The analysis would provide very valuable information regarding why myriad 
signaling pathways converge onto EGFR transactivation in umbrella cells and what genes are 
activated/ down regulated, leading to late phase exocytosis.  
Furthermore, we still don’t know if the early- and late-phase exocytic pathways lead to 
the exocytosis of distinct DFV populations. There is a possibility that there are two distinct 
population of DFVs, the Rab11a and the Rab27 positive vesicles (24). It will be interesting to 
know what are the deciding factors within the cell that determine which population of vesicles 
will be exocytosed.  
To delineate between the roles of Rab11a positive DFVs and Rab27 positive DFVs the 
adenoviral-mediated knockdown strategy can be employed. By knocking down either Rab11a or 
Rab27 and activating A1AR or stretch in Ussing chamber apparatus, the protein involved in two 
phase of exocytosis can be ascertained.  
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4.4 CLOSING COMMENTS 
 This dissertation has furthered our understanding of the role of adenosine on bladder 
function both at the organ level and at the cellular level. From a clinical perspective, the 
discovery that adenosine regulates bladder function by lowering the threshold pressure has 
therapeutic potential in treating urinary bladder stress-related disorders. From a cell biology 
perspective, the discovery that A1AR transactivates EGFR in the umbrella cells, and that the 
pathway involves ADAM17 are key findings that open many new avenues of research in 
umbrella cell biology. Finally, while this work has answered few questions, has given rise to 
many more critical questions. Further investigation is required to better understand the sensory 
function of the umbrella cells and the other polarized epithelial cells of our body.  
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5.0   MATERIALS AND METHODS 
5.1  CHAPTER 2 MATERIALS AND METHODS 
5.1.1  Reagents 
Unless otherwise specified, all chemicals were obtained from Sigma (St. Louis, MO) and were of 
reagent grade or better. Adenosine, adenosine agonists, and modulators of adenosine turnover 
were freshly prepared as stocks in the following diluents: a 10 mM stock of CCPA was made in 
DMSO, 25 mg/ml of cyclophosphamide was prepared in distilled H2O, a 10 mM stock solution 
of S-(4-nitrobenzyl)-6-thioinosine (NBTI) was prepared in DMSO, 100 µM 5-iodotubericidin 
(IDT; Tocris, Ellisville, MO), 10mM stock of erythro-9-(2-hydroxy-3-nonyl)adenine 
hydrochloride (EHNA; Tocris) was made in DMSO, and a 10 mM stock of 1,3-dipropyl-8-
cyclopentylxanthine (DPCPX) made in DMSO. Adenosine was freshly prepared and dissolved in 
Krebs buffer (110 mM NaCl, 5.8 mM KCl, 25 NaHCO3, 1.2 mM KH2PO4, 2.0 mM CaCl2, 1.2 
mM MgSO4, 11.1 mM glucose, pH 7.4). Beuthanasia-D and butorphanol (Torbugesic-SA) were 
purchased from Butler Schein (Dublin, OH). Lidocaine (LMX4) and isoflurane were purchased 
from Webster Veterinary (Webster, NY). The polyclonal anti-A1 receptor rabbit antibody was 
obtained from Abcam (ab82477; Cambridge, MA), fluorphore- or HRP-conjugated secondary 
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antibodies were purchased from Jackson Immunoresearch (West Grove, PA), and TRITC-labeled 
phalloidin and To-Pro3 were procured from Molecular Probes/Invitrogen (Grand Island, NY). 
 
5.1.2 Animals 
Animals used in this study were female New Zealand white rabbits (3–4 kg; Myrtle’s Rabbitry, 
Thompson Station, TN) and female Sprague-Dawley rats (250–300 g; Harlan Laboratories). 
Rabbits were euthanized by intravenous injection of 300 mg of pentobarbital sodium (Buthensia 
D) into the ear vein after the area was numbed using topical lidocaine ointment. After euthanasia 
the bladders were rapidly excised and processed as described below. Rats were sedated by 
inhalation of isoflurane and then 1.2 g/kg urethane dissolved in H2O was injected 
subcutaneously. After 2 h, the rats were prepared for adenosine measurements or cystometry as 
detailed below. At the end of the experiments, the rats were euthanized by inhalation of 100% 
CO2, and a thoracotomy was performed to verify death. All animal studies were carried out with 
the approval of the University of Pittsburgh Animal Care and Use Committee. 
 
5.1.3 Mounting the uroepithelium in Ussing stretch chambers 
Mounting of tissue in Ussing stretch chambers was performed as described previously (28). 
Briefly, excised rabbit bladders were cut open longitudinally, washed with Krebs buffer, and 
then mounted on custom-made Teflon racks, mucosal side down. The smooth muscle layers were 
removed with sharp scissors and forceps. The remaining mucosal tissue, containing the 
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uroepithelium, was mounted on the pins of a plastic ring with a 2-cm2 opening. The ring, with 
tissue, was sandwiched between two halves of a modified Ussing stretch chamber. Each 
hemichamber (mucosal and serosal) was filled with 12.5 ml of Krebs solution and the serosal 
hemichamber was bubbled with gas containing 5% (vol/vol) CO2 and 95% (vol/vol) air. The 
tissue was equilibrated for 30 min before the start of the experiment.  
 
5.1.4  Measurement of adenosine, AMP, and inosine  
After mounting and equilibration, rabbit tissue was isovolumetrically washed three times with 60 
ml of Krebs buffer. After a 60-min incubation, the tissue was gradually stretched by infusing 
Krebs solution into the enclosed mucosal chamber at a rate of 100 µL/min until the chamber was 
filled (2 ml). Afterwards, the Luer ports providing access to the mucosal hemichamber were 
sealed and an additional 500 µL of buffer was pumped into the mucosal hemichamber, causing 
the uroepithelial tissue to completely bow outwards. The fully distended tissue was incubated for 
an additional 60 min. Samples, taken with replacement from the serosal or mucosal 
hemichambers at the designated time points, were heat inactivated, flash frozen in liquid 
nitrogen, and stored at -80°C.  
For in vivo studies, rats were anesthetized and two-h post urethane administration, a toe/tail 
pinch was used to confirm that the animals had reached an appropriate anesthetic depth. 
Anesthetized rats were placed on their backs and the hind legs secured to the table to provide 
easier access to the abdomen. The fur around the urethral opening and along the caudal midline 
was removed with a surgical grade trimmer (Oster, McMinnville, TN). The hairless area was 
wiped with 70% ethanol and a 1.5 -cm incision was made just to the left of the midline. The 
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subcutaneous fat and muscle layer were incised and the bladder was then located and 
exteriorized. The ureters were located, tied off using a 6-0 silk suture (Coviden, Mansfield, MA), 
and then cut to prevent urine from entering the bladder. The bladder was placed back in the body 
cavity and the incision sutured close. A 22g I.V. catheter was trimmed to a length of 1.5 cm, 
inserted through the urethra, and then residual urine was removed by gently pressing the 
abdomen to promote voiding. The bladder was then filled with sterile phosphate buffered saline 
containing 0.9 mM CaCl2 and 1.0 mM MgCl2 (PBS+) and the bladder voided. This was repeated 
two additional times. The bladder was then slowly filled for 60 min with PBS+ at a rate of 6 µl/ 
min. At the end of this incubation, the bladders were voided and the intravesicle fluid collected 
for analysis. Subsequently the bladder was again slow filled for 60 min, and then maintained in 
its filled state for an additional 60 min. At the end of the treatment the bladder was voided and 
fluid was then collected. Samples were treated and stored at -80˚ C as described above. 
Adenosine, AMP, and inosine concentrations in the samples were determined using a triple 
quadrupole mass spectrometer (TSQ Quantum-Ultra, ThermoFisher Scientific, San Jose, CA) as 
previously described (348). 
 
5.1.5 Cystometry analysis 
Rats were anesthetized and their bladder exposed as described above. Upon being exteriorized, 
the bladder was held in position by placing a plastic dowel behind the bladder. The bladder was 
moistened with normal saline and shallow purse string sutures were made around the dome using 
a 6-0 silk suture material. Care was taken to not puncture the bladder. The area within the 
boundary of the sutures was punctured with an 18 G needle, and a flame-flanged PE50 tube was 
 145 
inserted into the hole. The suture was tightened around the tubing and the tube was gently 
retracted until the flange was flush with the mucosa. The bladder was returned to the peritoneal 
cavity, and the surgical incision was closed around the PE50 tubing in two layers using 6-0 silk 
suture.  
The PE50 tubing was connected to a 3 way port: one branch led to a pressure transducer, 
while the other two were connected to syringes containing buffered urine substitute (BUS) ± 
drug. BUS, made in accordance with the published composition of Sprague-Dawley rat urine 
(349), had the following composition: 26 mM (NH4)2SO4, 149 mM NaCl, 267 mM KCl, 3 mM 
CaCl2, and 0.4% (w/v) MgPO4. The solution was titrated with NaOH until a pH of 6.5 was 
measured. The pressure transducer was connected to a Quad Bridge Amplifier and Powerlab 
4/30 (ADInstruments; Castle Hill, Australia), which was interfaced with an iMac computer 
(Apple; Cupertino, CA) running the Chart 5.0 program (ADInstruments; castle Hill, Australia). 
The syringes containing the buffers were placed in a syringe pump (New Era Syringe Pump 
Systems, Farmingdale, NY) and BUS was infused into the bladder at a rate of 50 µl/min for 45 
min, until uniform peaks were obtained. BUS (± drugs) was then infused for 60-90 minutes. The 
effluent was collected and the volume was measured to determine the fluid recovery.  
The cystometrograms (CMGs) were recorded using the Chart program (ADInstruments). 
Following a 45-min period of equilibration, data for 8-12 successive bladder cycles were 
collected and for each animal the average values for the following parameters were entered in an 
Excel spread sheet (MS Office, Microsoft, Redmond, WA): 1) the basal pressure was the lowest 
pressure point recorded immediately following a void; 2) the threshold pressure was the pressure 
point recorded just before the spike in pressure was observed as the bladder began to void; 3) the 
peak pressure was the maximum pressure recorded during voiding; 4) the intercontraction 
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interval (ICI) was the time between two consecutive peak pressures; 5) the percent fluid recovery 
was the ratio of the volume of fluid released versus that infused into the bladder. The mean and 
SEM were calculated for each similarly treated experimental group and the data analyzed for 
statistical significance using the techniques described below. 
 
5.1.6  Cyclophosphamide treatment 
An acute cyclophosphamide-induced cystitis was induced as described previously (284,350). In 
brief, rats were sedated with isoflurane and administered 1mg/kg butorphenol subcutaneously 
and 150 mg/kg cyclophosphamide intraperitoneally. Two h after these injections the rats were 
given 1.2 g/kg urethane subcutaneously, and then 2 h later the CMG analysis was performed as 
detailed above.  
 
5.1.7 Immunofluorescence labeling and image acquisition  
Bladder tissue was fixed and processed as described previously (49) 
. Images were captured using a 63X 1.2 NA glycerol objective and the appropriate laser lines of 
a Leica TCS SP5 CW-STED confocal microscope (in normal confocal mode). The 
photomultipliers were set at 900-1200 and images collected using an average of six line scans. 
Serial 0.25 µm z-sections were acquired. The images were imported into Volocity 4-D software 
(Perkin Elmers; Waltham, MA) and following image reconstruction and contrast correction 
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exported as TIFF files. The exported images were opened in Adobe Photoshop CS5, converted to 
JPEG format, and the composite images prepared in Adobe Illustrator CS5.  
 
5.1.8  Western blot analysis 
Lysates of uroepithelial cells and western blotting was performed as described previously (43). 
 
5.1.9 Statistical analysis 
Statistical significance between means was determined by Student’s t-test or in the case of 
multiple comparisons by analysis of variance (ANOVA). If a significant difference in the means 
was detected by ANOVA, multiple comparisons were performed using Dunnett’s post-test 
correction. Statistical analyses were performed using Prism 5 software (GraphPad, La Jolla, CA) 
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5.2  CHAPTER 3 MATERIALS AND METHODS 
5.2.1  Reagents and antibodies 
Unless otherwise specified, all chemicals were obtained from Sigma (St. Louis, MO) and were of 
reagent grade or better. Adenosine was freshly prepared and dissolved in Krebs buffer (110 mM 
NaCl, 5.8 mM KCl, 25 NaHCO3, 1.2 mM KH2PO4, 2.0 mM CaCl2, 1.2 mM MgSO4, 11.1 mM 
glucose, pH 7.4). The following stock solutions were prepared in DMSO: AG1478 (10 mM), 
calphostin-C (250 µM), 2-Chloro-N6-Cyclopentyladenosine (CCPA) (10 mM), GM6001 (15 
mM), Tapi-2 (15 mM, Tocris, Bristol, U.K) and U0126 (10 mM). A 10mM stock of phorbol 
myristate acetate (PMA) was prepared in ethanol, and the following stocks were prepared in 
molecular biology grade water: pertussis toxin (100 μg/ml), CRM197 (25 ng/ml), and M119K 
(10 mM, purchased from the National Cancer Institute, Bethesda, MD). WGA-FITC was 
purchased from Vector labs (Burlingame, CA) Beuthanasia-D was purchased from Butler Schein 
(Dublin, OH). Lidocaine (LMX4) and isoflurane were purchased from Webster Veterinary 
(Webster, NY). The polyclonal anti-A1AR rabbit antibody was obtained from Abcam (ab82477; 
Cambridge, MA), anti-ADAM17 rabbit polyclonal antibody from EMD-Millipore (Billerica, 
MA), anti-EGFR and anti-EGFR-phopho-Y-1173 rabbit polyclonal antibodies from Cell 
Signaling Technology (Danvers, MA) fluorphore- or HRP-conjugated secondary antibodies were 
purchased from Jackson Immunoresearch (West Grove, PA), and TRITC-labeled phalloidin and 
To-Pro3 were procured from Molecular Probes/Invitrogen (Grand Island, NY). 
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5.2.2 Animals 
Animals used in this study were female New Zealand white rabbits (3–4 kg; Covance, Princeton, 
NJ) and female Sprague-Dawley rats (250–300 g; Harlan Laboratories, Indianapolis, IN). 
Rabbits were euthanized by intravenous injection of 300 mg of Buthensia D into the ear vein 
after the area was numbed using topical lidocaine ointment. After euthanasia, the bladders were 
rapidly excised and processed as described below. Rats were sedated by inhalation of isoflurane 
and kept under sedation during the adenoviral infection procedure (see description below) by 
constant inhalation of isoflurane. At the end of the procedure, the rats were allowed to revive. 
Twenty-four h after infection, the rats were euthanized by inhalation of 100% CO2, a 
thoracotomy was performed, and the bladder was excised. All animal studies were carried out 
with the approval of the University of Pittsburgh Animal Care and Use Committee. 
5.2.3 Cell Culture 
293A cells (Invitrogen) were used to prepare ADAM17- or scrambled-shRNA viruses. The cells 
were grown in DMEM purchased from Corning Cellgro (Corning, NY) supplemented with 10% 
v/v fetal bovine serum (Thermo scientific, Logan, UT), 1% v/v MEM non-essential amino acids 
(Life Technologies, Grand Island, NY), 2mM glutamate (Sigma), and 1% v/v 
penicillin/streptomycin (Lonza, Walkersville, MD). cre8 cells were grown in DMEM purchased 
from Sigma supplemented with 10% v/v defined fetal bovine serum (Thermo scientific) and 1% 
v/v penicillin/streptomycin. HEK293 cells were grown in DMEM supplemented with 10% v/v 
fetal bovine serum and 1% v/v penicillin/streptomycin. When producing viruses, cells were 
grown in their respective media, but without penicillin/streptomycin. 
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5.2.4 Immunofluorescence labeling and image acquisition  
Bladder tissue was fixed and processed as described previously. Briefly, tissues fixed with 4% 
PFA fixative (4% paraformaldehyde in 100 mM (CH3)2AsO2Na · 3H2O) were embedded in 
OCT-based cryo-blocks. 4μm sections cryosections were obtained using a Leica CM1950 
cryostat on the hydrophobic surface of glass slides. The sections were washed three times 5 min 
each with PBS and the fixative was quenched with quench buffer (20mM Glycine, 75mM 
NH4Cl) for 10 min. When staining for ADAM17, the sections were quenched for 7 min and were 
subsequently quenched with quench buffer supplemented with 0.05% w/v SDS for an additional 
3 min. The tissue was then washed with PBS and blocked with block buffer (7% w/v Fish 
gelatin, 0.25% saponin v/v and 0.05% NaN3 w/v made in PBS) for 1-h at room temp. 1:200 
dilution of the antibodies where made in the block buffer, applied on the section and incubated at 
room temp for 2 hr in the case of ADAM17 or overnight at 4°C for A1AR or UP3a. The primary 
antibody was washed away with PBS and detected using either Alexa488- or Cy3-labelled 
secondary antibodies. Actin and nuclei were stained with either rhodamine or fluorescein 
phalloidin and TOPRO-3 respectively. The sections were post-fixed for 10 min with 4% PFA 
fixative, mounting buffer (1% w/v phenyldiamine, 20mM Tris, 90% v/v glycerol, pH 8.0) was 
applied on the section and covered with a glass cover slip. The slide and coverslip assembly was 
sealed with nail polish.    Images were captured using a 63 X 1.2 NA glycerol objective and the 
appropriate laser lines of a Leica TCS SP5 CW-STED confocal microscope (in normal confocal 
mode). The photomultipliers were set at 900-1200 V and images collected using an average of 
six line scans. Serial 0.25 µm Z-sections were acquired. The images were imported into Volocity 
4-D software (Perkin Elmers; Waltham, MA) and following image reconstruction and contrast 
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correction exported as TIFF files. The exported images were opened in Adobe Photoshop CS5, 
converted to JPEG format, and the composite images prepared in Adobe Illustrator CS5.  
 
5.2.5 Mounting rabbit uroepithelium or rat bladders in Ussing stretch chambers 
Isolation of rabbit uroepithelium from the underlying muscle layers and mounting in Ussing 
stretch chambers were performed as described earlier. Briefly, rabbit bladder was excised, slit 
open vertically along one of the lateral veins and spread on a custom made Teflon rack with the 
uroepithelium facing down. The muscles were carefully removed with the pair of tweezers and 
sharp scissors. The remaining tissue containing the intact uroepithelium was mounted on the pins 
at the outer edges of a plastic ring with an opening of 2 cm2. The rings were locked between two 
Ussing stretch hemichambers, which were clamped into position on a Teflon base. Warm Krebs 
buffer was simultaneously added to the mucosal (apical facing) and serosal (muscle facing) 
chambers. The tissue was gassed with 95% air/5% CO2 during a 30-45 min equilibration period 
and treated with the indicated drug added to the mucosal and serosal hemichambers bathing the 
tissue. However, CCPA, CRM197, or PMA were added only to the mucosal hemichamber. The 
tissue capacitance (CT) and transepithelial resistance were measured for a period up to 300 min.  
Rat bladder tissue was processed as described earlier. Briefly, the bladder was excised, 
cut open along one of the lateral veins and then carefully spread and pinned out on rubber 
dissection mats. The dissected bladders were then mounted on the pins of a plastic ring with an 
opening of 0.75 cm2 and the rings clamped between two Ussing stretch hemichambers. The 
chambers were filled with Krebs buffer and equilibrated. To stretch the tissue, buffer was added 
to the mucosal hemichamber chamber via Luer ports at a rate of 35 μl/min using a syringe pump 
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(New Era pump systems, Farmingdale, NY). Once the chamber was filled, an additional 250 μl 
was then pumped into the chamber to stretch the tissue 
 
5.2.6 Western blot analysis 
To prepare lysates, bladder tissue was placed on a rubber dissection mat with the mucosal 
surface facing up. The tissue was held in place by pinning it at the four corners using 20G ¾” 
needles (BD Biosciences). An aliquot (35-50 μl) of SDS lysis buffer (50mM Triethanolamine, 
pH 8.6, 100 mM NaCl, 5mM EDTA, 0.2% w/v NaN3, 0.5% w/v SDS) containing a protease and 
phosphatase inhibitor cocktail (Cell Signaling Technologies, Boston, MA) was added to the 
mucosal surface and the uroepithelium recovered by gently scraping the cells using an rubber 
cell scraper (Sarstedt, Newton, NC). The cell lysate was transferred to a 1.6 ml Eppendorf tube, 
vortex-mixed at 4°C for 10 min using a model 5432 mixer (Eppendorf, Hauppauge, NY ) and 
centrifuged at 13,000 rpm for 10 min at 4° in a table top model 5415D microcentrifuge 
(Eppendorf). The clear supernatant was collected, flash frozen, and stored at -80°C. The protein 
concentration was quantified using the BCA assay (Pierce, Rockford, IL). Equal amounts of 
protein from the bladder lysates was resolved by electrophoresis on 4-15% polyacrylamide 
gradient gels (BioRad, Hercules, CA) at 200 V and constant current for 30 min. For ADAM17 
and hGH, proteins were transferred to Immobilon P membranes (Millipore) at 375 mA constant 
current using a 100 mM CAPS, pH 11.0 running buffer. In the case of the EGFR, proteins were 
transferred to nitrocellulose membranes (GE healthcare) at 375 mA constant current using a Tris-
glycine running buffer (25mM Tris, 190mM Glycine) for 2 hr. The membrane was blocked for 
30 min with 5% w/v non-fat milk made in TBST buffer (TBS + 0.1% Tween 20). Following the 
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blocking step, the membrane was incubated with primary antibodies overnight at 4°C. After 
adequate washes with TBST, the membrane was incubated with goat-anti rabbit-HRP or goat-
anti mouse-HRP secondary antibodies for 1h at room temp and washed with TBST. The bands 
were detected by incubating the membrane with ECL chemiluminesence solution for 2 min 
(Pierce, Rockford, IL), followed by film capture on Carestream Kodak Biomax films 
(Carestream, Rochester, NY). Data were quantified using QuantityOne quantification software 
(Biorad)    
5.2.7 Reverse transcriptase PCR 
Total RNA was isolated using the RNAquous kit (Invitrogen) according to the vendor protocol. 
Briefly, excised rat bladders were slit open along the lateral veins using a scalpel and the bladder 
pinned out as described above. Cell lysis buffer (50μl) was added to the mucosal surface and the 
surface was gently scrapped with a rubber cell scraper to lyse the uroepithelium. The lysate was 
collected, mixed with the provided 64% ethanol buffer, filtered through the included filter 
cartridges, and total mRNA eluted using the elution buffer provided with the kit. The isolated 
RNA was treated with DNAse (Turbo DNA, Ambion) to deplete any residual genomic DNA.  
The purified total RNA was used to generate cDNA using the Retroscript first strand synthesis 
kit (Life technologies) with random decamer oligos provided with the kit according to the 
vendor’s protocol. The cDNA was used as a PCR template and amplification of ADAMs and β-
Actin were performed using standard PCR protocol and rat specific sequence primers as follows: 
target, forward 5’-primer, 3’ reverse primer:  
ADAM9: AATTGTCACTGTGAAGATGGCTGGGCTCC, GCAGCCGCAACCAGGGGGATGATTAGG 
ADAM10: CAAGTGTGCATTGGGCAATGTGCAGG, TGTTCCACTGCAAAGAGCCTGTACTGG 
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ADAM12: AGGATCATGCAACATGTACCAATAGCAGCC, AGGATGTTAGGCTGACCATCATTGCTTGG  
ADAM15: CTCCTCAGCCTCCTGTTGTTATTGGTCC, GGGTACTGGAAAGCTGACATTAGCTTGC 
ADAM17: GAAGTTTCTGGCAGACAACATCGTTGGG, GGAACGGCTTGATAATGCGAACAGATGC 
βActin: TCCATCATGAAGTGTGACGTTGACATCC, GGAGCAATGATCTTGATCTTCATGGTGC.  
The PCR products were resolved using gel electrophoresis in a 1% agarose gel. The 
image was captured using a GelDoc image capture system (BioRad).  
5.2.8  Generation of adenoviruses encoding ADAM17 shRNA  
The iRNAi software (Nucleobytes.com) was used to search the Rat ADAM17 cDNA (Pubmed 
accession number NM_020306) for optimal sequences containing the sequence AA(N19). Four 
shRNA sequences were selected. The top and the bottom strands were individually synthesized 
(IDT, Coralville, IA) and annealed by mixing the two strands in equal concentrations, heating to 
94°C and cooling gradually to room temperature. The annealed shRNA sequences where then 
ligated into the linearized pU6/ENTR vector (Life Technologies). The ability of the different 
shRNA sequences to silence ADAM17 was determined by co-transfecting HEK293ft cells with 
shRNA-pU6/ENTR vectors and ADAM17 cDNA. Twenty-four h later, cells were lysed, the 
proteins were resolved by SDS-PAGE, and ADAM17 detected by western blotting using the 
techniques described above. Of the four, the sequence that had maximum silencing efficiency 
(>80%; 5’- GGATTAGCTTACGTTGGTTCT-3’) was selected and recombined into the 
pBLOCKiT Adenovirus System vector (Invitrogen) using an in vitro clonase-mediated 
recombination reaction according to vendor’s protocol. The recombined pBLOCKiT vector was 
linearized by Pac1 restriction digestion, and transfected into 293A cells using Lipofectamine 
2000 reagent (Life Technologies). Eleven days post transfection, when the cytopathic effect was 
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greater than 75%, the cells in this first P1 generation were harvested by tituration, and lysed by 
freezing the cells at -70˚ C and thawing them for 5-10 min in a 37˚ C waterbath.  Three freeze-
thaw cycles were typically sufficient to lyse the cells. The lysate, containing released virus, was 
used to infect a new round of cells (P2), a process that was repeated one additional time (P3). 
The P3 viruses were produced by infecting ten 15-cm petri dishes (BD Falcon San Jose, CA) of 
293A cells with virus-containing lysate from P2. On the third day, when the cells showed more 
than 85% cytopathic effect, the were recovered by tituration, pooled, centrifuged at 3500g 
(Eppendorf 5810 R)  for 14 min at 4˚ C, and mixed in 7 ml of re-suspension buffer (100 mM 
Tris, pH 7.4, 10 mM EDTA). The concentrated cell suspension was lysed by repeated freeze-
thaw cycles as described above. The lysate was separated from the cell debris by centrifuging at 
5000 x g (Eppendorf 5810 R) for 15 min at 4°C. The supernatant was carefully removed and 
applied to the top of a step gradient containing 2.5 ml of 1.25 g/ml CsCl solution, which was 
layered on top of 2.5 ml of 1.4 g/ml CsCl loaded into clear 13 ml PET ultracentrifugation tube 
(Thermo Scientific). The sample was centrifuged at 35,000 rpm for 1hr at 4°C using a Beckman 
Coulter (Brea, CA) using SW-41 swinging bucket rotor. The concentrated virus, which appeared 
as an off-white band at the interface of the two CsCl layers, was collected by piercing the side 
wall of the tube with an 18G needle and aspiration into a connected 5 cc syringe (BD 
Biosciences). The viruses were further purified by passage through a PE10 gel filtration column 
(GE Healthcare) equilibrated with virus suspension buffer (PBS containing 10% v/v glycerol). 
The virus-containing fractions were detected by monitoring the A260, pooled, and stored at -70˚ C 
in small aliquots, which were thawed in a 37˚ C water bath just prior to use.  
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5.2.9 In situ adenoviral transduction and detection of human growth hormone (hGH) 
release  
In situ transduction of rat bladder uroepithelium and measurement of hGH release was 
performed as described earlier (22). Briefly, rats were sedated with isoflurane and a Jelco IV 
catheter (Smith Medicals, Southington, CT) was introduced into the bladder via the urethra. The 
bladder was rinsed with PBS, and filled with 400 μl of 0.1% w/v dodecyl-β-D-maltoside 
dissolved in PBS. The urethra was clamped, and after 5 min unclamped to allow the detergent to 
void. The latter step was facilitated by applying slight pressure to the lower abdomen. The 
bladder was filled with 400 μl PBS containing adenoviruses expressing hGH alone or with 
adenoviruses encoding scrambled-shRNA, ADAM17-shRNA, or the ADAM17-HA constructs 
described below (2.5 x 108 infectious virus particles, typically in a volume of 2-10 µl). The 
bladder was then clamped. After 30 min the clamp was removed and the virus solution was 
allowed to void. The bladder was rinsed with PBS, anesthesia was discontinued, and the rats 
were allowed to revive. Thirty-h post infection, the animals were sacrificed by inhalation of CO2 
and the bladder was immediately excised, slit open, and mounted on tissue rings as described 
above. After 90 min of equilibration, the buffer bathing the apical surface was isovolumetrically 
replaced with fresh buffer and treated ± 500nM CCPA. Sixty-min later the apical buffer was 
removed and concentrated using 10K molecular weight cutoff Amicon Centricon (Millipore) to a 
volume of 250 μL. The corresponding tissue was unmounted from its tissue ring and a lysate was 
prepared prior to Western blot analysis to detect hGH.  
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5.2.10 WGA-FITC labeling experiment 
Rat bladders were mounted in Ussing chambers, and after equilibration were incubated with 25 
μg/ml WGA-FITC for 2-h ± 500 nM CCPA added to the mucosal hemichamber. The tissues 
were then unmounted from the chambers, washed with ice cold 100 mM N-Acetyl D-
glucosamine for 4 times, 20 min each and then through washed with ice cold PBS for 3 times 15 
min each and fixed with 4% PFA fixative for 30 min at 37°C.  The tissue was stained and the 
images were captured and processed as described above. 
5.2.11 Generation of shRNA resistant-ADAM17 and S811A and S811D point mutants 
ADAM17 cDNA (from Addgene plasmid 19141(351)) was cloned into pADLOX vector and 
cDNA encoding HA was added in-frame to the C-terminus of ADAM17 after a gap of two 
amino acids. A silent mutation was engineered into the ADAM17 sequence (5’ 
GGATTAGCGTACGTTGGTTCT) using the QuickChange XL mutagenesis kit (Agilent), 
making the construct resistant to the ADAM17 shRNA described above. This resulting construct, 
called pADLOX-ADAM17R-HA, was further mutagenized to convert serine at position 811 to an 
alanine or aspartate residue, generating pADLOX-ADAM17R/S811A-HA (TCA to GCC) and 
pADLOX-ADAM17R/S811D-HA (TCA to GAC). The constructs (3 µg) were preincubated with 
Lipofectamine 2000 Opti-MEM media for 30 min, mixed with 3 µg Ψ5 adenoviral genomic 
DNA (Ad5 strain), and added to Cre8 cells (22,352). Preparation of the adnoviruses and in situ 
transduction were performed as described above.   
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5.2.12  Statistical analysis 
Statistical significance between means was determined by Student’s t-test or in the case 
of multiple comparisons by analysis of variance (ANOVA). If a significant difference in the 
means was detected by ANOVA, multiple comparisons were performed using Dunnett’s post-
test correction. Statistical analyses were performed using Prism 5 software (GraphPad, La Jolla, 
CA) 
 
5.3 ADDITIONAL MATERIALS AND METHODS 
5.3.1 Generation of lentiviral vectors encoding A1AR shRNA 
iRNAi software was used to design the shRNA sequences. Rat A1AR cDNA sequence (Pubmed 
accession number NM64299.1) was analyzed using the software and the shRNA sequences were 
searched using the 19 (AA) parameter used for ADAM17 shRNAs. Four sequences were 
selected and the shRNAs were synthesized with CTCGAG loop sequence. An Xba1 site was 
engineered at the 3’ end of the sequence, for quick determination of success of cloning. The 
sequences were cloned into the AgeI-EcoRI site of pLKO.1.GFP.AgeI(-). The clones were 
verified by sequencing and used to determine which sequence had the best knockdown 
efficiency. The selected sequence was then used to make the lentivirus using the following 
protocol: 
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HEK293ft cells were grown in a 10cm plate in DMEM with 10%FBS and 500mg/ml Geneticin. 
When the cells reached   85-90% confluence, the media was removed and 5ml Optimem 
supplemented with 5% FBS was added. 9μL of Virapower cocktail (Invitrogen) + 3μG of 
pLKO.1.GFP.Age(-).A1ARshRNA plasmid were transfected into the cell using 
Lipofectamine2000. 24-h post transfection, the Optimem was removed and 10ml of DMEM + 
10% FBS was added to the cells. 72-h post transfection, the media containing the virus was 
removed and filtered through a 0.44μM PVDF filter. 1ml viral aliquots were stored in -80°C.   
5.3.2 DNA and plasmids 
Rat A1AR cDNA in pcDNA3.1 vector (pcDNA.ratA1ARcDNA) was a kind gift from Dr. Joel 
Linden. pLKO.1.GFP was a kind gift from Dr. Elaine Fuchs. However, the vector had an 
additional AgeI site within the hist2h2be-eGFP cassette that impaired cloning of the shRNA 
sequences as the cloning sites were AgeI-EcoRI. Therefore, the extra AgeI site was removed 
using site directed mutagenesis and the cloning competent plasmid was called 
pLKO.1.GFP.Age(-).  
5.3.3 Procedure 
5.3.3.1 Lentiviral infection in HEK293 cells 
HEK293 cells were grown in 6 well plates and rat pcDNA.ratA1AR cDNA was transfected into 
the cells using Lipofectamine. 24-h post transfection 10μL of lentivirus was added to each well. 
24- and 48-h post addition the cells were harvested and lysed.  
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5.3.3.2 Lentiviral infection in rats   
Lentiviral infection in rats were performed as explained in section 5.2.9.  
5.3.4 Western blot 
Western blots were performed as explained in section 5.2.6. Rabbit anti-A1AR antibody was 
purchased from Abcam and used at a concentration of 1:2000.  
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APPENDIX A 
KNOCKDOWN OF A1AR USING LENTIVIRAL-BASED SHRNA VECTORS 
A1AR was the cornerstone of my project. Therefore,  I initiated a pilot project to determine 
the impact of knocking down A1AR in umbrella cells. The scope of the project was twofold. 1) 
To determine the impact of umbrella cell-specific A1AR knockdown on the function of the 
bladder and 2) To develop a novel in situ lentiviral-based shRNA-knockdown technique that can 
be used to study other proteins in that are involved in membrane trafficking in umbrella cells. 
The GFP-tagged pLKO.1 vector was a kind gift from Dr. Elaine Fuchs. The vector was designed 
on a pLKO.1 backbone, where a hist2h2be-eGFP gene was engineered in the place of the 
puromycin gene cassette. The shRNA expression was driven by a U6 RNA promoter which was 
upstream to an EcoR1-Age1 cloning site (353). A1AR shRNA was designed using the iRNAi 
shRNA software using the AA(19) parameter used for ADAM17 shRNA design and cloned into 
the lentiviral vector. The sequences were tested in HEK293 cells where A1AR was exogenously 
expressed using a pcDNA A1AR plasmid construct (a kind gift from Dr. Joel Linden). Of the 
four sequences tested, A1AR-shRNA sequence 2 (5’- GATCCCTCTCCGGTACAAG-3’) was 
effective in completely knocking down A1AR expression (Figure 25). The constructs were used 
to prepare lentiviruses and tested on umbrella cells.  
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Unfortunately, the transduction efficiency of lentiviruses in the umbrella cells was very poor. 
This could be because the lentivirus particles were pseudotyped to express vesicular stomatitis 
virus- glycoprotein G (VSV-G) on their surface for enhancing their tropism. However, VSV-G 
requires clathrin machinery for uptake. Because endocytosis mechanism in umbrella cells does 
not occur via clathrin coated pits, this might have hampered entry of the lentiviral particles into 
the umbrella cell (42).  
Figure 25 A1AR knockdown using lentiviral vectors 
 
 
 
HEK293 cells expressing either wild type A1AR or wild type A1AR + one of the shRNA 
sequences were harvested 24-h post transfection. Equal quantities of the protein were loaded and 
the western blots were probed with either rabbit anti-A1AR antibody or rabbit anti-actin 
antibody. Sequence 2 showed maximum knockdown of A1AR.  
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APPENDIX B 
A RAB11A-RAB8A-MYO5B NETWORK PROMOTES STRETCH-REGULATED 
EXOCYTOSIS IN BLADDER UMBRELLA CELLS 
As a pilot project, I worked in collaboration with Dr. Khandelwal to determine the role of 
myosin5B actin motor protein in stretch-mediated apical exocytosis in rats. The work completed 
my dissertation project as it furthered our understanding of how the network of Rabs and their 
interplay with the cortical actin cytoskeleton regulates apical exocytosis in umbrella cells. 
The work was published in MBoC in February 2013. I have presented an abstract of the work 
here. The complete work can be accessed from pubmed (PMID: 23389633) 
Multiple Rabs are associated with secretory granules/vesicles, but how these GTPases are 
coordinated to promote regulated exocytosis is not well understood. In bladder umbrella cells a 
subapical pool of discoidal/fusiform-shaped vesicles (DFVs) undergoes Rab11a-dependent 
regulated exocytosis in response to bladder filling. We show that Rab11a-associated vesicles are 
enmeshed in an apical cytokeratin meshwork and that Rab11a likely acts upstream of Rab8a to 
promote exocytosis. Surprisingly, expression of Rabin8, a previously described Rab11a effector 
and guanine nucleotide exchange factor for Rab8, stimulates stretch-induced exocytosis in a 
manner that is independent of its catalytic activity. Additional studies demonstrate that the 
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unconventional motor protein myosin5B motor (Myo5B) works in association with the Rab8a-
Rab11a module to promote exocytosis, possibly by ensuring transit of DFVs through a subapical, 
cortical actin cytoskeleton before fusion. Our results indicate that Rab11a, Rab8a, and Myo5B 
function as part of a network to promote stretch-induced exocytosis, and we predict that similarly 
organized Rab networks will be common to other regulated secretory pathways 
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APPENDIX C 
BLADDER FILLING AND VOIDING AFFECT UMBRELLA CELL TIGHT JUNCTION 
ORGANIZATION AND FUNCTION 
I worked on another project with Dr. Marcelo to understand the effect of bladder filling and 
voiding on the organization of the tight junctional complex of the umbrella cells. The study 
furthered our understanding of how stress impacts the tight junctions. Though not a part of my 
study, it will be interesting to investigate the impact of A1AR signaling on the tight junction 
complex too. 
 The work was published in AJP-Renal Physiology in July 2013. I have presented an 
abstract of the work here. The complete work can be accessed from pubmed (PMID: 23884145) 
Epithelial cells are continuously exposed to mechanical forces including shear stress and 
stretch, though the impact these forces have on tight junction (TJ) organization and function are 
poorly understood. Umbrella cells form the outermost layer of the stratified uroepithelium and 
undergo large cell shape and surface area changes during the bladder cycle. Here we investigated 
the effects of bladder filling and voiding on the umbrella cell TJ. We found that bladder filling 
promoted a significant increase in the length of the TJ ring, which was quickly reversed within 5 
min of voiding. Interestingly, when isolated uroepithelial tissue was mounted in Ussing 
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chambers and exposed to physiological stretch, we observed a tenfold drop in both transepithelial 
electrical resistance (TER) and the umbrella cell junctional resistance. The effects of stretch on 
TER were reversible and dependent on the applied force. Furthermore, the integrity of the 
umbrella cell TJ was maintained in the stretched uroepithelium, as suggested by the limited 
permeability of biotin, fluorescein, and ruthenium red. Finally, we found that depletion of 
extracellular Ca2+ by EGTA completely disrupted the TER of unstretched, but not of stretched 
uroepithelium. Taken together our studies indicate that the umbrella cell TJ undergoes major 
structural and functional reorganization during the bladder cycle. The impact of these changes on 
bladder function is discussed.  
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